0001493152-23-017083.txt : 20230515 0001493152-23-017083.hdr.sgml : 20230515 20230515121734 ACCESSION NUMBER: 0001493152-23-017083 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 55 CONFORMED PERIOD OF REPORT: 20230331 FILED AS OF DATE: 20230515 DATE AS OF CHANGE: 20230515 FILER: COMPANY DATA: COMPANY CONFORMED NAME: bioAffinity Technologies, Inc. CENTRAL INDEX KEY: 0001712762 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 465211056 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-41463 FILM NUMBER: 23920110 BUSINESS ADDRESS: STREET 1: 22211 WEST INTERSTATE-10 STREET 2: SUITE 1206 CITY: SAN ANTONIO STATE: TX ZIP: 78257 BUSINESS PHONE: 210-698-5334 MAIL ADDRESS: STREET 1: 22211 WEST INTERSTATE-10 STREET 2: SUITE 1206 CITY: SAN ANTONIO STATE: TX ZIP: 78257 10-Q 1 form10-q.htm
0001712762 false --12-31 Q1 0001712762 2023-01-01 2023-03-31 0001712762 BIAF:CommonStockParValue.007PerShareMember 2023-01-01 2023-03-31 0001712762 BIAF:TradeableWarrantsToPurchaseCommonStockMember 2023-01-01 2023-03-31 0001712762 2023-05-12 0001712762 2023-03-31 0001712762 2022-12-31 0001712762 2022-01-01 2022-03-31 0001712762 us-gaap:PreferredStockMember 2022-12-31 0001712762 us-gaap:CommonStockMember 2022-12-31 0001712762 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001712762 us-gaap:RetainedEarningsMember 2022-12-31 0001712762 us-gaap:PreferredStockMember us-gaap:ConvertiblePreferredStockMember 2021-12-31 0001712762 us-gaap:CommonStockMember 2021-12-31 0001712762 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001712762 us-gaap:RetainedEarningsMember 2021-12-31 0001712762 2021-12-31 0001712762 us-gaap:PreferredStockMember 2023-01-01 2023-03-31 0001712762 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001712762 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001712762 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001712762 us-gaap:PreferredStockMember us-gaap:ConvertiblePreferredStockMember 2022-01-01 2022-03-31 0001712762 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001712762 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001712762 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001712762 us-gaap:PreferredStockMember 2023-03-31 0001712762 us-gaap:CommonStockMember 2023-03-31 0001712762 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001712762 us-gaap:RetainedEarningsMember 2023-03-31 0001712762 us-gaap:PreferredStockMember us-gaap:ConvertiblePreferredStockMember 2022-03-31 0001712762 us-gaap:CommonStockMember 2022-03-31 0001712762 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001712762 us-gaap:RetainedEarningsMember 2022-03-31 0001712762 2022-03-31 0001712762 us-gaap:SellingGeneralAndAdministrativeExpensesMember srt:RestatementAdjustmentMember 2022-03-31 0001712762 us-gaap:ConvertiblePreferredStockMember 2023-01-01 2023-03-31 0001712762 us-gaap:ConvertiblePreferredStockMember 2022-01-01 2022-03-31 0001712762 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0001712762 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0001712762 us-gaap:WarrantMember 2023-01-01 2023-03-31 0001712762 us-gaap:WarrantMember 2022-01-01 2022-03-31 0001712762 us-gaap:ConvertibleDebtSecuritiesMember 2023-01-01 2023-03-31 0001712762 us-gaap:ConvertibleDebtSecuritiesMember 2022-01-01 2022-03-31 0001712762 BIAF:LabEquipmentMember 2023-03-31 0001712762 BIAF:LabEquipmentMember 2022-12-31 0001712762 BIAF:ComputerAndSoftwareMember 2023-03-31 0001712762 BIAF:ComputerAndSoftwareMember 2022-12-31 0001712762 us-gaap:ShortTermDebtMember 2022-09-30 0001712762 us-gaap:ShortTermDebtMember 2022-09-01 2022-09-30 0001712762 2022-06-01 2022-06-30 0001712762 2022-06-30 0001712762 us-gaap:SeriesAPreferredStockMember 2023-03-31 0001712762 us-gaap:PrivatePlacementMember 2017-07-31 0001712762 us-gaap:SeriesAPreferredStockMember 2017-07-01 2017-07-31 0001712762 us-gaap:SeriesAPreferredStockMember 2017-07-31 0001712762 srt:MinimumMember 2021-11-30 0001712762 srt:MaximumMember 2021-11-30 0001712762 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 0001712762 us-gaap:RestrictedStockUnitsRSUMember 2023-03-31 0001712762 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-03-31 0001712762 us-gaap:RestrictedStockUnitsRSUMember 2022-03-31 0001712762 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-03-31 0001712762 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-03-31 0001712762 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-03-31 0001712762 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-03-31 0001712762 us-gaap:WarrantMember 2023-03-31 0001712762 us-gaap:WarrantMember 2022-12-31 0001712762 us-gaap:WarrantMember 2023-01-01 2023-03-31 0001712762 us-gaap:WarrantMember 2022-01-01 2022-03-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

 

  ☒

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly for the period ended March 31, 2023

     
  ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ______ to ______.

 

COMMISSION FILE NUMBER: 001-41463

 

bioAffinity Technologies, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   46-5211056
(State of Incorporation)   (I.R.S. Employer Identification No.)

 

22211 W. Interstate 10, Suite 1206, San Antonio, Texas   78257
(Address of principal executive offices)   (Zip Code)

 

(210) 698-5334

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol   Name of each exchange on which registered
Common Stock, par value $.007 per share   BIAF   The Nasdaq Stock Market LLC
Tradeable Warrants to purchase Common Stock   BIAFW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to the filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

  Large accelerated filer ☐ Accelerated filer ☐
  Non-accelerated filer ☒ Smaller reporting company ☒
    Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Sec 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

The number of shares of the issuer’s common stock outstanding as of May 12, 2023, was 8,518,981.

 

 

 

 

 

 

Throughout this Quarterly Report on Form 10-Q (this “Quarterly Report”), the terms “bioAffinity,” “bioAffinity Technologies,” “we,” “us,” “our” or “the Company” refer to bioAffinity Technologies, Inc., a Delaware corporation, and its wholly owned subsidiary, OncoSelect® Therapeutics, LLC, a Delaware limited liability company.

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This Quarterly Report contains forward-looking statements within the meaning of the federal securities laws. Forward-looking statements are predictive in nature, depend on or refer to future events or conditions, and are sometimes identified by words such as “may,” “could,” “plan,” “project,” “predict,” “pursue,” “believe,” “expect,” “estimate,” “anticipate,” “intend,” “target,” “seek,” “potentially,” “will likely result,” “outlook,” “budget, “objective,” “trend,” or similar expressions of a forward-looking nature and the negative versions of such expressions. The forward-looking information contained in this report is generally located under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations” but may be found in other locations as well. The forward-looking statements in this report generally relate to the plans and objectives for future operations of bioAffinity Technologies, Inc. and are based on our management’s reasonable estimates of future results or trends. Although we believe these forward-looking statements are reasonable, all forward-looking statements are subject to various risks and uncertainties, and our projections and expectations may be incorrect. The factors that may affect our expectations regarding our operations include, among others, the following:

 

  ● our projected financial position and estimated cash burn rate;
     
  ● our estimates regarding expenses, future revenues, and capital requirements;
     
  ● the success, cost, and timing of our clinical trials;
     
  ● our ability to obtain funding for our operations necessary to complete further development and commercialization of our diagnostic tests or therapeutic product candidates;
     
  ● our dependence on third parties in the conduct of our clinical trials;
     
  ● our ability to obtain the necessary regulatory approvals to market and commercialize our diagnostic tests or therapeutic product candidates;
     
  ● the potential that the results of our pre-clinical and clinical trials indicate our current diagnostic tests or any future diagnostic tests or therapeutic product candidates we may seek to develop are unsafe or ineffective;
     
  ● the results of market research conducted by us or others;
     
  ● our ability to obtain and maintain intellectual property (“IP”) protection for our current diagnostic tests or future diagnostic and therapeutic product candidates;
     
  ● our ability to protect our IP rights and the potential for us to incur substantial costs from lawsuits to enforce or protect our IP rights;
     
  ● the possibility that a third party may claim we or our third-party licensors have infringed, misappropriated or otherwise violated their IP rights and that we may incur substantial costs and be required to devote substantial time defending against such claims;
     
  ● our reliance on third parties;
     
  ● the success of competing therapies, diagnostic tests, and therapeutic products that are or will become available;
     
  ● our ability to expand our organization to accommodate potential growth and to retain and attract key personnel;

 

 

 

 

  ● our potential to incur substantial costs resulting from product liability lawsuits against us and the potential for such lawsuits to cause us to limit the commercialization of our diagnostic tests and therapeutic product candidates;
     
  ● market acceptance of our diagnostic tests and therapeutic product candidates, the size and growth of the potential markets for our current diagnostic tests and therapeutic product candidates, and any future diagnostic tests and therapeutic product candidates we may seek to develop, and our ability to serve those markets;
     
  ● the successful development of our commercialization capabilities, including sales and marketing capabilities;
     
  ● compliance with government regulations, including environmental, health, and safety regulations and liabilities thereunder;
     
  ● the ultimate impact of the ongoing COVID-19 pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems, or the global economy as a whole;
     
  ● general instability of economic and political conditions in the United States, including inflationary pressures, increased interest rates, economic slowdown or recession, and escalating geopolitical tensions;
     
  ● compliance with government regulations, including environmental, health, and safety regulations, and liabilities thereunder;
     
  ● our anticipated uses of net proceeds from our initial public offering (“IPO”);
     
  ● the increased expenses associated with being a public company; and
     
  ● other factors discussed elsewhere in this Quarterly Report.

 

Many of the foregoing risks and uncertainties, as well as risks and uncertainties that are currently unknown to us, are, and may be, exacerbated by factors such as the ongoing conflict between Ukraine and Russia, escalating tensions between China and Taiwan, increasing economic uncertainty and inflationary pressures, the evolving nature of the COVID-19 pandemic and the emergence of new viral variants, and any consequent worsening of the global business and economic environment. New factors emerge from time to time, and it is not possible for us to predict all such factors. Should one or more of the risks or uncertainties described in this Quarterly Report or any other filing with the Securities and Exchange Commission (the “SEC”) occur, or should the assumptions underlying the forward-looking statements we make herein and therein prove incorrect, our actual results and plans could differ materially from those expressed in any forward-looking statements. We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

 

You should read this Quarterly Report and the documents that we reference within it with the understanding that our actual future results, performance, and events and circumstances may be materially different from what we expect.

 

Website and Social Media Disclosure

 

We use our websites (www.bioaffinitytech.com and ir.bioaffinitytech.com) and at times our corporate Twitter account (@bioAffinity) and LinkedIn account (www.linkedin.com/company/bioaffinitytechnologies) to distribute company information. The information we post through these channels may be deemed material. Accordingly, investors should monitor these channels and review our press releases, filings with the SEC, and public conference calls and webcasts. In addition, investors and others can be automatically notified in real time when new information is posted on our websites by visiting the homepage of our Company website at www.bioaffinitytech.com and subscribing to “News from bioAffinity Technologies” or visiting the “Email Alerts” section of our investor relations website at ir.bioaffinitytech.com/news-events/email-alerts and enrolling an email address. Information contained on or that can be accessed through our websites and social media channels is not, however, incorporated by reference in this Quarterly Report. Investors should not consider any such information to be part of this Quarterly Report.

 

 

 

 

bioAffinity Technologies, Inc.

 

FORM 10-Q

TABLE OF CONTENTS

 

PART I

FINANCIAL INFORMATION
 
ITEM 1 - Condensed Consolidated Financial Statements (Unaudited) 3
  Condensed Consolidated Balance Sheets 3
  Unaudited Condensed Consolidated Statements of Operations 4
  Unaudited Condensed Consolidated Statements of Stockholders’ Equity (Deficit) 5
  Unaudited Condensed Consolidated Statements of Cash Flows 6
  Notes to Unaudited Condensed Consolidated Financial Statements 7
     
ITEM 2 - Management’s Discussion and Analysis of Financial Condition and Results of Operations 13
     
ITEM 3 - Quantitative and Qualitative Disclosures about Market Risk 18
     
ITEM 4 - Controls and Procedures 18
     
PART II
OTHER INFORMATION
 
ITEM 1 - Legal Proceedings 19
     
ITEM 1A - Risk Factors 19
     
ITEM 2 - Unregistered Sales of Equity Securities and Use of Proceeds 19
     
ITEM 3 - Defaults Upon Senior Securities 19
     
ITEM 4 - Mine Safety Disclosure 19
     
ITEM 5 - Other Information 19
     
ITEM 6 - Exhibits 20
     
  Signatures 21

 

2

 

 

PART I

FINANCIAL STATEMENTS

 

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED).

 

bioAffinity Technologies, Inc.

Condensed Consolidated Balance sheets

 

   March 31,   December 31, 
   2023   2022 
   (Unaudited)     
ASSETS          
Current assets:          
Cash and cash equivalents  $9,769,088   $11,413,759 
Accounts and other receivables, net   11,027    10,489 
Inventory   11,335    5,540 
Prepaid and other current assets   441,132    531,899 
           
Total current assets   10,232,582    11,961,687 
           
Property and equipment, net   225,067    214,438 
Other assets   6,920    6,000 
           
Total assets  $10,464,569   $12,182,125 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
           
Current liabilities:          
Accounts payable  $146,537   $345,042 
Accrued expenses   481,336    541,894 
Loan payable   168,430    251,746 
           
Total current liabilities   796,303    1,138,682 
           
Total liabilities   796,303    1,138,682 
           
Commitments and contingencies (See Note 8)   -    - 
           
Stockholders’ equity:          
Preferred stock, par value $0.001 per share; 20,000,000 shares authorized; no shares issued or outstanding at March 31, 2023, and December 31, 2022   —    — 
Common stock, par value $0.007 per share; 14,285,714 shares authorized; 8,463,052 issued and outstanding at March 31, 2023; and 8,381,324 shares issued and outstanding at December 31, 2022   59,241    58,669 
Additional paid-in capital   47,809,283    47,652,242 
Accumulated deficit   (38,200,258)   (36,667,468)
Total stockholders’ equity   9,668,266    11,043,443 
           
Total liabilities and stockholders’ equity  $10,464,569   $12,182,125 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

3

 

 

bioAffinity Technologies, Inc.

Unaudited Condensed Consolidated Statements of Operations

 

   2023   2022 
   Three Months Ended
March 31,		 
   2023   2022 
         
Revenue  $921   $— 
Cost of sales   87    — 
Gross profit   834    — 
           
Operating expenses:          
Research and development   369,617    279,848 
Clinical development   19,628    52,503 
Selling, general and administrative   1,169,559    394,692 
           
Total operating expenses   1,558,804    727,043 
           
Loss from operations   (1,557,970)   (727,043)
           
Other income (expense):          
Interest income (expense), net   36,999    (1,147,012)
Fair value adjustments on convertible notes payable   —    404,194 
           
Loss before income taxes   (1,520,971)   (1,469,861)
           
Income tax expense   11,819    2,159 
           
Net loss  $(1,532,790)  $(1,472,020)
           
Net loss per common share, basic and diluted  $(0.18)  $(0.55)
           
Weighted average common shares outstanding   8,433,689    2,681,221 

 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

4

 

 

bioAffinity Technologies, Inc.

Unaudited Condensed Consolidated Statements of Stockholders’ Equity (Deficit)

 

                                    
   For the Three Months Ended March 31, 2023 
   Preferred Stock   Common Stock   Additional
Paid-in		   Accumulated   Stockholders’ 
   Shares   Amount   Shares   Amount   Capital   Deficit   Equity 
                             
Balance at December 31, 2022   —   $—    8,381,324   $58,669   $47,652,242   $(36,667,468)  $11,043,443 
                                    
Stock-based compensation expense   —    —    81,728    572    157,041    —    157,613 
                                    
Net loss   —    —    —    —    —    (1,532,790)   (1,532,790)
                                    
Balance at March 31, 2023 (Unaudited)   —   $—    8,463,052   $59,241   $47,809,283   $(38,200,258)  $9,668,266 

 

                                    
   For the Three Months Ended March 31, 2022 
   Convertible
Preferred Stock		   Common Stock   Additional
Paid-in		   Accumulated   Stockholders’ 
   Shares   Amount   Shares   Amount   Capital   Deficit   Deficit 
                             
Balance at December 31, 2021   756,558   $4,044,318    2,677,140   $18,740   $12,703,896   $(28,513,355)  $(15,790,719)
                                    
Stock-based compensation expense   —    —    15,772    110    105,937    —    106,047 
                                    
Beneficial conversion feature for bridge notes   —    —    —    —    213,942    —    213,942 
                                    
Debt discount for warrants issued   —    —    —    —    217,973    —    217,973 
                                    
Net loss   —    —    —    —    —    (1,472,020)   (1,472,020)
                                    
Balance at March 31, 2022 (Unaudited)   756,558   $4,044,318    2,692,912   $18,850   $13,241,748   $(29,985,375)  $(16,724,777)

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

5

 

 

bioAffinity Technologies, Inc.

Unaudited Condensed Consolidated Statements of Cash Flows

 

   2023   2022 
   Three Months Ended March 31,, 
   2023   2022 
         
Cash flows from operating activities          
Net loss  $(1,532,790)  $(1,472,020)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation and amortization   21,685    1,039 
Accretion of debt issuance costs   —    978,217 
Fair value adjustments on convertible notes payable   —    (404,194)
Stock-based compensation expense   157,613    106,047 
Changes in operating assets and liabilities:          
Accounts and other receivables   (538)   (5,331)
Inventory   (5,795)   (5,803)
Prepaid expenses and other assets   89,847    11,143 
Accounts payable   (198,505)   17,284 
Accrued expenses   (60,558)   (29,649)
Accrued interest   —    169,300 
Net cash used in operating activities   (1,529,041)   (633,967)
           
Cash flows from investing activities          
Purchase of equipment   (32,314)   — 
Net cash used in investing activities   (32,314)   — 
           
Cash flows from financing activities          
Payment on loan payable   (83,316)   — 
Proceeds from issuance of convertible notes payable   —    475,000 
Payment of deferred offering costs   —    (117,986)
Payment of debt issuance costs   —    (55,651)
Net cash (used in) provided by financing activities   (83,316)   301,363 
           
Net decrease in cash and cash equivalents   (1,644,671)   (332,604)
Cash and cash equivalents at beginning of period   11,413,759    1,360,638 
Cash and cash equivalents at end of period  $9,769,088   $1,028,034 
           
Supplemental disclosures of cash flow information:          
Income taxes paid in cash  $11,819   $2,159 
Interest expense paid in cash  $1,655   $— 
Noncash financing activities:          
Fair value of warrants issued to placement agents  $—   $217,973 
Beneficial conversion feature for bridge notes  $—   $213,942 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

6

 

 

bioAffinity Technologies, Inc.

Notes To Condensed Consolidated Financial Statements

(unaudited)

 

Note 1. NATURE OF OPERATIONS, ORGANIZATION, AND BASIS OF PRESENTATION

 

Description of Business

 

bioAffinity Technologies, Inc., a Delaware corporation (the “Company,” “we,” or “our”), addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung. Our Company also is conducting early-stage research focused on advancing therapeutic discoveries that could result in broad-spectrum cancer treatments. bioAffinity Technologies develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. Our first diagnostic test, CyPath® Lung, is a noninvasive test for early detection of lung cancer, the leading cause of cancer-related deaths. Research and optimization of our proprietary platform for in vitro diagnostics and technologies are conducted in our laboratories at The University of Texas at San Antonio. We are developing our platform technologies so that in the future, they will be able to detect, monitor, and treat diseases of the lung and other cancers.

 

Organization

 

The Company was formed on March 26, 2014, as a Delaware corporation with its corporate offices located in San Antonio, Texas. On June 15, 2016, the Company formed a wholly owned subsidiary, OncoSelect® Therapeutics, LLC, as a Delaware limited liability company.

 

Basis of Presentation

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) and pursuant to the rules and regulations of the SEC for interim financial reporting. The condensed consolidated financial statements are unaudited, and in management’s opinion include all adjustments, including normal recurring adjustments and accruals, necessary for a fair presentation of the results for the interim periods presented. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the fiscal year ended December 31, 2023, or any future period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited annual consolidated financial statements and notes included in the Company’s Form 10-K filed with the SEC on March 31, 2023.

 

In accordance with Accounting Standards Update (“ASU”) 2014-15, Presentation of Financial Statements – Going Concern (Subtopic 205-40), the Company has evaluated whether there are conditions and events that raise substantial doubt about the Company’s ability to continue as a going concern for at least one year after the date the condensed consolidated financial statements are issued.

 

The Company has incurred significant losses and negative cash flows from operations since inception and expects to continue to incur losses and negative cash flows for the foreseeable future. As a result, the Company had an accumulated deficit of $38.2 million at March 31, 2023. The Company’s cash and cash equivalents at March 31, 2023, were approximately $9.8 million, representing 93% of total assets. Based on the Company’s current expected level of operating expenditures, the Company believes its cash on hand at March 31, 2023, is sufficient to fund the Company’s ongoing operations for a period of a least twelve (12) months subsequent to the issuance of the accompanying unaudited condensed consolidated financial statements. Thereafter, the Company may need to raise further capital through the sale of additional equity or debt securities or other debt instruments, strategic relationships or grants, or other arrangements to support its future operations. If such funding is not available or not available on terms acceptable to the Company, the Company’s current development plan may be curtailed.

 

COVID-19

 

The rapid global spread of the COVID-19 virus since December 2019 has affected production and sales worldwide, disrupted supply chains across a range of industries, and created significant economic volatility. The impact of COVID-19 on the Company’s operational and financial performance will depend on numerous factors, including the spread, duration, and intensity of the pandemic (including resurgences), the emergence of new viral variants, and the impact of the pandemic on the Company’s customers, employees, clinical trial sites, and vendors.

 

7

 

 

As the COVID-19 pandemic continues to evolve, the ultimate impact of the pandemic on the Company’s operations is highly uncertain and subject to change and will depend on future developments, which cannot be accurately predicted, including the duration of the pandemic, additional or modified government actions, and the actions taken to contain COVID-19 or address its impact, among others. Management does not yet know the full extent of potential delays or impacts on the Company, clinical trials, research programs, healthcare systems, or the global economy but continues to monitor the situation closely.

 

Note 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Use of Estimates

 

The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include: the valuation allowance on the Company’s deferred tax assets; the useful lives of fixed assets; and the fair value of the convertible notes payable.

 

Principles of Consolidation

 

The accompanying condensed consolidated financial statements include all of the accounts of the Company and its wholly owned subsidiary, OncoSelect® Therapeutics, LLC. All significant intercompany balances and transactions have been eliminated.

 

Advertising expense

 

The Company expenses all advertising costs as incurred. Advertising expense was approximately $6,000 and $3,000 for the three months ended March 31, 2023 and 2022, respectively.

 

Loss Per Share

 

Basic earnings (loss) per share is computed by dividing net income (loss) attributable to common stockholders by the weighted-average number of Common Shares outstanding during the period. Diluted earnings per share is computed by dividing net income attributable to common stockholders by the sum of the weighted-average number of Common Shares outstanding during the period and the weighted-average number of dilutive Common Share equivalents outstanding during the period, using the treasury stock method. Dilutive Common Share equivalents are comprised of in-the-money stock options, convertible notes payable, and warrants based on the average stock price for each period using the treasury stock method.

 

The following potentially dilutive securities have been excluded from the computations of weighted average shares outstanding as of March 31, 2023 and 2022, as they would be anti-dilutive:

 

   2023   2022 
   As of March 31, 
   2023   2022 
Convertible preferred stock   —    756,558 
Shares underlying options outstanding   806,392    884,094 
Shares underlying warrants outstanding   4,649,952    2,057,740 
Shares underlying convertible notes   —    2,511,345 
Anti-dilutive securities   5,556,344    6,209,737 

 

8

 

 

Revenue Recognition

 

Revenue is generated exclusively from royalties for the Company’s first diagnostic test, CyPath® Lung, from sales by Precision Pathology Services, a CAP-accredited, CLIA-certified clinical pathology laboratory and the Company’s licensee, that began a limited market launch in the second quarter of 2022 to pulmonologists in the South Texas area, designed to refine future positioning and develop strategic insight for the Company’s CyPath® Lung test. The services are completed upon release of a patient’s test result to the ordering healthcare provider.

 

To determine revenue recognition for the arrangements that the Company determines are within the scope of ASC 606, Revenue from Contracts with Customers, the Company performs the following five steps: (1) identify the contract(s) with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract and (5) recognize revenue when (or as) the entity satisfies a performance obligation.

 

Reclassifications

 

Certain prior year balances have been reclassified to conform to current year presentation. The Company reclassified patent expenses and annuity costs of approximately $42,000 from research and development to selling, general and administrative for the three months ended March 31, 2022, respectively.

 

Recent Accounting Pronouncements

 

The Company continues to monitor new accounting pronouncements issued by the Financial Accounting Standards Board (“FASB”) and does not believe any accounting pronouncements issued through the date of this report will have a material impact on the Company’s condensed consolidated financial statements.

 

Note 3. PREPAID EXPENSES AND OTHER CURRENT ASSETS

 

Prepaid expenses and other current assets are summarized below:

   March 31, 2023   December 31, 2022 
         
Prepaid insurance  $222,742   $340,078 
Legal and professional   84,077    72,048 
Other   134,313    119,773 
Total prepaid expenses and other current assets  $441,132   $531,899 

 

Note 4. PROPERTY AND EQUIPMENT, NET

 

Property and equipment are summarized below:

 

   March 31, 2023   December 31, 2022 
         
Lab equipment  $488,718   $462,155 
Computers and software   27,214    21,463 
Property and equipment, gross   515,932    483,618 
Accumulated depreciation   (290,865)   (269,180)
Total property and equipment, net  $225,067   $214,438 

 

Depreciation expense was approximately $22,000 and $1,000 for the three months ended March 31, 2023 and 2022, respectively.

 

9

 

 

Note 5. ACCRUED EXPENSES

 

Accrued expenses are summarized below:

   March 31, 2023   December 31, 2022 
         
Compensation  $281,085   $340,680 
Legal and professional   131,819    144,440 
Clinical   58,262    50,922 
Other   10,170    5,852 
Total accrued expenses  $481,336   $541,894 

 

Note 6. LOAN PAYABLE

 

In September 2022, the Company obtained short-term financing of approximately $0.5 million with ten monthly payments of approximately $42,000 and interest at a 4.3% fixed annual rate for director and officer insurance policies.

 

Note 7. FAIR VALUE MEASUREMENTS

 

The Company analyzes all financial instruments with features of both liabilities and equity under the FASB accounting standard for such instruments. Under this standard, financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.

 

The estimated fair value of certain financial instruments, including cash and cash equivalents, accounts and other receivables, prepaid and other current assets, accounts payable, accrued expenses and loan payable, are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments.

 

Note 8. COMMITMENTS AND CONTINGENCIES

 

Operating Leases

 

The Company leases its corporate offices under a month-to-month agreement and leases its laboratory and additional office space under an operating lease that is renewable annually by written notice by the Company and will require renewal in February 2024. Rent expense for office and lab space amounted to approximately $26,000 and $13,000 for each of the three months ended March 31, 2023 and 2022, respectively.

 

Legal Matters

 

From time to time, the Company is involved in various disputes and litigation matters that arise in the ordinary course of business. To date, the Company has no material pending legal proceedings.

 

Note 9. CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT

 

In June 2022, the Company completed a 1-for-7 reverse stock split of its Common Stock. All share and per share amounts have been adjusted on a retroactive basis in these condensed consolidated financial statements to reflect the effect of the reverse stock split. The Company made a cash payment to stockholders for all fractional shares that it would otherwise be required to issue as a result of the stock split. In addition, the stock split resulted in the par value of the Company’s Common Stock increasing to $0.007 per share.

 

Convertible Preferred Stock

 

The Company has authorized a total of 20,000,000 shares of preferred stock, $0.001 par value per share. Prior to the initial public offering (“IPO”), the Company issued 5,296,044 shares of preferred stock, designated as Series A. In July 2017, the Company completed a private placement of securities in which 1.3 million shares of Series A Preferred Stock were sold, resulting in net proceeds of $1.5 million. As part of the closing, the Company issued 4.0 million shares of Series A Preferred Stock in exchange for $2.6 million of the Company’s convertible notes payable and related accrued interest.

 

10

 

 

In accordance with the Certificate of Designation of the Series A Preferred Stock, all of the shares of Series A Preferred Stock that were issued and outstanding at the time of the IPO closing were automatically converted into 745,558 fully paid and nonassessable shares of Common Stock at a 1-for-7 conversion rate (as adjusted for the 1-for-7 reverse stock split). The shares of Series A Preferred Stock that were so converted ceased to be part of the Company’s authorized stock and will never again be issued by the Company. As of March 31, 2023, and December 31, 2022, no Preferred Stock was outstanding.

 

Common Stock

 

The Company has authorized a total of 14,285,714 shares of Common Stock, $0.007 par value per share. In November 2021, the Company received stockholder approval to increase the number of authorized shares from 7,142,857 shares to 14,285,714 shares. The Company has issued 8,463,052 shares of Common Stock as of March 31, 2023, and 8,381,324 shares of Common Stock as of December 31, 2022.

 

Note 10. STOCK-BASED COMPENSATION

 

The Company grants options under its 2014 Equity Incentive Plan (the “Plan”). Under the Plan, the Company is authorized to grant options for up to 1.1 million shares of Common Stock. The Company has reserved 1.0 million shares to be used under the Plan. Options may be granted to employees, the Company’s board of directors, and external consultants who provide services to the Company. Options granted under the Plan have vesting schedules with terms of one to three years and become fully exercisable based on specific terms imposed at the date of grant. The Plan will terminate according to the respective terms of the Plan in September 2026.

 

The Company has recorded stock-based compensation expense (credit) related to the issuance of stock option awards in the following line items in the accompanying condensed consolidated statement of operations:

 

   2023   2022 
   Three Months Ended
March 31,		 
   2023   2022 
         
Research and development  $11,268   $4,643 
General and administrative   146,345    101,404 
Total stock-based compensation expense  $157,613   $106,047 

 

The following table summarizes stock option activity under the Plan:

 

   Number of
options		   Weighted-average
exercise price		   Weighted-average
remaining
contractual term
(in years)		   Aggregate
intrinsic value		 
Outstanding at December 31, 2022   806,392   $4.33           
Granted   —    —           
Exercised   —    —           
Forfeited   —    —           
Outstanding at March 31, 2023   806,392   $4.33    3.8   $271,298 
                     
Vested and exercisable at March 31, 2023   803,218   $4.31    3.7   $271,298 

 

11

 

 

As of March 31, 2023, there was no unrecognized compensation cost related to non-vested stock options. During the three months ended March 31, 2023 and 2022, no options were exercised. During the three months ended March 31, 2023, no options were issued by the Company to purchase shares of Common Stock. During the three months ended March 31, 2022, the Company issued options to purchase 7,142 shares of Common Stock. The per share weighted-average fair value of the options granted during 2022 was estimated at $2.84 on the date of grant.

 

During the three months ended March 31, 2023, the Company issued restricted stock units (RSUs) for 64,016 shares of Common Stock to employees, non-employees and the board of directors. The shares vest in equal monthly installments over terms of between immediately up to one year, subject to the employees and non-employees providing continuous service through the vesting date. During the three months ended March 31, 2023, approximately 82,000 shares vested from RSUs previously issued.

 

During the three months ended March 31, 2022, the Company issued RSUs for 14,999 shares of Common Stock to employees and non-employees. The shares vest in equal monthly installments over terms of between immediately up to one year, subject to the employees and non-employees providing continuous service through the vesting date. During the three months ended March 31, 2022, approximately 16,000 shares vested from RSUs previously issued.

 

The following table summarizes weighted-average assumptions using the Black-Scholes option-pricing model used on the date of the grants issued during the three months ended March 31, 2022:

 

   2022 
Fair value of Common Stock  $4.62 
Volatility   63.9%
Expected term (years)   6.0 
Risk-free interest rate   2.20%
Dividend yield   0%

 

Note 11. WARRANTS

 

We account for Common Stock warrants as either equity instruments or derivative liabilities depending on the specific terms of the warrant agreement. Warrants are accounted for as derivative liabilities if the warrants allow for cash settlement or provide for modification of the warrant exercise price in the event subsequent sales of Common Stock by the Company are at a lower price per share than the then-current warrant exercise price. We classify derivative warrant liabilities on the condensed consolidated balance sheet at fair value, and changes in fair value during the periods presented in the condensed consolidated statement of operations, which is revalued at each balance sheet date subsequent to the initial issuance of the stock warrant.

 

As of March 31, 2023, and December 31, 2022, the Company had 4,649,952 warrants outstanding to purchase one share of the Company’s Common Stock for each warrant at a weighted average exercise price of $6.39 and expire at various dates through September 2027. During the three months ended March 31, 2023 and 2022, no warrants were exercised into an equivalent number of Common Shares.

 

Note 12. SUBSEQUENT EVENTS

 

The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the condensed consolidated financial statements were available to be issued. Based upon this review, the Company did not identify any subsequent events that would have required adjustment or disclosure in the condensed consolidated financial statements.

 

12

 

 

ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

This section presents management’s perspective on our financial condition and results of operations. The following discussion and analysis (the “MD&A”) is intended to highlight and supplement data and information presented elsewhere in this Quarterly Report, and should be read in conjunction with our interim unaudited condensed consolidated financial statements and notes elsewhere in this Quarterly Report and our audited consolidated financial statements and the related notes and the discussion under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations” for the year ended December 31, 2022, included in our Form 10-K filed with the SEC on March 31, 2023. The MD&A is also intended to provide you with information that will assist you in understanding our consolidated financial statements, the changes in key items in those consolidated financial statements from year to year, and the primary factors that accounted for those changes. To the extent that this discussion describes prior performance, the descriptions relate only to the periods listed, which may not be indicative of our future financial outcomes. In addition to historical information, this discussion contains forward-looking statements that involve risks, uncertainties, and assumptions that could cause the Company’s financial results to differ materially from management’s expectations. Factors that could cause such differences are discussed in the “Cautionary Note Regarding Forward-Looking Statements” section of this Quarterly Report and in the “Risk Factors” section of our Form 10-K.

 

Data as of and for the three months ended March 31, 2023 and 2022, has been derived from our unaudited condensed consolidated financial statements appearing at the beginning of this Quarterly Report. Results for any interim period should not be construed as an inference of what our results would be for any full fiscal year or future period.

 

Our MD&A is organized as follows:

 

  ● Company Overview – Discussion of our business plan and strategy to provide context for the remainder of the MD&A.
     
  ● Results of Operations – Analysis of our financial results comparing the three months ended March 31, 2023, to the comparable period in 2022.
     
  ● Liquidity and Capital Resources – Analysis of changes in our cash flows, and discussion of our financial condition and potential sources of liquidity.
     
  ● Critical Accounting Policies and Use of Estimates – Accounting policies that we believe are important to understanding the assumptions and judgments incorporated in our reported financial results and forecasts.

 

Company Overview

 

Business

 

bioAffinity Technologies, Inc. (the “Company,” “we,” or “our”) develops noninvasive, early-stage diagnostics to detect lung cancer and other diseases of the lung. Our Company also is conducting early-stage research focused on advancing therapeutic discoveries that could result in broad-spectrum cancer treatments. We develop proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. Research and optimization of our platform technologies are conducted in our laboratories at The University of Texas at San Antonio.

 

Our first diagnostic test, CyPath® Lung, addresses the need for noninvasive detection of early-stage lung cancer. Lung cancer is the leading cause of cancer-related deaths. Physicians are able to order CyPath® Lung to assist in their assessment of patients who are at high risk for lung cancer. The CyPath® Lung test enables physicians to more confidently distinguish between patients who will likely benefit from timely intervention and more invasive follow-up procedures from patients who are likely without lung cancer and should continue annual screening. CyPath® Lung has the potential to increase overall diagnostic accuracy of lung cancer, which could lead to increased survival, fewer unnecessary invasive procedures, reduced patient anxiety, and lower medical costs.

 

13

 

 

Through our wholly owned subsidiary, OncoSelect® Therapeutics, LLC, our research has led to discoveries and advancement of novel cancer therapeutics that specifically and selectively target cancer cells. We are focused on expanding our broad-spectrum platform technologies to continue developing tests that detect and therapies that target various types of cancer and potentially other diseases.

 

Recent Developments

 

  ● On May 2, 2023, the Company announced that Michael Dougherty, CPA, MBA, will be the Chief Financial Officer (“CFO”) of bioAffinity Technologies. Mr. Dougherty most recently was CFO of Amazon’s Alexa AI and Voice division, where he was responsible for financial strategy over Alexa’s multi-billion-dollar investments in AI-generated customer experiences. Michael Edwards stepped down as bioAffinity CFO but continues to assist Mr. Dougherty in a consulting capacity.

 

Financial

 

To date, we have devoted a substantial portion of our efforts and financial resources to the development of our first diagnostic test, CyPath® Lung. As a result, since our inception in 2014, we have funded our operations principally through private sales of our equity or debt securities. As of March 31, 2023, we had cash and cash equivalents of $9.8 million. We believe that our available cash will be sufficient to fund our planned operations for at least 12 months following the date of this Quarterly Report.

 

In the second quarter of 2022, we started to recognize revenue from sales of the CyPath® Lung test by our licensee, Precision Pathology Services (“Precision Pathology”), a CAP-accredited, CLIA-certified clinical pathology laboratory. We have never been profitable, and as of March 31, 2023, we had total working capital of $9.4 million and an accumulated deficit of approximately $38.2 million. We expect to continue to incur significant operating losses for the foreseeable future as we continue the development of our diagnostic tests and therapeutic products and advance our diagnostic tests through clinical trials. We intend to license our therapeutic products for clinical development should animal and pre-clinical studies prove successful.

 

We anticipate raising additional cash needed through the private or public sales of equity or debt securities, collaborative arrangements, or a combination thereof, to continue to fund our operations and develop our products. There is no assurance that any such collaborative arrangement will be entered into or that financing will be available to us when needed in order to allow us to continue our operations, or if available, on terms acceptable to us. If we do not raise sufficient funds in a timely manner, we may be forced to curtail operations, delay our clinical trials, cease operations altogether, or file for bankruptcy.

 

Results of Operations

 

Three Months Ended March 31, 2023, Compared to Three Months Ended March 31, 2022

 

Net loss for the three months ended March 31, 2023, was approximately $1.5 million, compared to a net loss of approximately $1.5 million for the three months ended March 31, 2022, resulting from the operational activities described below.

 

Revenue

 

Our revenue is generated exclusively from royalties for our first diagnostic test, CyPath® Lung, from sales by Precision Pathology. Although Precision Pathology placed CyPath® Lung on its list of tests offered to physicians in second quarter 2022, there has been limited marketing of the product as we assemble a marketing team of experts focused on demonstrating the clinical value of CyPath® Lung in the marketplace. The limited test market launch in South Texas is designed to evaluate our marketing program and help us ensure each step in the care pathway – from the initial order by physicians to sputum collection and processing, to generating and delivering the patient report – is efficient and effective. This limited test market approach allows us to refine future positioning and develop strategic insight for our CyPath® Lung test before expanding to a larger market. We had revenue of approximately $1,000 during the three months ended March 31, 2023, from the sale of CyPath® Lung ‌as a laboratory developed test (“LDT”), compared to no revenue in 2022.

 

14

 

 

We expect our from CyPath® Lung revenue to continue to grow as we add physicians prescribing our diagnostic test and expand our outreach to other geographic areas. Our revenues are affected by the test volume of our products, patient adherence rates, payer mix, the levels of reimbursement, and payment patterns of payers and patients.

 

Cost of Sales

 

Cost of sales is comprised primarily of costs related to inventory production and usage and shipment of collection kits to patients and healthcare providers. The increase in cost of sales for the three months ended March 31, 2023, is primarily due to sales of our diagnostic kits during the quarter, compared to no sales in the prior year.

 

Operating Expenses

 

  

Three Months Ended

March 31,(1)

  

Change in 2023

Versus 2022

 
   2023   2022   $   % 
   (amount in thousands)         
Operating Expenses                    
Research and development  $370   $280   $90    32%
Clinical development   20    53    (33)   -62%
Selling, general and administrative   1,170    395    775    196%
Total operating expenses  $1,560   $728   $832    114%

 

(1) Represents operating expenses from our unaudited condensed consolidated financial statements for the three-month period ended March 31, 2023 and 2022, respectively. Refer to our notes to unaudited condensed consolidated financial statements for further discussion.

 

Operating expenses totaled approximately $1.5 million and $0.7 million during the three months ended March 31, 2023 and 2022, respectively. The increase in operating expenses is the result of the following factors.

 

Research and Development Expenses

 

Our research and development expenses consist primarily of expenditures for lab operations, preclinical studies, compensation, and consulting costs.

 

Research and development expenses totaled approximately $370,000 and $280,000 for the three months ended March 31, 2023, and 2022, respectively. The increase of approximately $90,000, or 32%, for the three months ended March 31, 2023, compared to the same period in 2022, was primarily due to an increase in compensation costs and benefits as we added research personnel, as well as a related increase in costs for lab supplies and reagents. Additionally, equipment costs, including depreciation and maintenance costs, increased as we purchased capital equipment to support research and development efforts.

 

Clinical Development

 

Clinical development expenses totaled approximately $20,000 and $53,000 for the three months ended March 31, 2023 and 2022, respectively. The decrease of approximately $33,000, or 62%, for the three months ended March 31, 2023, compared to the same period in 2022, was primarily attributable to a decrease in professional fees, including consulting fees, related to evaluating the clinical strategy in the prior year for our pivotal clinical trial designed to confirm the sensitivity and specificity of CyPath® Lung in detecting lung cancer in persons at high risk for the disease, including patients who display indeterminate lung nodules between 6mm and 30mm in size which often present a challenge in diagnosis.

 

15

 

 

Selling, General and Administrative

 

Our selling, general and administrative expenses consist primarily of expenditures related to employee compensation, legal, accounting and tax, other professional services, and general operating expenses.

 

Selling, general and administrative expenses totaled approximately $1.2 million and $395,000 for the three months ended March 31, 2023 and 2022, respectively. The increase of approximately $775,000, or 196%, for the three months ended March 31, 2023, compared to the same period in 2022, was primarily attributable to an increase in consulting, legal and professional fees incurred in 2023 compared to 2022 to comply with the reporting requirements of a public company, as well as an increase related to board compensation. Patent costs increased in the current year as we maintain and expand our patent portfolio to protect our diagnostic and therapeutic platforms. Additionally, compensation increased due to additional personnel and support services to support the launch of sales of our diagnostic test, CyPath® Lung.

 

Other Income (Expense)

 

   Three Months Ended   Change in 2023 
   March 31,   Versus 2022 
   2023   2022   $   % 
   (amount in thousands)         
Interest income (expense), net  $37   $(1,146)  $1,183    103%
Gain (loss) on change in fair value of convertible notes   —    404    (404)   -100%
Total other income (expense)  $37   $(742)  $779    105%

 

Other income (expense), net totaled approximately $37,000 and ($0.7) million for the three-month period ended March 31, 2023 and 2022, respectively.

 

Interest Income (Expense), net

 

Interest income (expense), net was approximately $37,000 for the three months ended March 31, 2023, compared to ($0.7) million for the three months ended March 31, 2022. The change was due to no convertible notes outstanding during the current year compared to the same period in the prior year, as substantially all convertible and bridge notes were converted as a result of our IPO in the prior year. Additionally, in 2022 the Company recorded interest expense for the amortization of debt discount related to the issuance of bridge notes.

 

Gain (loss) on change in fair value of convertible notes

 

There was a loss of approximately $0.4 million on the change in fair value of convertible notes during the three months ended March 31, 2022, compared to no loss during the three months ended March 31, 2023. The change in the fair value of convertible notes resulted primarily from changes in the calculation of the fair value of our stock, the reduction in the expected term, and other assumptions during the reported periods. Substantially all convertible and bridge notes were converted as a result of our IPO in the prior year, resulting in no additional changes in fair value related to the convertible and bridge notes.

 

Liquidity and Capital Resources

 

To date, we have funded our operations primarily through our initial public offering, exercise of warrants, and the sale of our equity and debt securities, resulting in gross proceeds of approximately $34.3 million.

 

We have incurred losses since our inception in 2014 as a result of significant expenditures for operations and research and development and, prior to April 2022, the lack of any approved diagnostic test or therapeutic products to generate revenue. For the three months ended March 31, 2023 and 2022, we had net losses of $1.5 million and $1.5 million, respectively, and we expect to incur substantial additional losses in future periods. We have an accumulated deficit of approximately $38.2 million as of March 31, 2023. Cash and cash equivalents were approximately $9.8 million as of March 31, 2023. Based on our current level of expected operating expenditures, we expect to be able to fund our operations for at least 12 months following the date of this Quarterly Report.

 

16

 

 

We continue to seek sources of financing to fund our continued operations and research and development programs. To raise additional capital, we may sell additional equity or debt securities, or enter into collaborative, strategic, and/or licensing transactions. There can be no assurance that we will be able to complete any financing transaction in a timely manner or on acceptable terms or otherwise or enter into a collaborative or strategic transaction. If we are not able to raise additional cash, we may be forced to delay, curtail, or cease development of our diagnostic tests or therapeutic products, or cease operations altogether.

 

Summary Statements of Cash Flows

 

The following information reflects cash flows for the periods presented:

 

   Three Months Ended 
   March 31, 
   2023   2022 
   (amounts in thousands) 
Cash and cash equivalents at beginning of period  $11,414   $1,361 
Net cash used in operating activities   (1,529)   (634)
Net cash used in investing activities   (32)   — 
Net cash (used in) provided by financing activities   (83)   301 
Cash and cash equivalents at end of period  $9,769   $1,028 

 

Net Cash Used in Operating Activities

 

Net cash used in operating activities was approximately $1.5 million and $0.6 million for the three months ended March 31, 2023 and 2022, respectively. The increase of approximately $0.9 million in cash used by operations during the three months ended March 31, 2023, compared to the same period in 2022, was attributable to an increase of $0.1 million in our loss from operations as compared to the prior year as described above. This increase was partially offset by fair value adjustments of approximately $1.0 million and the amortization of debt discount of $0.4 million related to the issuance of bridge notes in the prior year, as well as changes in prepaid and other assets, accounts payable and accrued interest.

 

Net Cash Used in Investing Activities

 

The Company used approximately $32,000 for the three months ended March 31, 2023, in investing activities related to the purchase of computer and lab equipment, compared to no cash used in investing activities for the three months ended March 31, 2022.

 

Net Cash Provided by Financing Activities

 

Cash used in financing activities was approximately $83,000 compared to cash provided by financing activities of approximately $0.3 million for the three months ended March 31, 2023, and 2022, respectively. The change in cash used in financing activities for the three months ended March 31, 2023, compared to 2022, was a result of the Company obtaining short-term financing for director and officer insurance policies, compared to net proceeds from bridge notes of approximately $0.5 million in the same period in the prior year, offset by the payment of deferred issuance costs related to the anticipated IPO completed in September 2022.

 

Contractual Obligations and Commitments

 

We enter into contracts in the normal course of business with third-party contract organizations for clinical trials, and other services and products used for research and development and operating purposes. These contracts generally provide for termination following a certain period after notice, and therefore we believe that any non-cancelable obligations under these agreements are not material.

 

17

 

 

Critical Accounting Policies and Use of Estimates

 

The preparation of financial statements in conformity with U.S. GAAP requires management to make significant judgments and estimates that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases these significant judgments and estimates on historical experience and other assumptions it believes to be reasonable based upon information presently available. Actual results could differ from those estimates under different assumptions, judgments or conditions.

 

Stock-Based Compensation

 

We follow ASC 718, Compensation – Stock Compensation, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, directors, and non-employees based on estimated fair values. We have used the Black-Scholes option pricing model to estimate grant date fair value for all option grants. The assumptions we use in calculating the fair value of share-based payment awards represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As such, as we use different assumptions based on a change in factors, our stock-based compensation expense could be materially different in the future.

 

Accounting for Income Taxes

 

We are governed by U.S. income tax laws, which are administered by the Internal Revenue Service (“IRS”). We follow ASC 740, Accounting for Income Taxes, which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income and the reversal of deferred tax liabilities during the period in which the related temporary difference becomes deductible.

 

Emerging Growth Company Status

 

We are both an “emerging growth company” and a “smaller reporting company” as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and are therefore subject to reduced public company reporting requirements.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

 

As a smaller reporting company, pursuant to Item 305(e) of Regulation S-K promulgated under the Securities Act, we are not required to provide the information required by this Item 3.

 

ITEM 4. CONTROLS AND PROCEDURES.

 

Evaluation of Disclosure Controls and Procedures

 

As of the end of the period covered by this Quarterly Report, our Chief Executive Officer and Chief Financial Officer evaluated the effectiveness of our “disclosure controls and procedures” (as defined in the Exchange Act) Rules 13a-15(e)and 15d-15(e)). Based on that evaluation, management has concluded that due to limited resources and limited number of employees, its internal control over financial reporting was ineffective as of March 31, 2023, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with U.S. GAAP. To mitigate the limited resources and employees, we rely heavily on direct management oversight of transactions, along with the use of legal and accounting professionals. As we grow, we expect to increase the number of employees, which we believe will enable us to implement adequate segregation of duties within the internal control framework.

 

18

 

 

Changes in Internal Control over Financial Reporting

 

There were no changes in our internal controls (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) over financial reporting during the three months ended March 31, 2023, covered by this Quarterly Report that could materially affect, or are reasonably likely to materially affect, our financial reporting.

 

PART II

 

ITEM 1. LEGAL PROCEEDINGS.

 

From time to time, the Company is involved in various disputes and litigation matters that arise in the ordinary course of business. To date, the Company has had no material pending legal proceedings, and we are not engaged in any legal proceedings that are expected, individually or in the aggregate to have a material adverse impact on our financial position or results of operations.

 

ITEM 1A. RISK FACTORS.

 

As a smaller reporting company, we are not required to provide disclosure pursuant to this Item 1A. However, in addition to other information set forth in this Quarterly Report, you should carefully consider the “Risk Factors” discussed in our Final Prospectus filed with the SEC on September 2, 2022, pursuant to Rule 424(b)(4) under the Securities Act for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in this Quarterly Report. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial might materially adversely affect our actual business, financial condition, and operating results.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

 

Unregistered Sales of Equity Securities

 

None

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

 

Not applicable.

 

ITEM 4. MINE SAFETY DISCLOSURES.

 

Not applicable.

 

ITEM 5. OTHER INFORMATION.

 

Not applicable.

 

19

 

 

ITEM 6. EXHIBITS.

 

Exhibit No.   Title of Document
     
31.1*   Certification of Chief Executive Officer pursuant to Section 302 of Sarbanes-Oxley Act of 2002
     
31.2*   Certification of Chief Financial Officer pursuant to Section 302 of Sarbanes-Oxley Act of 2002
     
32.1†   Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of Sarbanes-Oxley Act of 2002
     
101*   The following financial statements from the bioAffinity Technologies, Inc. Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, formatted in Inline XBRL: (i) Condensed Consolidated Balance Sheet, (ii) Condensed Consolidated Statement of Operations, (iii) Condensed Consolidated Statement of Stockholders’ Equity, (iv) Condensed Consolidated Statement of Cash Flows, and (v) Notes to Condensed Consolidated Financial Statements, tagged as blocks of text and including detailed tags.
     
104*   The cover page from the bioAffinity Technologies, Inc. Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, formatted in Inline XBRL
     
101.INS   Inline XBRL Instance Document *
     
101.SCH   Inline XBRL Taxonomy Extension Schema Document *
     
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase *
     
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document *
     
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document *
     
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document *

 

* Filed herewith.

† Furnished herewith.

 

20

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  bioAffinity Technologies, Inc.
  (Registrant)
   
  By: /s/ Maria Zannes
    Maria Zannes
    Chief Executive Officer, President, Founder, and Director
   
  By: /s/ Michael Dougherty
    Vice President and Chief Financial Officer

 

21

 EX-31.1 2 ex31-1.htm

 

Exhibit 31.1

 

Certification

For the Quarterly Period Ended March 31, 2023

 

I, Maria Zannes, certify that:

 

1. I have reviewed this report on Form 10-Q of bioAffinity Technologies, Inc. (“registrant”);
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

 

  (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  (b) [intentionally omitted];
     
  (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: May 15, 2023

 

  /s/ Maria Zannes
  Maria Zannes
  President and Chief Executive Officer

 

 

 EX-31.2 3 ex31-2.htm

 

Exhibit 31.2

 

Certification

For the Quarterly Period Ended March 31, 2023

 

I, Michael Dougherty, certify that:

 

1. I have reviewed this report on Form 10-Q of bioAffinity Technologies, Inc. (“registrant”);
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

 

  (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  (b) [intentionally omitted];
     
  (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: May 15, 2023

 

  /s/ Michael Dougherty
  Michael Dougherty
  Vice President and Chief Financial Officer

 

 

 EX-32.1 4 ex32-1.htm

 

Exhibit 32.1

 

Certification Pursuant to

18 U.S.C. Section 1350

As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

In connection with the Quarterly Report on Form 10-Q of bioAffinity Technologies, Inc., a Delaware Corporation (“Company”), for the period ended March 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (“Report”), each of the undersigned officers of the Company hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of such officer’s knowledge:

 

  1) the Report complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
     
  2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of March 31, 2023 (the last date of the period covered by the Report).

 

  /s/ Maria Zannes
  Maria Zannes
  President and Chief Executive Officer
  Date: May 15, 2023
   
  /s/ Michael Dougherty
  Michael Dougherty
  Vice President and Chief Financial Officer
  Date: May 15, 2023

 

 

 EX-101.SCH 5 biaf-20230331.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - NATURE OF OPERATIONS, ORGANIZATION, AND BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - PROPERTY AND EQUIPMENT, NET link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - ACCRUED EXPENSES link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - LOAN PAYABLE link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - FAIR VALUE MEASUREMENTS link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - WARRANTS link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - ACCRUED EXPENSES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - STOCK-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - NATURE OF OPERATIONS, ORGANIZATION, AND BASIS OF PRESENTATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - SCHEDULE OF ACCRUED EXPENSES (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - LOAN PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - SUMMARY OF STOCK-BASED COMPENSATION EXPENSE RECOGNIZED FOR STOCK OPTION AWARDS (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - SUMMARY OF OPTION ACTIVITY (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - SCHEDULE OF FAIR VALUE ASSUMPTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - WARRANTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 biaf-20230331_cal.xml XBRL CALCULATION FILE EX-101.DEF 7 biaf-20230331_def.xml XBRL DEFINITION FILE EX-101.LAB 8 biaf-20230331_lab.xml XBRL LABEL FILE Class of Stock [Axis] Common Stock, Par Value $.007 per share Tradeable Warrants to Purchase Common Stock Equity Components [Axis] Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Convertible Preferred Stock [Member] Income Statement Location [Axis] Selling, General and Administrative Expenses [Member] Revision of Prior Period [Axis] Revision of Prior Period, Adjustment [Member] Antidilutive Securities [Axis] Share-Based Payment Arrangement, Option [Member] Warrant [Member] Convertible Debt Securities [Member] Long-Lived Tangible Asset [Axis] Lab Equipment [Member] Computer And Software [Member] Debt Instrument [Axis] Short-Term Debt [Member] Series A Preferred Stock [Member] Sale of Stock [Axis] Private Placement [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Award Type [Axis] Restricted Stock Units (RSUs) [Member] Research and Development Expense [Member] Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] ASSETS Current assets: Cash and cash equivalents Accounts and other receivables, net Inventory Prepaid and other current assets Total current assets Property and equipment, net Other assets Total assets LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable Accrued expenses Loan payable Total current liabilities Total liabilities Commitments and contingencies (See Note 8) Stockholders’ equity: Preferred stock, par value $0.001 per share; 20,000,000 shares authorized; no shares issued or outstanding at March 31, 2023, and December 31, 2022 Common stock, par value $0.007 per share; 14,285,714 shares authorized; 8,463,052 issued and outstanding at March 31, 2023; and 8,381,324 shares issued and outstanding at December 31, 2022 Additional paid-in capital Accumulated deficit Total stockholders’ equity Total liabilities and stockholders’ equity Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenue Cost of sales Gross profit Operating expenses: Research and development Clinical development Selling, general and administrative Total operating expenses Loss from operations Other income (expense): Interest income (expense), net Fair value adjustments on convertible notes payable Loss before income taxes Income tax expense Net loss Net loss per common share, basic and diluted Weighted average common shares outstanding Balance, value Balance, shares Stock-based compensation expense Stock-based compensation expense, shares Net loss Beneficial conversion feature for bridge notes Debt discount for warrants issued Balance, value Balance, shares Statement of Cash Flows [Abstract] Cash flows from operating activities Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization Accretion of debt issuance costs Fair value adjustments on convertible notes payable Stock-based compensation expense Changes in operating assets and liabilities: Accounts and other receivables Inventory Prepaid expenses and other assets Accounts payable Accrued expenses Accrued interest Net cash used in operating activities Cash flows from investing activities Purchase of equipment Net cash used in investing activities Cash flows from financing activities Payment on loan payable Proceeds from issuance of convertible notes payable Payment of deferred offering costs Payment of debt issuance costs Net cash (used in) provided by financing activities Net decrease in cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Supplemental disclosures of cash flow information: Income taxes paid in cash Interest expense paid in cash Noncash financing activities: Fair value of warrants issued to placement agents Beneficial conversion feature for bridge notes Organization, Consolidation and Presentation of Financial Statements [Abstract] NATURE OF OPERATIONS, ORGANIZATION, AND BASIS OF PRESENTATION Accounting Policies [Abstract] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Prepaid Expenses And Other Current Assets PREPAID EXPENSES AND OTHER CURRENT ASSETS Property, Plant and Equipment [Abstract] PROPERTY AND EQUIPMENT, NET Payables and Accruals [Abstract] ACCRUED EXPENSES Debt Disclosure [Abstract] LOAN PAYABLE Fair Value Disclosures [Abstract] FAIR VALUE MEASUREMENTS Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Equity [Abstract] CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT Share-Based Payment Arrangement [Abstract] STOCK-BASED COMPENSATION Warrants WARRANTS Subsequent Events [Abstract] SUBSEQUENT EVENTS Use of Estimates Principles of Consolidation Advertising expense Loss Per Share Revenue Recognition Reclassifications Recent Accounting Pronouncements SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS SCHEDULE OF PROPERTY AND EQUIPMENT SCHEDULE OF ACCRUED EXPENSES SUMMARY OF STOCK-BASED COMPENSATION EXPENSE RECOGNIZED FOR STOCK OPTION AWARDS SUMMARY OF OPTION ACTIVITY SCHEDULE OF FAIR VALUE ASSUMPTIONS Accumulated deficit Total assets, percent Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Anti-dilutive securities Advertising expense Patent and annuity costs Schedule Of Prepaid Expenses And Other Current Assets Prepaid insurance Legal and professional Other Total prepaid expenses and other current assets Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Property and equipment, gross Accumulated depreciation Total property and equipment, net Depreciation Compensation Legal and professional Clinical Other Total accrued expenses Schedule of Short-Term Debt [Table] Short-Term Debt [Line Items] Loan payment term Loan periodic payment amount Loan interest rate Rent expense Schedule of Stock by Class [Table] Class of Stock [Line Items] Reverse stock split Preferred stock par value Proceeds from issuance of private placement Net proceeds Shares issued for exchange of notes payable and accrued interest Number of shares issued in debt conversion Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Total stock-based compensation expense Options Outstanding, beginning balance Weighted-Average Exercise Price Outstanding, beginning balance Options Granted Weighted-Average Exercise Price, Granted Options Exercised Weighted-Average Exercise Price, Exercised Options, Forfeited Weighted-Average Exercise Price,Forfeited Options Outstanding, ending balance Weighted-Average Exercise Price Outstanding, ending balance Weighted- Average Remaining Contractual Term, Outstanding Aggregate Intrinsic Value Outstanding, ending balance Options, Vested and exercisable Weighted-Average Exercise Price, Vested and exercisable Weighted- Average Remaining Contractual Term, Vested and exercisable Aggregate Intrinsic Value, Vested and exercisable Fair value of Common Stock Volatility Expected term (in years) Risk-free interest rate Dividend yield Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Grant option, outstanding Shares reserved Unrecognized compensation Options exercised, shares Grant date fair value of options granted Weighted-average grant date fair value of options granted Unissued shares Warrant outstanding Weighted average exercise price Exercise of warrants Tradeable Warrants to Purchase Common Stock [Member] Common Stock, Par Value $.007 per share [Member] Prepaid Expenses And Other Current Assets [Text Block] Schedule of Prepaid Expenses And Other Current Assets [Table Text Block] Prepaid legal and professional. Accrued clinical expense current. Clinical development expense. Fair value adjustments on convertible notes payable. Warrants Disclosure [Text Block] Fair value of warrants issued. Beneficial conversion feature for bridge notes. Payment of deferred offering costs. Total assets, percent. Share based compensation arrangement by share based payment non options outstanding period increase decrease weighted average exercise price. Assets, Current Assets Liabilities, Current Liabilities Equity, Attributable to Parent Liabilities and Equity Gross Profit Operating Expenses Operating Income (Loss) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Shares, Outstanding Share-Based Payment Arrangement, Noncash Expense Increase (Decrease) in Accounts and Other Receivables Increase (Decrease) in Inventories Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Accounts Payable Increase (Decrease) in Accrued Liabilities Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities Repayments of Bank Debt PaymentOfDeferredOfferingCosts Payments of Debt Issuance Costs Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations BeneficialConversionFeatureForBridgeNotes Advertising Expense Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Accrued Professional Fees, Current Other Accrued Liabilities, Current Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value EX-101.PRE 9 biaf-20230331_pre.xml XBRL PRESENTATION FILE XML 10 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover - shares
 3 Months Ended
Mar. 31, 2023
May 12, 2023
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Mar. 31, 2023  
Document Fiscal Period Focus Q1  
Document Fiscal Year Focus 2023  
Current Fiscal Year End Date --12-31  
Entity File Number 001-41463  
Entity Registrant Name bioAffinity Technologies, Inc.  
Entity Central Index Key 0001712762  
Entity Tax Identification Number 46-5211056  
Entity Incorporation, State or Country Code DE  
Entity Address, Address Line One 22211 W. Interstate 10  
Entity Address, Address Line Two Suite 1206  
Entity Address, City or Town San Antonio  
Entity Address, State or Province TX  
Entity Address, Postal Zip Code 78257  
City Area Code (210)  
Local Phone Number 698-5334  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Elected Not To Use the Extended Transition Period false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   8,518,981
Common Stock, Par Value $.007 per share    
Title of 12(b) Security Common Stock, par value $.007 per share  
Trading Symbol BIAF  
Security Exchange Name NASDAQ  
Tradeable Warrants to Purchase Common Stock    
Title of 12(b) Security Tradeable Warrants to purchase Common Stock  
Trading Symbol BIAFW  
Security Exchange Name NASDAQ  
XML 11 R2.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
Mar. 31, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 9,769,088 $ 11,413,759
Accounts and other receivables, net 11,027 10,489
Inventory 11,335 5,540
Prepaid and other current assets 441,132 531,899
Total current assets 10,232,582 11,961,687
Property and equipment, net 225,067 214,438
Other assets 6,920 6,000
Total assets 10,464,569 12,182,125
Current liabilities:    
Accounts payable 146,537 345,042
Accrued expenses 481,336 541,894
Loan payable 168,430 251,746
Total current liabilities 796,303 1,138,682
Total liabilities 796,303 1,138,682
Commitments and contingencies (See Note 8)
Stockholders’ equity:    
Preferred stock, par value $0.001 per share; 20,000,000 shares authorized; no shares issued or outstanding at March 31, 2023, and December 31, 2022
Common stock, par value $0.007 per share; 14,285,714 shares authorized; 8,463,052 issued and outstanding at March 31, 2023; and 8,381,324 shares issued and outstanding at December 31, 2022 59,241 58,669
Additional paid-in capital 47,809,283 47,652,242
Accumulated deficit (38,200,258) (36,667,468)
Total stockholders’ equity 9,668,266 11,043,443
Total liabilities and stockholders’ equity $ 10,464,569 $ 12,182,125
XML 12 R3.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares
Mar. 31, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]    
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares authorized 20,000,000 20,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock par value $ 0.007 $ 0.007
Common stock, shares authorized 14,285,714 14,285,714
Common stock, shares issued 8,463,052 8,381,324
Common stock, shares outstanding 8,463,052 8,381,324
XML 13 R4.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Income Statement [Abstract]    
Revenue $ 921
Cost of sales 87
Gross profit 834
Operating expenses:    
Research and development 369,617 279,848
Clinical development 19,628 52,503
Selling, general and administrative 1,169,559 394,692
Total operating expenses 1,558,804 727,043
Loss from operations (1,557,970) (727,043)
Other income (expense):    
Interest income (expense), net 36,999 (1,147,012)
Fair value adjustments on convertible notes payable 404,194
Loss before income taxes (1,520,971) (1,469,861)
Income tax expense 11,819 2,159
Net loss $ (1,532,790) $ (1,472,020)
Net loss per common share, basic and diluted $ (0.18) $ (0.55)
Weighted average common shares outstanding 8,433,689 2,681,221
XML 14 R5.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($)
Preferred Stock [Member]
Preferred Stock [Member]
Convertible Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Balance, value at Dec. 31, 2021   $ 4,044,318 $ 18,740 $ 12,703,896 $ (28,513,355) $ (15,790,719)
Balance, shares at Dec. 31, 2021   756,558 2,677,140      
Stock-based compensation expense   $ 110 105,937 106,047
Stock-based compensation expense, shares     15,772      
Net loss   (1,472,020) (1,472,020)
Beneficial conversion feature for bridge notes   213,942 213,942
Debt discount for warrants issued   217,973 217,973
Balance, value at Mar. 31, 2022   $ 4,044,318 $ 18,850 13,241,748 (29,985,375) (16,724,777)
Balance, shares at Mar. 31, 2022   756,558 2,692,912      
Balance, value at Dec. 31, 2022   $ 58,669 47,652,242 (36,667,468) 11,043,443
Balance, shares at Dec. 31, 2022   8,381,324      
Stock-based compensation expense   $ 572 157,041 157,613
Stock-based compensation expense, shares     81,728      
Net loss   (1,532,790) (1,532,790)
Balance, value at Mar. 31, 2023   $ 59,241 $ 47,809,283 $ (38,200,258) $ 9,668,266
Balance, shares at Mar. 31, 2023     8,463,052      
XML 15 R6.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Cash flows from operating activities    
Net loss $ (1,532,790) $ (1,472,020)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 21,685 1,039
Accretion of debt issuance costs 978,217
Fair value adjustments on convertible notes payable (404,194)
Stock-based compensation expense 157,613 106,047
Changes in operating assets and liabilities:    
Accounts and other receivables (538) (5,331)
Inventory (5,795) (5,803)
Prepaid expenses and other assets 89,847 11,143
Accounts payable (198,505) 17,284
Accrued expenses (60,558) (29,649)
Accrued interest 169,300
Net cash used in operating activities (1,529,041) (633,967)
Cash flows from investing activities    
Purchase of equipment (32,314)
Net cash used in investing activities (32,314)
Cash flows from financing activities    
Payment on loan payable (83,316)
Proceeds from issuance of convertible notes payable 475,000
Payment of deferred offering costs (117,986)
Payment of debt issuance costs (55,651)
Net cash (used in) provided by financing activities (83,316) 301,363
Net decrease in cash and cash equivalents (1,644,671) (332,604)
Cash and cash equivalents at beginning of period 11,413,759 1,360,638
Cash and cash equivalents at end of period 9,769,088 1,028,034
Supplemental disclosures of cash flow information:    
Income taxes paid in cash 11,819 2,159
Interest expense paid in cash 1,655
Noncash financing activities:    
Fair value of warrants issued to placement agents 217,973
Beneficial conversion feature for bridge notes $ 213,942
XML 16 R7.htm IDEA: XBRL DOCUMENT v3.23.1
NATURE OF OPERATIONS, ORGANIZATION, AND BASIS OF PRESENTATION
 3 Months Ended
Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
NATURE OF OPERATIONS, ORGANIZATION, AND BASIS OF PRESENTATION

Note 1. NATURE OF OPERATIONS, ORGANIZATION, AND BASIS OF PRESENTATION

 

Description of Business

 

bioAffinity Technologies, Inc., a Delaware corporation (the “Company,” “we,” or “our”), addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung. Our Company also is conducting early-stage research focused on advancing therapeutic discoveries that could result in broad-spectrum cancer treatments. bioAffinity Technologies develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. Our first diagnostic test, CyPath® Lung, is a noninvasive test for early detection of lung cancer, the leading cause of cancer-related deaths. Research and optimization of our proprietary platform for in vitro diagnostics and technologies are conducted in our laboratories at The University of Texas at San Antonio. We are developing our platform technologies so that in the future, they will be able to detect, monitor, and treat diseases of the lung and other cancers.

 

Organization

 

The Company was formed on March 26, 2014, as a Delaware corporation with its corporate offices located in San Antonio, Texas. On June 15, 2016, the Company formed a wholly owned subsidiary, OncoSelect® Therapeutics, LLC, as a Delaware limited liability company.

 

Basis of Presentation

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) and pursuant to the rules and regulations of the SEC for interim financial reporting. The condensed consolidated financial statements are unaudited, and in management’s opinion include all adjustments, including normal recurring adjustments and accruals, necessary for a fair presentation of the results for the interim periods presented. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the fiscal year ended December 31, 2023, or any future period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited annual consolidated financial statements and notes included in the Company’s Form 10-K filed with the SEC on March 31, 2023.

 

In accordance with Accounting Standards Update (“ASU”) 2014-15, Presentation of Financial Statements – Going Concern (Subtopic 205-40), the Company has evaluated whether there are conditions and events that raise substantial doubt about the Company’s ability to continue as a going concern for at least one year after the date the condensed consolidated financial statements are issued.

 

The Company has incurred significant losses and negative cash flows from operations since inception and expects to continue to incur losses and negative cash flows for the foreseeable future. As a result, the Company had an accumulated deficit of $38.2 million at March 31, 2023. The Company’s cash and cash equivalents at March 31, 2023, were approximately $9.8 million, representing 93% of total assets. Based on the Company’s current expected level of operating expenditures, the Company believes its cash on hand at March 31, 2023, is sufficient to fund the Company’s ongoing operations for a period of a least twelve (12) months subsequent to the issuance of the accompanying unaudited condensed consolidated financial statements. Thereafter, the Company may need to raise further capital through the sale of additional equity or debt securities or other debt instruments, strategic relationships or grants, or other arrangements to support its future operations. If such funding is not available or not available on terms acceptable to the Company, the Company’s current development plan may be curtailed.

 

COVID-19

 

The rapid global spread of the COVID-19 virus since December 2019 has affected production and sales worldwide, disrupted supply chains across a range of industries, and created significant economic volatility. The impact of COVID-19 on the Company’s operational and financial performance will depend on numerous factors, including the spread, duration, and intensity of the pandemic (including resurgences), the emergence of new viral variants, and the impact of the pandemic on the Company’s customers, employees, clinical trial sites, and vendors.

 

 

As the COVID-19 pandemic continues to evolve, the ultimate impact of the pandemic on the Company’s operations is highly uncertain and subject to change and will depend on future developments, which cannot be accurately predicted, including the duration of the pandemic, additional or modified government actions, and the actions taken to contain COVID-19 or address its impact, among others. Management does not yet know the full extent of potential delays or impacts on the Company, clinical trials, research programs, healthcare systems, or the global economy but continues to monitor the situation closely.

 
XML 17 R8.htm IDEA: XBRL DOCUMENT v3.23.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 3 Months Ended
Mar. 31, 2023
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Note 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Use of Estimates

 

The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include: the valuation allowance on the Company’s deferred tax assets; the useful lives of fixed assets; and the fair value of the convertible notes payable.

 

Principles of Consolidation

 

The accompanying condensed consolidated financial statements include all of the accounts of the Company and its wholly owned subsidiary, OncoSelect® Therapeutics, LLC. All significant intercompany balances and transactions have been eliminated.

 

Advertising expense

 

The Company expenses all advertising costs as incurred. Advertising expense was approximately $6,000 and $3,000 for the three months ended March 31, 2023 and 2022, respectively.

 

Loss Per Share

 

Basic earnings (loss) per share is computed by dividing net income (loss) attributable to common stockholders by the weighted-average number of Common Shares outstanding during the period. Diluted earnings per share is computed by dividing net income attributable to common stockholders by the sum of the weighted-average number of Common Shares outstanding during the period and the weighted-average number of dilutive Common Share equivalents outstanding during the period, using the treasury stock method. Dilutive Common Share equivalents are comprised of in-the-money stock options, convertible notes payable, and warrants based on the average stock price for each period using the treasury stock method.

 

The following potentially dilutive securities have been excluded from the computations of weighted average shares outstanding as of March 31, 2023 and 2022, as they would be anti-dilutive:

 

   2023   2022 
   As of March 31, 
   2023   2022 
Convertible preferred stock   —    756,558 
Shares underlying options outstanding   806,392    884,094 
Shares underlying warrants outstanding   4,649,952    2,057,740 
Shares underlying convertible notes   —    2,511,345 
Anti-dilutive securities   5,556,344    6,209,737 

 

 

Revenue Recognition

 

Revenue is generated exclusively from royalties for the Company’s first diagnostic test, CyPath® Lung, from sales by Precision Pathology Services, a CAP-accredited, CLIA-certified clinical pathology laboratory and the Company’s licensee, that began a limited market launch in the second quarter of 2022 to pulmonologists in the South Texas area, designed to refine future positioning and develop strategic insight for the Company’s CyPath® Lung test. The services are completed upon release of a patient’s test result to the ordering healthcare provider.

 

To determine revenue recognition for the arrangements that the Company determines are within the scope of ASC 606, Revenue from Contracts with Customers, the Company performs the following five steps: (1) identify the contract(s) with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract and (5) recognize revenue when (or as) the entity satisfies a performance obligation.

 

Reclassifications

 

Certain prior year balances have been reclassified to conform to current year presentation. The Company reclassified patent expenses and annuity costs of approximately $42,000 from research and development to selling, general and administrative for the three months ended March 31, 2022, respectively.

 

Recent Accounting Pronouncements

 

The Company continues to monitor new accounting pronouncements issued by the Financial Accounting Standards Board (“FASB”) and does not believe any accounting pronouncements issued through the date of this report will have a material impact on the Company’s condensed consolidated financial statements.

 
XML 18 R9.htm IDEA: XBRL DOCUMENT v3.23.1
PREPAID EXPENSES AND OTHER CURRENT ASSETS
 3 Months Ended
Mar. 31, 2023
Prepaid Expenses And Other Current Assets  
PREPAID EXPENSES AND OTHER CURRENT ASSETS

Note 3. PREPAID EXPENSES AND OTHER CURRENT ASSETS

 

Prepaid expenses and other current assets are summarized below:

   March 31, 2023   December 31, 2022 
         
Prepaid insurance  $222,742   $340,078 
Legal and professional   84,077    72,048 
Other   134,313    119,773 
Total prepaid expenses and other current assets  $441,132   $531,899 

 
XML 19 R10.htm IDEA: XBRL DOCUMENT v3.23.1
PROPERTY AND EQUIPMENT, NET
 3 Months Ended
Mar. 31, 2023
Property, Plant and Equipment [Abstract]  
PROPERTY AND EQUIPMENT, NET

Note 4. PROPERTY AND EQUIPMENT, NET

 

Property and equipment are summarized below:

 

   March 31, 2023   December 31, 2022 
         
Lab equipment  $488,718   $462,155 
Computers and software   27,214    21,463 
Property and equipment, gross   515,932    483,618 
Accumulated depreciation   (290,865)   (269,180)
Total property and equipment, net  $225,067   $214,438 

 

Depreciation expense was approximately $22,000 and $1,000 for the three months ended March 31, 2023 and 2022, respectively.

 

 
XML 20 R11.htm IDEA: XBRL DOCUMENT v3.23.1
ACCRUED EXPENSES
 3 Months Ended
Mar. 31, 2023
Payables and Accruals [Abstract]  
ACCRUED EXPENSES

Note 5. ACCRUED EXPENSES

 

Accrued expenses are summarized below:

   March 31, 2023   December 31, 2022 
         
Compensation  $281,085   $340,680 
Legal and professional   131,819    144,440 
Clinical   58,262    50,922 
Other   10,170    5,852 
Total accrued expenses  $481,336   $541,894 

 
XML 21 R12.htm IDEA: XBRL DOCUMENT v3.23.1
LOAN PAYABLE
 3 Months Ended
Mar. 31, 2023
Debt Disclosure [Abstract]  
LOAN PAYABLE

Note 6. LOAN PAYABLE

 

In September 2022, the Company obtained short-term financing of approximately $0.5 million with ten monthly payments of approximately $42,000 and interest at a 4.3% fixed annual rate for director and officer insurance policies.

 
XML 22 R13.htm IDEA: XBRL DOCUMENT v3.23.1
FAIR VALUE MEASUREMENTS
 3 Months Ended
Mar. 31, 2023
Fair Value Disclosures [Abstract]  
FAIR VALUE MEASUREMENTS

Note 7. FAIR VALUE MEASUREMENTS

 

The Company analyzes all financial instruments with features of both liabilities and equity under the FASB accounting standard for such instruments. Under this standard, financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.

 

The estimated fair value of certain financial instruments, including cash and cash equivalents, accounts and other receivables, prepaid and other current assets, accounts payable, accrued expenses and loan payable, are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments.

 
XML 23 R14.htm IDEA: XBRL DOCUMENT v3.23.1
COMMITMENTS AND CONTINGENCIES
 3 Months Ended
Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES

Note 8. COMMITMENTS AND CONTINGENCIES

 

Operating Leases

 

The Company leases its corporate offices under a month-to-month agreement and leases its laboratory and additional office space under an operating lease that is renewable annually by written notice by the Company and will require renewal in February 2024. Rent expense for office and lab space amounted to approximately $26,000 and $13,000 for each of the three months ended March 31, 2023 and 2022, respectively.

 

Legal Matters

 

From time to time, the Company is involved in various disputes and litigation matters that arise in the ordinary course of business. To date, the Company has no material pending legal proceedings.

 
XML 24 R15.htm IDEA: XBRL DOCUMENT v3.23.1
CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT
 3 Months Ended
Mar. 31, 2023
Equity [Abstract]  
CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT

Note 9. CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT

 

In June 2022, the Company completed a 1-for-7 reverse stock split of its Common Stock. All share and per share amounts have been adjusted on a retroactive basis in these condensed consolidated financial statements to reflect the effect of the reverse stock split. The Company made a cash payment to stockholders for all fractional shares that it would otherwise be required to issue as a result of the stock split. In addition, the stock split resulted in the par value of the Company’s Common Stock increasing to $0.007 per share.

 

Convertible Preferred Stock

 

The Company has authorized a total of 20,000,000 shares of preferred stock, $0.001 par value per share. Prior to the initial public offering (“IPO”), the Company issued 5,296,044 shares of preferred stock, designated as Series A. In July 2017, the Company completed a private placement of securities in which 1.3 million shares of Series A Preferred Stock were sold, resulting in net proceeds of $1.5 million. As part of the closing, the Company issued 4.0 million shares of Series A Preferred Stock in exchange for $2.6 million of the Company’s convertible notes payable and related accrued interest.

 

 

In accordance with the Certificate of Designation of the Series A Preferred Stock, all of the shares of Series A Preferred Stock that were issued and outstanding at the time of the IPO closing were automatically converted into 745,558 fully paid and nonassessable shares of Common Stock at a 1-for-7 conversion rate (as adjusted for the 1-for-7 reverse stock split). The shares of Series A Preferred Stock that were so converted ceased to be part of the Company’s authorized stock and will never again be issued by the Company. As of March 31, 2023, and December 31, 2022, no Preferred Stock was outstanding.

 

Common Stock

 

The Company has authorized a total of 14,285,714 shares of Common Stock, $0.007 par value per share. In November 2021, the Company received stockholder approval to increase the number of authorized shares from 7,142,857 shares to 14,285,714 shares. The Company has issued 8,463,052 shares of Common Stock as of March 31, 2023, and 8,381,324 shares of Common Stock as of December 31, 2022.

 
XML 25 R16.htm IDEA: XBRL DOCUMENT v3.23.1
STOCK-BASED COMPENSATION
 3 Months Ended
Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]  
STOCK-BASED COMPENSATION

Note 10. STOCK-BASED COMPENSATION

 

The Company grants options under its 2014 Equity Incentive Plan (the “Plan”). Under the Plan, the Company is authorized to grant options for up to 1.1 million shares of Common Stock. The Company has reserved 1.0 million shares to be used under the Plan. Options may be granted to employees, the Company’s board of directors, and external consultants who provide services to the Company. Options granted under the Plan have vesting schedules with terms of one to three years and become fully exercisable based on specific terms imposed at the date of grant. The Plan will terminate according to the respective terms of the Plan in September 2026.

 

The Company has recorded stock-based compensation expense (credit) related to the issuance of stock option awards in the following line items in the accompanying condensed consolidated statement of operations:

 

   2023   2022 
   Three Months Ended
March 31,		 
   2023   2022 
         
Research and development  $11,268   $4,643 
General and administrative   146,345    101,404 
Total stock-based compensation expense  $157,613   $106,047 

 

The following table summarizes stock option activity under the Plan:

 

   Number of
options		   Weighted-average
exercise price		   Weighted-average
remaining
contractual term
(in years)		   Aggregate
intrinsic value		 
Outstanding at December 31, 2022   806,392   $4.33           
Granted   —    —           
Exercised   —    —           
Forfeited   —    —           
Outstanding at March 31, 2023   806,392   $4.33    3.8   $271,298 
                     
Vested and exercisable at March 31, 2023   803,218   $4.31    3.7   $271,298 

 

 

As of March 31, 2023, there was no unrecognized compensation cost related to non-vested stock options. During the three months ended March 31, 2023 and 2022, no options were exercised. During the three months ended March 31, 2023, no options were issued by the Company to purchase shares of Common Stock. During the three months ended March 31, 2022, the Company issued options to purchase 7,142 shares of Common Stock. The per share weighted-average fair value of the options granted during 2022 was estimated at $2.84 on the date of grant.

 

During the three months ended March 31, 2023, the Company issued restricted stock units (RSUs) for 64,016 shares of Common Stock to employees, non-employees and the board of directors. The shares vest in equal monthly installments over terms of between immediately up to one year, subject to the employees and non-employees providing continuous service through the vesting date. During the three months ended March 31, 2023, approximately 82,000 shares vested from RSUs previously issued.

 

During the three months ended March 31, 2022, the Company issued RSUs for 14,999 shares of Common Stock to employees and non-employees. The shares vest in equal monthly installments over terms of between immediately up to one year, subject to the employees and non-employees providing continuous service through the vesting date. During the three months ended March 31, 2022, approximately 16,000 shares vested from RSUs previously issued.

 

The following table summarizes weighted-average assumptions using the Black-Scholes option-pricing model used on the date of the grants issued during the three months ended March 31, 2022:

 

   2022 
Fair value of Common Stock  $4.62 
Volatility   63.9%
Expected term (years)   6.0 
Risk-free interest rate   2.20%
Dividend yield   0%

 
XML 26 R17.htm IDEA: XBRL DOCUMENT v3.23.1
WARRANTS
 3 Months Ended
Mar. 31, 2023
Warrants  
WARRANTS

Note 11. WARRANTS

 

We account for Common Stock warrants as either equity instruments or derivative liabilities depending on the specific terms of the warrant agreement. Warrants are accounted for as derivative liabilities if the warrants allow for cash settlement or provide for modification of the warrant exercise price in the event subsequent sales of Common Stock by the Company are at a lower price per share than the then-current warrant exercise price. We classify derivative warrant liabilities on the condensed consolidated balance sheet at fair value, and changes in fair value during the periods presented in the condensed consolidated statement of operations, which is revalued at each balance sheet date subsequent to the initial issuance of the stock warrant.

 

As of March 31, 2023, and December 31, 2022, the Company had 4,649,952 warrants outstanding to purchase one share of the Company’s Common Stock for each warrant at a weighted average exercise price of $6.39 and expire at various dates through September 2027. During the three months ended March 31, 2023 and 2022, no warrants were exercised into an equivalent number of Common Shares.

 
XML 27 R18.htm IDEA: XBRL DOCUMENT v3.23.1
SUBSEQUENT EVENTS
 3 Months Ended
Mar. 31, 2023
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS

Note 12. SUBSEQUENT EVENTS

 

The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the condensed consolidated financial statements were available to be issued. Based upon this review, the Company did not identify any subsequent events that would have required adjustment or disclosure in the condensed consolidated financial statements.
XML 28 R19.htm IDEA: XBRL DOCUMENT v3.23.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
 3 Months Ended
Mar. 31, 2023
Accounting Policies [Abstract]  
Use of Estimates

Use of Estimates

 

The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include: the valuation allowance on the Company’s deferred tax assets; the useful lives of fixed assets; and the fair value of the convertible notes payable.

 
Principles of Consolidation

Principles of Consolidation

 

The accompanying condensed consolidated financial statements include all of the accounts of the Company and its wholly owned subsidiary, OncoSelect® Therapeutics, LLC. All significant intercompany balances and transactions have been eliminated.

 
Advertising expense

Advertising expense

 

The Company expenses all advertising costs as incurred. Advertising expense was approximately $6,000 and $3,000 for the three months ended March 31, 2023 and 2022, respectively.

 
Loss Per Share

Loss Per Share

 

Basic earnings (loss) per share is computed by dividing net income (loss) attributable to common stockholders by the weighted-average number of Common Shares outstanding during the period. Diluted earnings per share is computed by dividing net income attributable to common stockholders by the sum of the weighted-average number of Common Shares outstanding during the period and the weighted-average number of dilutive Common Share equivalents outstanding during the period, using the treasury stock method. Dilutive Common Share equivalents are comprised of in-the-money stock options, convertible notes payable, and warrants based on the average stock price for each period using the treasury stock method.

 

The following potentially dilutive securities have been excluded from the computations of weighted average shares outstanding as of March 31, 2023 and 2022, as they would be anti-dilutive:

 

   2023   2022 
   As of March 31, 
   2023   2022 
Convertible preferred stock   —    756,558 
Shares underlying options outstanding   806,392    884,094 
Shares underlying warrants outstanding   4,649,952    2,057,740 
Shares underlying convertible notes   —    2,511,345 
Anti-dilutive securities   5,556,344    6,209,737 

 

 
Revenue Recognition

Revenue Recognition

 

Revenue is generated exclusively from royalties for the Company’s first diagnostic test, CyPath® Lung, from sales by Precision Pathology Services, a CAP-accredited, CLIA-certified clinical pathology laboratory and the Company’s licensee, that began a limited market launch in the second quarter of 2022 to pulmonologists in the South Texas area, designed to refine future positioning and develop strategic insight for the Company’s CyPath® Lung test. The services are completed upon release of a patient’s test result to the ordering healthcare provider.

 

To determine revenue recognition for the arrangements that the Company determines are within the scope of ASC 606, Revenue from Contracts with Customers, the Company performs the following five steps: (1) identify the contract(s) with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract and (5) recognize revenue when (or as) the entity satisfies a performance obligation.

 
Reclassifications

Reclassifications

 

Certain prior year balances have been reclassified to conform to current year presentation. The Company reclassified patent expenses and annuity costs of approximately $42,000 from research and development to selling, general and administrative for the three months ended March 31, 2022, respectively.

 
Recent Accounting Pronouncements

Recent Accounting Pronouncements

 

The Company continues to monitor new accounting pronouncements issued by the Financial Accounting Standards Board (“FASB”) and does not believe any accounting pronouncements issued through the date of this report will have a material impact on the Company’s condensed consolidated financial statements.
XML 29 R20.htm IDEA: XBRL DOCUMENT v3.23.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
 3 Months Ended
Mar. 31, 2023
Accounting Policies [Abstract]  
SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES

The following potentially dilutive securities have been excluded from the computations of weighted average shares outstanding as of March 31, 2023 and 2022, as they would be anti-dilutive:

 

   2023   2022 
   As of March 31, 
   2023   2022 
Convertible preferred stock   —    756,558 
Shares underlying options outstanding   806,392    884,094 
Shares underlying warrants outstanding   4,649,952    2,057,740 
Shares underlying convertible notes   —    2,511,345 
Anti-dilutive securities   5,556,344    6,209,737 
XML 30 R21.htm IDEA: XBRL DOCUMENT v3.23.1
PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)
 3 Months Ended
Mar. 31, 2023
Prepaid Expenses And Other Current Assets  
SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS

Prepaid expenses and other current assets are summarized below:

   March 31, 2023   December 31, 2022 
         
Prepaid insurance  $222,742   $340,078 
Legal and professional   84,077    72,048 
Other   134,313    119,773 
Total prepaid expenses and other current assets  $441,132   $531,899 
XML 31 R22.htm IDEA: XBRL DOCUMENT v3.23.1
PROPERTY AND EQUIPMENT, NET (Tables)
 3 Months Ended
Mar. 31, 2023
Property, Plant and Equipment [Abstract]  
SCHEDULE OF PROPERTY AND EQUIPMENT

Property and equipment are summarized below:

 

   March 31, 2023   December 31, 2022 
         
Lab equipment  $488,718   $462,155 
Computers and software   27,214    21,463 
Property and equipment, gross   515,932    483,618 
Accumulated depreciation   (290,865)   (269,180)
Total property and equipment, net  $225,067   $214,438 
XML 32 R23.htm IDEA: XBRL DOCUMENT v3.23.1
ACCRUED EXPENSES (Tables)
 3 Months Ended
Mar. 31, 2023
Payables and Accruals [Abstract]  
SCHEDULE OF ACCRUED EXPENSES

Accrued expenses are summarized below:

   March 31, 2023   December 31, 2022 
         
Compensation  $281,085   $340,680 
Legal and professional   131,819    144,440 
Clinical   58,262    50,922 
Other   10,170    5,852 
Total accrued expenses  $481,336   $541,894 
XML 33 R24.htm IDEA: XBRL DOCUMENT v3.23.1
STOCK-BASED COMPENSATION (Tables)
 3 Months Ended
Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]  
SUMMARY OF STOCK-BASED COMPENSATION EXPENSE RECOGNIZED FOR STOCK OPTION AWARDS

The Company has recorded stock-based compensation expense (credit) related to the issuance of stock option awards in the following line items in the accompanying condensed consolidated statement of operations:

 

   2023   2022 
   Three Months Ended
March 31,		 
   2023   2022 
         
Research and development  $11,268   $4,643 
General and administrative   146,345    101,404 
Total stock-based compensation expense  $157,613   $106,047 
SUMMARY OF OPTION ACTIVITY

The following table summarizes stock option activity under the Plan:

 

   Number of
options		   Weighted-average
exercise price		   Weighted-average
remaining
contractual term
(in years)		   Aggregate
intrinsic value		 
Outstanding at December 31, 2022   806,392   $4.33           
Granted   —    —           
Exercised   —    —           
Forfeited   —    —           
Outstanding at March 31, 2023   806,392   $4.33    3.8   $271,298 
                     
Vested and exercisable at March 31, 2023   803,218   $4.31    3.7   $271,298 
SCHEDULE OF FAIR VALUE ASSUMPTIONS

The following table summarizes weighted-average assumptions using the Black-Scholes option-pricing model used on the date of the grants issued during the three months ended March 31, 2022:

 

   2022 
Fair value of Common Stock  $4.62 
Volatility   63.9%
Expected term (years)   6.0 
Risk-free interest rate   2.20%
Dividend yield   0%
XML 34 R25.htm IDEA: XBRL DOCUMENT v3.23.1
NATURE OF OPERATIONS, ORGANIZATION, AND BASIS OF PRESENTATION (Details Narrative) - USD ($)
Mar. 31, 2023
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Accumulated deficit $ 38,200,258 $ 36,667,468
Cash and cash equivalents $ 9,769,088 $ 11,413,759
Total assets, percent 93.00%  
XML 35 R26.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES (Details) - shares
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Anti-dilutive securities 5,556,344 6,209,737
Convertible Preferred Stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Anti-dilutive securities 756,558
Share-Based Payment Arrangement, Option [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Anti-dilutive securities 806,392 884,094
Warrant [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Anti-dilutive securities 4,649,952 2,057,740
Convertible Debt Securities [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Anti-dilutive securities 2,511,345
XML 36 R27.htm IDEA: XBRL DOCUMENT v3.23.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Advertising expense $ 6,000 $ 3,000
Selling, General and Administrative Expenses [Member] | Revision of Prior Period, Adjustment [Member]    
Patent and annuity costs   $ 42,000
XML 37 R28.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) - USD ($)
Mar. 31, 2023
Dec. 31, 2022
Prepaid Expenses And Other Current Assets    
Prepaid insurance $ 222,742 $ 340,078
Legal and professional 84,077 72,048
Other 134,313 119,773
Total prepaid expenses and other current assets $ 441,132 $ 531,899
XML 38 R29.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($)
Mar. 31, 2023
Dec. 31, 2022
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 515,932 $ 483,618
Accumulated depreciation (290,865) (269,180)
Total property and equipment, net 225,067 214,438
Lab Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 488,718 462,155
Computer And Software [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 27,214 $ 21,463
XML 39 R30.htm IDEA: XBRL DOCUMENT v3.23.1
PROPERTY AND EQUIPMENT, NET (Details Narrative) - USD ($)
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Property, Plant and Equipment [Abstract]    
Depreciation $ 22,000 $ 1,000
XML 40 R31.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF ACCRUED EXPENSES (Details) - USD ($)
Mar. 31, 2023
Dec. 31, 2022
Payables and Accruals [Abstract]    
Compensation $ 281,085 $ 340,680
Legal and professional 131,819 144,440
Clinical 58,262 50,922
Other 10,170 5,852
Total accrued expenses $ 481,336 $ 541,894
XML 41 R32.htm IDEA: XBRL DOCUMENT v3.23.1
LOAN PAYABLE (Details Narrative) - USD ($)
 1 Months Ended
Sep. 30, 2022
Mar. 31, 2023
Dec. 31, 2022
Short-Term Debt [Line Items]      
Loan payable   $ 168,430 $ 251,746
Short-Term Debt [Member]      
Short-Term Debt [Line Items]      
Loan payable $ 500,000    
Loan payment term ten monthly payments    
Loan periodic payment amount $ 42,000    
Loan interest rate 4.30%    
XML 42 R33.htm IDEA: XBRL DOCUMENT v3.23.1
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]    
Rent expense $ 26,000 $ 13,000
XML 43 R34.htm IDEA: XBRL DOCUMENT v3.23.1
CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT (Details Narrative) - USD ($)
$ / shares in Units, $ in Millions
 1 Months Ended
Jun. 30, 2022
Jul. 31, 2017
Mar. 31, 2023
Dec. 31, 2022
Nov. 30, 2021
Class of Stock [Line Items]          
Reverse stock split 1-for-7 reverse stock split        
Common stock par value $ 0.007   $ 0.007 $ 0.007  
Preferred stock, shares authorized     20,000,000 20,000,000  
Preferred stock par value     $ 0.001 $ 0.001  
Proceeds from issuance of private placement     0 0  
Preferred stock, shares outstanding     0 0  
Common stock, shares authorized     14,285,714 14,285,714  
Common stock, shares issued     8,463,052 8,381,324  
Minimum [Member]          
Class of Stock [Line Items]          
Common stock, shares authorized         7,142,857
Maximum [Member]          
Class of Stock [Line Items]          
Common stock, shares authorized         14,285,714
Private Placement [Member]          
Class of Stock [Line Items]          
Proceeds from issuance of private placement   1,300,000      
Series A Preferred Stock [Member]          
Class of Stock [Line Items]          
Reverse stock split   1-for-7 reverse stock split      
Proceeds from issuance of private placement   4,000,000.0 5,296,044    
Net proceeds   $ 1.5      
Shares issued for exchange of notes payable and accrued interest   $ 2.6      
Number of shares issued in debt conversion   745,558      
XML 44 R35.htm IDEA: XBRL DOCUMENT v3.23.1
SUMMARY OF STOCK-BASED COMPENSATION EXPENSE RECOGNIZED FOR STOCK OPTION AWARDS (Details) - USD ($)
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Total stock-based compensation expense $ 157,613 $ 106,047
Research and Development Expense [Member]    
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Total stock-based compensation expense 11,268 4,643
Selling, General and Administrative Expenses [Member]    
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Total stock-based compensation expense $ 146,345 $ 101,404
XML 45 R36.htm IDEA: XBRL DOCUMENT v3.23.1
SUMMARY OF OPTION ACTIVITY (Details) - USD ($)
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Share-Based Payment Arrangement [Abstract]    
Options Outstanding, beginning balance 806,392  
Weighted-Average Exercise Price Outstanding, beginning balance $ 4.33  
Options Granted 7,142
Weighted-Average Exercise Price, Granted  
Options Exercised 0
Weighted-Average Exercise Price, Exercised  
Options, Forfeited  
Weighted-Average Exercise Price,Forfeited  
Options Outstanding, ending balance 806,392  
Weighted-Average Exercise Price Outstanding, ending balance $ 4.33  
Weighted- Average Remaining Contractual Term, Outstanding 3 years 9 months 18 days  
Aggregate Intrinsic Value Outstanding, ending balance $ 271,298  
Options, Vested and exercisable 803,218  
Weighted-Average Exercise Price, Vested and exercisable $ 4.31  
Weighted- Average Remaining Contractual Term, Vested and exercisable 3 years 8 months 12 days  
Aggregate Intrinsic Value, Vested and exercisable $ 271,298  
XML 46 R37.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF FAIR VALUE ASSUMPTIONS (Details)
 3 Months Ended
Mar. 31, 2022
$ / shares
Share-Based Payment Arrangement [Abstract]  
Fair value of Common Stock $ 4.62
Volatility 63.90%
Expected term (in years) 6 years
Risk-free interest rate 2.20%
Dividend yield 0.00%
XML 47 R38.htm IDEA: XBRL DOCUMENT v3.23.1
STOCK-BASED COMPENSATION (Details Narrative) - USD ($)
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Grant option, outstanding 1,100,000  
Shares reserved 1,000,000.0  
Unrecognized compensation $ 0  
Options exercised, shares 0
Grant date fair value of options granted 7,142
Weighted-average grant date fair value of options granted   $ 2.84
Restricted Stock Units (RSUs) [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Grant date fair value of options granted 64,016 14,999
Unissued shares 82,000 16,000
XML 48 R39.htm IDEA: XBRL DOCUMENT v3.23.1
WARRANTS (Details Narrative) - $ / shares
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Warrant outstanding 4,649,952   4,649,952
Warrant [Member]      
Weighted average exercise price $ 6.39   $ 6.39
Exercise of warrants 0 0  
XML 49 form10-q_htm.xml IDEA: XBRL DOCUMENT 0001712762 2023-01-01 2023-03-31 0001712762 BIAF:CommonStockParValue.007PerShareMember 2023-01-01 2023-03-31 0001712762 BIAF:TradeableWarrantsToPurchaseCommonStockMember 2023-01-01 2023-03-31 0001712762 2023-05-12 0001712762 2023-03-31 0001712762 2022-12-31 0001712762 2022-01-01 2022-03-31 0001712762 us-gaap:PreferredStockMember 2022-12-31 0001712762 us-gaap:CommonStockMember 2022-12-31 0001712762 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001712762 us-gaap:RetainedEarningsMember 2022-12-31 0001712762 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001712762 us-gaap:CommonStockMember 2021-12-31 0001712762 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001712762 us-gaap:RetainedEarningsMember 2021-12-31 0001712762 2021-12-31 0001712762 us-gaap:PreferredStockMember 2023-01-01 2023-03-31 0001712762 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001712762 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001712762 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001712762 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-03-31 0001712762 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001712762 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001712762 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001712762 us-gaap:PreferredStockMember 2023-03-31 0001712762 us-gaap:CommonStockMember 2023-03-31 0001712762 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001712762 us-gaap:RetainedEarningsMember 2023-03-31 0001712762 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-03-31 0001712762 us-gaap:CommonStockMember 2022-03-31 0001712762 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001712762 us-gaap:RetainedEarningsMember 2022-03-31 0001712762 2022-03-31 0001712762 srt:RestatementAdjustmentMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-03-31 0001712762 us-gaap:ConvertiblePreferredStockMember 2023-01-01 2023-03-31 0001712762 us-gaap:ConvertiblePreferredStockMember 2022-01-01 2022-03-31 0001712762 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0001712762 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0001712762 us-gaap:WarrantMember 2023-01-01 2023-03-31 0001712762 us-gaap:WarrantMember 2022-01-01 2022-03-31 0001712762 us-gaap:ConvertibleDebtSecuritiesMember 2023-01-01 2023-03-31 0001712762 us-gaap:ConvertibleDebtSecuritiesMember 2022-01-01 2022-03-31 0001712762 BIAF:LabEquipmentMember 2023-03-31 0001712762 BIAF:LabEquipmentMember 2022-12-31 0001712762 BIAF:ComputerAndSoftwareMember 2023-03-31 0001712762 BIAF:ComputerAndSoftwareMember 2022-12-31 0001712762 us-gaap:ShortTermDebtMember 2022-09-30 0001712762 us-gaap:ShortTermDebtMember 2022-09-01 2022-09-30 0001712762 2022-06-01 2022-06-30 0001712762 2022-06-30 0001712762 us-gaap:SeriesAPreferredStockMember 2023-03-31 0001712762 us-gaap:PrivatePlacementMember 2017-07-31 0001712762 us-gaap:SeriesAPreferredStockMember 2017-07-01 2017-07-31 0001712762 us-gaap:SeriesAPreferredStockMember 2017-07-31 0001712762 srt:MinimumMember 2021-11-30 0001712762 srt:MaximumMember 2021-11-30 0001712762 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 0001712762 us-gaap:RestrictedStockUnitsRSUMember 2023-03-31 0001712762 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-03-31 0001712762 us-gaap:RestrictedStockUnitsRSUMember 2022-03-31 0001712762 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-03-31 0001712762 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-03-31 0001712762 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-03-31 0001712762 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-03-31 0001712762 us-gaap:WarrantMember 2023-03-31 0001712762 us-gaap:WarrantMember 2022-12-31 0001712762 us-gaap:WarrantMember 2023-01-01 2023-03-31 0001712762 us-gaap:WarrantMember 2022-01-01 2022-03-31 iso4217:USD shares iso4217:USD shares pure 0001712762 false --12-31 Q1 10-Q true 2023-03-31 2023 false 001-41463 bioAffinity Technologies, Inc. DE 46-5211056 22211 W. Interstate 10 Suite 1206 San Antonio TX 78257 (210) 698-5334 Common Stock, par value $.007 per share BIAF NASDAQ Tradeable Warrants to purchase Common Stock BIAFW NASDAQ Yes Yes Non-accelerated Filer true true false false 8518981 9769088 11413759 11027 10489 11335 5540 441132 531899 10232582 11961687 225067 214438 6920 6000 10464569 12182125 146537 345042 481336 541894 168430 251746 796303 1138682 796303 1138682 0.001 0.001 20000000 20000000 0 0 0 0 0.007 0.007 14285714 14285714 8463052 8463052 8381324 8381324 59241 58669 47809283 47652242 -38200258 -36667468 9668266 11043443 10464569 12182125 921 87 834 369617 279848 19628 52503 1169559 394692 1558804 727043 -1557970 -727043 36999 -1147012 404194 -1520971 -1469861 11819 2159 -1532790 -1472020 -0.18 -0.55 8433689 2681221 8381324 58669 47652242 -36667468 11043443 81728 572 157041 157613 -1532790 -1532790 8463052 59241 47809283 -38200258 9668266 756558 4044318 2677140 18740 12703896 -28513355 -15790719 756558 4044318 2677140 18740 12703896 -28513355 -15790719 15772 110 105937 106047 213942 213942 217973 217973 -1472020 -1472020 756558 4044318 2692912 18850 13241748 -29985375 -16724777 756558 4044318 2692912 18850 13241748 -29985375 -16724777 -1532790 -1472020 21685 1039 978217 404194 157613 106047 538 5331 5795 5803 -89847 -11143 -198505 17284 -60558 -29649 169300 -1529041 -633967 32314 -32314 83316 475000 117986 55651 -83316 301363 -1644671 -332604 11413759 1360638 9769088 1028034 11819 2159 1655 217973 213942 <p id="xdx_809_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zaFT2vXpWbhj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 1. <span style="text-transform: uppercase"><span id="xdx_829_z12uG41IpbEk">NATURE OF OPERATIONS, ORGANIZATION, AND BASIS OF PRESENTATION</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Description of Business</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">bioAffinity Technologies, Inc., a Delaware corporation (the “Company,” “we,” or “our”), addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung. Our Company also is conducting early-stage research focused on advancing therapeutic discoveries that could result in broad-spectrum cancer treatments. bioAffinity Technologies develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. Our first diagnostic test, CyPath<sup>®</sup> Lung, is a noninvasive test for early detection of lung cancer, the leading cause of cancer-related deaths. Research and optimization of our proprietary platform for <i>in vitro </i>diagnostics and technologies are conducted in our laboratories at The University of Texas at San Antonio. We are developing our platform technologies so that in the future, they will be able to detect, monitor, and treat diseases of the lung and other cancers.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Organization</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company was formed on March 26, 2014, as a Delaware corporation with its corporate offices located in San Antonio, Texas. On June 15, 2016, the Company formed a wholly owned subsidiary, OncoSelect<sup>® </sup>Therapeutics, LLC, as a Delaware limited liability company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Basis of Presentation</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) and pursuant to the rules and regulations of the SEC for interim financial reporting. The condensed consolidated financial statements are unaudited, and in management’s opinion include all adjustments, including normal recurring adjustments and accruals, necessary for a fair presentation of the results for the interim periods presented. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the fiscal year ended December 31, 2023, or any future period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited annual consolidated financial statements and notes included in the Company’s Form 10-K filed with the SEC on March 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with Accounting Standards Update (“ASU”) 2014-15, Presentation of Financial Statements – Going Concern (Subtopic 205-40), the Company has evaluated whether there are conditions and events that raise substantial doubt about the Company’s ability to continue as a going concern for at least one year after the date the condensed consolidated financial statements are issued.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has incurred significant losses and negative cash flows from operations since inception and expects to continue to incur losses and negative cash flows for the foreseeable future. As a result, the Company had an accumulated deficit of $<span id="xdx_900_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20230331_zJExcr5NgDW6" title="Accumulated deficit">38.2</span> million at March 31, 2023. The Company’s cash and cash equivalents at March 31, 2023, were approximately $<span id="xdx_90F_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20230331_zF6QeMN4TMmc" title="Cash and cash equivalents">9.8</span> million, representing <span id="xdx_901_ecustom--TotalAssetsPercent_iI_pid_dp_c20230331_zUPhMBtf4NIg" title="Total assets, percent">93</span>% of total assets. Based on the Company’s current expected level of operating expenditures, the Company believes its cash on hand at March 31, 2023, is sufficient to fund the Company’s ongoing operations for a period of a least twelve (12) months subsequent to the issuance of the accompanying unaudited condensed consolidated financial statements. Thereafter, the Company may need to raise further capital through the sale of additional equity or debt securities or other debt instruments, strategic relationships or grants, or other arrangements to support its future operations. If such funding is not available or not available on terms acceptable to the Company, the Company’s current development plan may be curtailed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>COVID-19</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The rapid global spread of the COVID-19 virus since December 2019 has affected production and sales worldwide, disrupted supply chains across a range of industries, and created significant economic volatility. The impact of COVID-19 on the Company’s operational and financial performance will depend on numerous factors, including the spread, duration, and intensity of the pandemic (including resurgences), the emergence of new viral variants, and the impact of the pandemic on the Company’s customers, employees, clinical trial sites, and vendors.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As the COVID-19 pandemic continues to evolve, the ultimate impact of the pandemic on the Company’s operations is highly uncertain and subject to change and will depend on future developments, which cannot be accurately predicted, including the duration of the pandemic, additional or modified government actions, and the actions taken to contain COVID-19 or address its impact, among others. Management does not yet know the full extent of potential delays or impacts on the Company, clinical trials, research programs, healthcare systems, or the global economy but continues to monitor the situation closely.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> -38200000 9800000 0.93 <p id="xdx_802_eus-gaap--SignificantAccountingPoliciesTextBlock_zORxH7AglaNl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2. <span id="xdx_827_zxTmjc9i7Fsk">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_84F_eus-gaap--UseOfEstimates_z0I8v3EazSuc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zJH3ThwATV3j">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include: the valuation allowance on the Company’s deferred tax assets; the useful lives of fixed assets; and the fair value of the convertible notes payable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--ConsolidationPolicyTextBlock_zUqJ3T1T6BM" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zeZaogyYZPh6">Principles of Consolidation</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying condensed consolidated financial statements include all of the accounts of the Company and its wholly owned subsidiary, OncoSelect<sup>® </sup>Therapeutics, LLC. All significant intercompany balances and transactions have been eliminated.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_843_eus-gaap--AdvertisingCostsPolicyTextBlock_zP93wZOv9Kh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zPeDc8WtRSGd">Advertising expense</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company expenses all advertising costs as incurred. Advertising expense was approximately $<span id="xdx_90B_eus-gaap--AdvertisingExpense_c20230101__20230331_z7BNk35SA2K3" title="Advertising expense">6,000</span> and $<span id="xdx_90A_eus-gaap--AdvertisingExpense_c20220101__20220331_zRztjMPVfKY9" title="Advertising expense">3,000</span> for the three months ended March 31, 2023 and 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_zdWN0WHHl8J5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_z72TEJqzlyxh">Loss Per Share</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic earnings (loss) per share is computed by dividing net income (loss) attributable to common stockholders by the weighted-average number of Common Shares outstanding during the period. Diluted earnings per share is computed by dividing net income attributable to common stockholders by the sum of the weighted-average number of Common Shares outstanding during the period and the weighted-average number of dilutive Common Share equivalents outstanding during the period, using the treasury stock method. Dilutive Common Share equivalents are comprised of in-the-money stock options, convertible notes payable, and warrants based on the average stock price for each period using the treasury stock method.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zthOnUl4wZJ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following potentially dilutive securities have been excluded from the computations of weighted average shares outstanding as of March 31, 2023 and 2022, as they would be anti-dilutive:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_zYnKwON8Rlnb" style="display: none">SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20230101__20230331_zJDF7CDL6hM3" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20220101__20220331_zh3CNl8ZDIXe" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">As of March 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zyJhGy9DRGWf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: justify">Convertible preferred stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0424">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">756,558</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zgZqyNXPpp95" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Shares underlying options outstanding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">806,392</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">884,094</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zJmYWUA1HmVh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Shares underlying warrants outstanding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,649,952</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,057,740</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zZ6LxYWUjTBh" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Shares underlying convertible notes</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0433">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,511,345</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zkuxldkEdv69" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-dilutive securities</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">5,556,344</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">6,209,737</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A2_zGkBN06w10Bi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_84A_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zcskC6IPDAR6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zo7URa1nJvl6">Revenue Recognition</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue is generated exclusively from royalties for the Company’s first diagnostic test, CyPath<sup>®</sup> Lung, from sales by Precision Pathology Services, a CAP-accredited, CLIA-certified clinical pathology laboratory and the Company’s licensee, that began a limited market launch in the second quarter of 2022 to pulmonologists in the South Texas area, designed to refine future positioning and develop strategic insight for the Company’s CyPath<sup>®</sup> Lung test. The services are completed upon release of a patient’s test result to the ordering healthcare provider.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To determine revenue recognition for the arrangements that the Company determines are within the scope of ASC 606, Revenue from Contracts with Customers, the Company performs the following five steps: (1) identify the contract(s) with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract and (5) recognize revenue when (or as) the entity satisfies a performance obligation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_z5pIjxOSVIt3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_z6ryzgrtUit4">Reclassifications</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior year balances have been reclassified to conform to current year presentation. The Company reclassified patent expenses and annuity costs of approximately $<span id="xdx_907_eus-gaap--FiniteLivedPatentsGross_iI_c20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember__srt--RestatementAxis__srt--RestatementAdjustmentMember_zk4bRXjqRzi4" title="Patent and annuity costs">42,000</span> from research and development to selling, general and administrative for the three months ended March 31, 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zPHOLvq8V5hh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zmwUAi3Kzxl4">Recent Accounting Pronouncements</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company continues to monitor new accounting pronouncements issued by the Financial Accounting Standards Board (“FASB”) and does not believe any accounting pronouncements issued through the date of this report will have a material impact on the Company’s condensed consolidated financial statements.</span></p> <p id="xdx_85F_z3viBG5Pupl1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_84F_eus-gaap--UseOfEstimates_z0I8v3EazSuc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zJH3ThwATV3j">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include: the valuation allowance on the Company’s deferred tax assets; the useful lives of fixed assets; and the fair value of the convertible notes payable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--ConsolidationPolicyTextBlock_zUqJ3T1T6BM" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zeZaogyYZPh6">Principles of Consolidation</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying condensed consolidated financial statements include all of the accounts of the Company and its wholly owned subsidiary, OncoSelect<sup>® </sup>Therapeutics, LLC. All significant intercompany balances and transactions have been eliminated.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_843_eus-gaap--AdvertisingCostsPolicyTextBlock_zP93wZOv9Kh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zPeDc8WtRSGd">Advertising expense</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company expenses all advertising costs as incurred. Advertising expense was approximately $<span id="xdx_90B_eus-gaap--AdvertisingExpense_c20230101__20230331_z7BNk35SA2K3" title="Advertising expense">6,000</span> and $<span id="xdx_90A_eus-gaap--AdvertisingExpense_c20220101__20220331_zRztjMPVfKY9" title="Advertising expense">3,000</span> for the three months ended March 31, 2023 and 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 6000 3000 <p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_zdWN0WHHl8J5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_z72TEJqzlyxh">Loss Per Share</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic earnings (loss) per share is computed by dividing net income (loss) attributable to common stockholders by the weighted-average number of Common Shares outstanding during the period. Diluted earnings per share is computed by dividing net income attributable to common stockholders by the sum of the weighted-average number of Common Shares outstanding during the period and the weighted-average number of dilutive Common Share equivalents outstanding during the period, using the treasury stock method. Dilutive Common Share equivalents are comprised of in-the-money stock options, convertible notes payable, and warrants based on the average stock price for each period using the treasury stock method.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zthOnUl4wZJ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following potentially dilutive securities have been excluded from the computations of weighted average shares outstanding as of March 31, 2023 and 2022, as they would be anti-dilutive:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_zYnKwON8Rlnb" style="display: none">SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20230101__20230331_zJDF7CDL6hM3" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20220101__20220331_zh3CNl8ZDIXe" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">As of March 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zyJhGy9DRGWf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: justify">Convertible preferred stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0424">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">756,558</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zgZqyNXPpp95" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Shares underlying options outstanding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">806,392</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">884,094</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zJmYWUA1HmVh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Shares underlying warrants outstanding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,649,952</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,057,740</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zZ6LxYWUjTBh" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Shares underlying convertible notes</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0433">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,511,345</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zkuxldkEdv69" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-dilutive securities</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">5,556,344</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">6,209,737</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A2_zGkBN06w10Bi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_89C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zthOnUl4wZJ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following potentially dilutive securities have been excluded from the computations of weighted average shares outstanding as of March 31, 2023 and 2022, as they would be anti-dilutive:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_zYnKwON8Rlnb" style="display: none">SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20230101__20230331_zJDF7CDL6hM3" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20220101__20220331_zh3CNl8ZDIXe" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">As of March 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zyJhGy9DRGWf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: justify">Convertible preferred stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0424">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">756,558</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zgZqyNXPpp95" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Shares underlying options outstanding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">806,392</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">884,094</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zJmYWUA1HmVh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Shares underlying warrants outstanding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,649,952</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,057,740</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zZ6LxYWUjTBh" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Shares underlying convertible notes</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0433">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,511,345</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zkuxldkEdv69" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-dilutive securities</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">5,556,344</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">6,209,737</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 756558 806392 884094 4649952 2057740 2511345 5556344 6209737 <p id="xdx_84A_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zcskC6IPDAR6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zo7URa1nJvl6">Revenue Recognition</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue is generated exclusively from royalties for the Company’s first diagnostic test, CyPath<sup>®</sup> Lung, from sales by Precision Pathology Services, a CAP-accredited, CLIA-certified clinical pathology laboratory and the Company’s licensee, that began a limited market launch in the second quarter of 2022 to pulmonologists in the South Texas area, designed to refine future positioning and develop strategic insight for the Company’s CyPath<sup>®</sup> Lung test. The services are completed upon release of a patient’s test result to the ordering healthcare provider.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To determine revenue recognition for the arrangements that the Company determines are within the scope of ASC 606, Revenue from Contracts with Customers, the Company performs the following five steps: (1) identify the contract(s) with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract and (5) recognize revenue when (or as) the entity satisfies a performance obligation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_z5pIjxOSVIt3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_z6ryzgrtUit4">Reclassifications</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior year balances have been reclassified to conform to current year presentation. The Company reclassified patent expenses and annuity costs of approximately $<span id="xdx_907_eus-gaap--FiniteLivedPatentsGross_iI_c20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember__srt--RestatementAxis__srt--RestatementAdjustmentMember_zk4bRXjqRzi4" title="Patent and annuity costs">42,000</span> from research and development to selling, general and administrative for the three months ended March 31, 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> 42000 <p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zPHOLvq8V5hh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zmwUAi3Kzxl4">Recent Accounting Pronouncements</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company continues to monitor new accounting pronouncements issued by the Financial Accounting Standards Board (“FASB”) and does not believe any accounting pronouncements issued through the date of this report will have a material impact on the Company’s condensed consolidated financial statements.</span></p> <p id="xdx_802_ecustom--PrepaidExpensesAndOtherCurrentAssetsTextBlock_zHPegFulenc8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 3. <span id="xdx_822_zdqQR6yRnIlb">PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_897_ecustom--ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_zG7BSoSf7rac" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid expenses and other current assets are summarized below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_zuh3CE11Px8h" style="display: none">SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20230331_zIcFXmQNwZze" style="border-bottom: Black 1.5pt solid; text-align: center">March 31, 2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20221231_z2yB7ym8FgCd" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_40C_eus-gaap--PrepaidInsurance_iI_maPEAOAzlO0_zAaaAPL6RDYh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 64%; text-align: justify">Prepaid insurance</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">222,742</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">340,078</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_ecustom--PrepaidLegalAndProfessional_iI_maPEAOAzlO0_zSx8CEXZwt43" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Legal and professional</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">84,077</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">72,048</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--OtherPrepaidExpenseCurrent_iI_maPEAOAzlO0_z8mQaIxxTUH5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">134,313</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">119,773</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtPEAOAzlO0_z06zEKxyIU4l" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">441,132</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">531,899</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A1_z0H1DlHhR5Y2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_897_ecustom--ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_zG7BSoSf7rac" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid expenses and other current assets are summarized below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_zuh3CE11Px8h" style="display: none">SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20230331_zIcFXmQNwZze" style="border-bottom: Black 1.5pt solid; text-align: center">March 31, 2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20221231_z2yB7ym8FgCd" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_40C_eus-gaap--PrepaidInsurance_iI_maPEAOAzlO0_zAaaAPL6RDYh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 64%; text-align: justify">Prepaid insurance</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">222,742</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">340,078</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_ecustom--PrepaidLegalAndProfessional_iI_maPEAOAzlO0_zSx8CEXZwt43" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Legal and professional</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">84,077</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">72,048</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--OtherPrepaidExpenseCurrent_iI_maPEAOAzlO0_z8mQaIxxTUH5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">134,313</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">119,773</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtPEAOAzlO0_z06zEKxyIU4l" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">441,132</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">531,899</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 222742 340078 84077 72048 134313 119773 441132 531899 <p id="xdx_80B_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zo8qN2huCoi2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 4. <span id="xdx_82E_zpM6R957IEPf">PROPERTY AND EQUIPMENT, NET</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--PropertyPlantAndEquipmentTextBlock_zTmDYLcnPzo9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment are summarized below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zzGtFm2x6ON7" style="display: none">SCHEDULE OF PROPERTY AND EQUIPMENT</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20230331_z4BLIfU81l83" style="border-bottom: Black 1.5pt solid; text-align: center">March 31, 2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20221231_z7yLErw0IIvc" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentMember_zFu0sJ6nJyr2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: justify">Lab equipment</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">488,718</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">462,155</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerAndSoftwareMember_zlZRY1DKnfW9" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Computers and software</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">27,214</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,463</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzFLE_zfQGNhnG6yXi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, gross</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">515,932</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">483,618</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzFLE_zz5FMJcW0oZj" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Accumulated depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(290,865</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(269,180</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzFLE_zeJ2bZ7YUaS6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 2.5pt">Total property and equipment, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">225,067</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">214,438</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A9_zl1Seu2hViji" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation expense was approximately $<span id="xdx_90A_eus-gaap--Depreciation_c20230101__20230331_zgKnsKOKxLk3" title="Depreciation">22,000</span> and $<span id="xdx_907_eus-gaap--Depreciation_c20220101__20220331_zV0W2L6RqSE2" title="Depreciation">1,000</span> for the three months ended March 31, 2023 and 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_895_eus-gaap--PropertyPlantAndEquipmentTextBlock_zTmDYLcnPzo9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment are summarized below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zzGtFm2x6ON7" style="display: none">SCHEDULE OF PROPERTY AND EQUIPMENT</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20230331_z4BLIfU81l83" style="border-bottom: Black 1.5pt solid; text-align: center">March 31, 2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20221231_z7yLErw0IIvc" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentMember_zFu0sJ6nJyr2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: justify">Lab equipment</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">488,718</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">462,155</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerAndSoftwareMember_zlZRY1DKnfW9" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Computers and software</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">27,214</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,463</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzFLE_zfQGNhnG6yXi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, gross</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">515,932</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">483,618</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzFLE_zz5FMJcW0oZj" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Accumulated depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(290,865</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(269,180</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzFLE_zeJ2bZ7YUaS6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 2.5pt">Total property and equipment, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">225,067</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">214,438</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 488718 462155 27214 21463 515932 483618 290865 269180 225067 214438 22000 1000 <p id="xdx_804_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zqQov3alMX5l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 5. <span id="xdx_822_zQBX1BXKkC45">ACCRUED EXPENSES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zmWcRYFIsgLe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued expenses are summarized below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zFhCpfdhcBVk" style="display: none">SCHEDULE OF ACCRUED EXPENSES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20230331_z18dxnhH536e" style="border-bottom: Black 1.5pt solid; text-align: center">March 31, 2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20221231_ze5FAzwcH9wh" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_402_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_maALCzgdS_zc1fu2dP31hc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: justify">Compensation</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">281,085</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">340,680</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AccruedProfessionalFeesCurrent_iI_maALCzgdS_zMeFEmachf7k" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Legal and professional</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">131,819</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">144,440</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--AccruedClinicalExpenseCurrent_iI_maALCzgdS_zcDvHYsYUYNh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Clinical</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">58,262</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50,922</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maALCzgdS_zlG2h7z8cwvb" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,170</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,852</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCzgdS_zb8ZaHzpBq47" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 2.5pt">Total accrued expenses</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">481,336</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">541,894</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A1_zoEPtTw970t" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zmWcRYFIsgLe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued expenses are summarized below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zFhCpfdhcBVk" style="display: none">SCHEDULE OF ACCRUED EXPENSES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20230331_z18dxnhH536e" style="border-bottom: Black 1.5pt solid; text-align: center">March 31, 2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20221231_ze5FAzwcH9wh" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_402_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_maALCzgdS_zc1fu2dP31hc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: justify">Compensation</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">281,085</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">340,680</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AccruedProfessionalFeesCurrent_iI_maALCzgdS_zMeFEmachf7k" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Legal and professional</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">131,819</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">144,440</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--AccruedClinicalExpenseCurrent_iI_maALCzgdS_zcDvHYsYUYNh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Clinical</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">58,262</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50,922</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maALCzgdS_zlG2h7z8cwvb" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,170</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,852</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCzgdS_zb8ZaHzpBq47" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 2.5pt">Total accrued expenses</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">481,336</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">541,894</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 281085 340680 131819 144440 58262 50922 10170 5852 481336 541894 <p id="xdx_805_eus-gaap--DebtDisclosureTextBlock_z2mM9hyDtzk5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 6. <span id="xdx_82F_z0BTltlaGThb">LOAN PAYABLE</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In September 2022, the Company obtained short-term financing of approximately $<span id="xdx_90C_eus-gaap--LoansPayableCurrent_iI_pn5n6_c20220930__us-gaap--DebtInstrumentAxis__us-gaap--ShortTermDebtMember_zMJpEOIIrIfh" title="Loan payable">0.5</span> million with <span id="xdx_901_eus-gaap--DebtInstrumentPaymentTerms_pn5n6_c20220901__20220930__us-gaap--DebtInstrumentAxis__us-gaap--ShortTermDebtMember_z8UMQ5RAQQX4" title="Loan payment term">ten monthly payments</span> of approximately $<span id="xdx_907_eus-gaap--DebtInstrumentPeriodicPayment_c20220901__20220930__us-gaap--DebtInstrumentAxis__us-gaap--ShortTermDebtMember_zRFTjAK4C9Ge" title="Loan periodic payment amount">42,000</span> and interest at a <span id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20220930__us-gaap--DebtInstrumentAxis__us-gaap--ShortTermDebtMember_zX3u2Np91hj" title="Loan interest rate">4.3</span>% fixed annual rate for director and officer insurance policies.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 500000 ten monthly payments 42000 0.043 <p id="xdx_80A_eus-gaap--FairValueDisclosuresTextBlock_zvU6DRmaabSd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 7. <span id="xdx_821_z42bSFaT8mWc">FAIR VALUE MEASUREMENTS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company analyzes all financial instruments with features of both liabilities and equity under the FASB accounting standard for such instruments. Under this standard, financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The estimated fair value of certain financial instruments, including cash and cash equivalents, accounts and other receivables, prepaid and other current assets, accounts payable, accrued expenses and loan payable, are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_802_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z2B90gIteaj1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 8. <span id="xdx_82E_zNKSPaqcEB5h">COMMITMENTS AND CONTINGENCIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Operating Leases</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company leases its corporate offices under a month-to-month agreement and leases its laboratory and additional office space under an operating lease that is renewable annually by written notice by the Company and will require renewal in February 2024. Rent expense for office and lab space amounted to approximately $<span id="xdx_90B_eus-gaap--PaymentsForRent_c20230101__20230331_zO3OvwVVftCd" title="Rent expense">26,000</span> and $<span id="xdx_909_eus-gaap--PaymentsForRent_c20220101__20220331_z7Hxq0O7TsNb" title="Rent expense">13,000</span> for each of the three months ended March 31, 2023 and 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Legal Matters</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, the Company is involved in various disputes and litigation matters that arise in the ordinary course of business. To date, the Company has no material pending legal proceedings.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 26000 13000 <p id="xdx_809_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zhvKNKSdyJae" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 9. <span id="xdx_82B_zeCNVp2wSoYe">CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2022, the Company completed a <span id="xdx_904_eus-gaap--StockholdersEquityReverseStockSplit_c20220601__20220630_z4TjraLec38e" title="Reverse stock split">1-for-7 reverse stock split</span> of its Common Stock. All share and per share amounts have been adjusted on a retroactive basis in these condensed consolidated financial statements to reflect the effect of the reverse stock split. The Company made a cash payment to stockholders for all fractional shares that it would otherwise be required to issue as a result of the stock split. In addition, the stock split resulted in the par value of the Company’s Common Stock increasing to $<span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20220630_zhc6lnobLTU8" title="Common stock, par value">0.007</span> per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Convertible Preferred Stock</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has authorized a total of <span id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_c20230331_zdZHOoXFaVgd" title="Preferred stock, shares authorized">20,000,000</span> shares of preferred stock, $<span id="xdx_907_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20230331_zrElK42VbCCe" title="Preferred stock par value">0.001</span> par value per share. Prior to the initial public offering (“IPO”), the Company issued <span id="xdx_90E_eus-gaap--PreferredStockSharesIssued_iI_c20230331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zgg4zbZlUZCc" title="Preferred stock, shares issue">5,296,044</span> shares of preferred stock, designated as Series A. In July 2017, the Company completed a private placement of securities in which <span id="xdx_90F_eus-gaap--PreferredStockSharesIssued_iI_pn5n6_c20170731__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z0neHCs5P7Sj" title="Proceeds from issuance of private placement">1.3</span> million shares of Series A Preferred Stock were sold, resulting in net proceeds of $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20170701__20170731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_ziVYrB7pamJf" title="Net proceeds">1.5</span> million. As part of the closing, the Company issued <span id="xdx_907_eus-gaap--PreferredStockSharesIssued_iI_pn5n6_c20170731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zrvfSpMyN7ke">4.0</span> million shares of Series A Preferred Stock in exchange for $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValuePurchaseOfAssets_pn5n6_c20170701__20170731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zADyEoBfnI3e" title="Shares issued for exchange of notes payable and accrued interest">2.6</span> million of the Company’s convertible notes payable and related accrued interest.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with the Certificate of Designation of the Series A Preferred Stock, all of the shares of Series A Preferred Stock that were issued and outstanding at the time of the IPO closing were automatically converted into <span id="xdx_902_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20170701__20170731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zkDlOolFioMi" title="Number of shares issued in debt conversion">745,558</span> fully paid and nonassessable shares of Common Stock at a 1-for-7 conversion rate (as adjusted for the <span id="xdx_902_eus-gaap--StockholdersEquityReverseStockSplit_c20170701__20170731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zPyf8V2aP0Sg">1-for-7 reverse stock split</span>). The shares of Series A Preferred Stock that were so converted ceased to be part of the Company’s authorized stock and will never again be issued by the Company. As of March 31, 2023, and December 31, 2022, <span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_c20230331_zHYjKFK6ezR2" title="Preferred stock, shares outstanding"><span id="xdx_901_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_c20221231_zLQM7k1vAcDd" title="Preferred stock, shares outstanding">no</span></span> Preferred Stock was outstanding.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common Stock</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has authorized a total of <span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20230331_zzkr5wqpJgHa" title="Common stock, shares authorized">14,285,714</span> shares of Common Stock, $<span id="xdx_90D_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20230331_zCbsBfl5iPR6" title="Common stock par value">0.007</span> par value per share. In November 2021, the Company received stockholder approval to increase the number of authorized shares from <span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20211130__srt--RangeAxis__srt--MinimumMember_zm0HVniIntYh" title="Common stock, shares authorized">7,142,857</span> shares to <span id="xdx_90C_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20211130__srt--RangeAxis__srt--MaximumMember_zUvwbgXyljxd" title="Common stock, shares authorized">14,285,714</span> shares. The Company has issued <span id="xdx_903_eus-gaap--CommonStockSharesIssued_iI_pid_c20230331_zhmUxo9pd3Dk" title="Common stock, shares issued">8,463,052</span> shares of Common Stock as of March 31, 2023, and <span id="xdx_90A_eus-gaap--CommonStockSharesIssued_iI_pid_c20221231_zkjdhDw8CdSl" title="Common stock, shares issued">8,381,324</span> shares of Common Stock as of December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1-for-7 reverse stock split 0.007 20000000 0.001 5296044 1300000 1500000 4000000.0 2600000 745558 1-for-7 reverse stock split 0 0 14285714 0.007 7142857 14285714 8463052 8381324 <p id="xdx_808_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zoxSEBdwN4qh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 10. <span id="xdx_827_zFxdjFeNJzsi">STOCK-BASED COMPENSATION</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company grants options under its 2014 Equity Incentive Plan (the “Plan”). Under the Plan, the Company is authorized to grant options for up to <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pn5n6_c20230331_z9mWoouLud4l" title="Grant option, outstanding">1.1</span> million shares of Common Stock. The Company has reserved <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_pn5n6_c20230101__20230331_zep4o5veFJ4l" title="Shares reserved">1.0</span> million shares to be used under the Plan. Options may be granted to employees, the Company’s board of directors, and external consultants who provide services to the Company. Options granted under the Plan have vesting schedules with terms of one to three years and become fully exercisable based on specific terms imposed at the date of grant. The Plan will terminate according to the respective terms of the Plan in September 2026.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zZ3TrFhUTOq9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: -0.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has recorded stock-based compensation expense (credit) related to the issuance of stock option awards in the following line items in the accompanying condensed consolidated statement of operations:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: -0.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zr9ErLaY5c7c" style="display: none">SUMMARY OF STOCK-BASED COMPENSATION EXPENSE RECOGNIZED FOR STOCK OPTION AWARDS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20230101__20230331_zhuIzlTMcF9b" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20220101__20220331_zTSCJH91wY5c" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Three Months Ended <br/>March 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_40A_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z72rMgGrApq8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: justify">Research and development</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">11,268</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">4,643</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zkEkycmhO5hl" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">146,345</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">101,404</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AllocatedShareBasedCompensationExpense_zbdPqD7kq0A3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total stock-based compensation expense</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">157,613</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">106,047</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AC_zXUVZaDvkFG6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z2iNMHmWLvm1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes stock option activity under the Plan:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zDcGt59bh8Bi" style="display: none">SUMMARY OF OPTION ACTIVITY</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number of <br/>options</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted-average <br/>exercise price</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted-average <br/>remaining <br/>contractual term <br/>(in years)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Aggregate <br/>intrinsic value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: justify">Outstanding at December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20230331_z7GupXSKACYh" style="width: 10%; text-align: right" title="Options Outstanding, beginning balance">806,392</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20230331_zBtJz1YPHMg4" style="width: 10%; text-align: right" title="Weighted-Average Exercise Price Outstanding, beginning balance">4.33</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20230331_zAN4Lua7Q13e" style="text-align: right" title="Options Granted"><span style="-sec-ix-hidden: xdx2ixbrl0584">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20230331_z9POYYR1ddi6" style="text-align: right" title="Weighted-Average Exercise Price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0586">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20230101__20230331_zXVQyAKp2GL8" style="text-align: right" title="Options Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0588">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20230331_zQ5jkMH9fpt5" style="text-align: right" title="Weighted-Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0590">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_pid_c20230101__20230331_zATSCKgP5w7j" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0592">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20230331_zVnV3eytyAq7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted-Average Exercise Price,Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0594">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Outstanding at March 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20230331_zUhorF8LlQO6" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding, ending balance">806,392</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20230331_zFqXNLS9DeAc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price Outstanding, ending balance">4.33</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20230331_zXZIkC9VdNE6" title="Weighted- Average Remaining Contractual Term, Outstanding">3.8</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20230101__20230331_zbPEESZJh2Bi" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Outstanding, ending balance">271,298</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Vested and exercisable at March 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iE_pid_c20230101__20230331_zLTHYElkZLti" style="border-bottom: Black 2.5pt double; text-align: right" title="Options, Vested and exercisable">803,218</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20230331_z3uqXqTwc0Gi" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price, Vested and exercisable">4.31</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20230331_zDBkFTiaFPml" title="Weighted- Average Remaining Contractual Term, Vested and exercisable">3.7</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iE_c20230101__20230331_zhVBgZvHHI13" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Vested and exercisable">271,298</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AF_zcggzqsmpIH3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2023, there was <span id="xdx_90B_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_do_c20230331_zFyxLPvKiiS1" title="Unrecognized compensation">no</span> unrecognized compensation cost related to non-vested stock options. During the three months ended March 31, 2023 and 2022, <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_dxL_c20230101__20230331_zJM7fqop9wt9" title="Options exercised, shares::XDX::-"><span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_do_c20220101__20220331_z4tx3mh3IgV6" title="Options exercised, shares"><span style="-sec-ix-hidden: xdx2ixbrl0614">no</span></span></span> options were exercised. During the three months ended March 31, 2023, <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_dxL_c20230101__20230331_zzdSfZg85Mye" title="Options issued, shares::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0618">no</span></span> options were issued by the Company to purchase shares of Common Stock. During the three months ended March 31, 2022, the Company issued options to purchase <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20220331_zv9ebd5RhLh2" title="Grant date fair value of options granted">7,142</span> shares of Common Stock. The per share weighted-average fair value of the options granted during 2022 was estimated at $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20220331_z8aNbmOhA696" title="Weighted-average grant date fair value of options granted">2.84</span> on the date of grant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three months ended March 31, 2023, the Company issued restricted stock units (RSUs) for <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zoBEOddbimak" title="Grant date fair value of options granted">64,016</span> shares of Common Stock to employees, non-employees and the board of directors. The shares vest in equal monthly installments over terms of between immediately up to one year, subject to the employees and non-employees providing continuous service through the vesting date. During the three months ended March 31, 2023, approximately <span id="xdx_90B_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z7i4vAjEcB9d" title="Unissued shares">82,000</span> shares vested from RSUs previously issued.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three months ended March 31, 2022, the Company issued RSUs for <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zCvNnDBwy0c2" title="Grant date fair value of options granted">14,999</span> shares of Common Stock to employees and non-employees. The shares vest in equal monthly installments over terms of between immediately up to one year, subject to the employees and non-employees providing continuous service through the vesting date. During the three months ended March 31, 2022, approximately <span id="xdx_902_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJxYSr3qs3hi" title="Unissued shares">16,000</span> shares vested from RSUs previously issued.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zfVSkcq8UPl9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes weighted-average assumptions using the Black-Scholes option-pricing model used on the date of the grants issued during the three months ended March 31, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zcuTqXkjL51" style="display: none">SCHEDULE OF FAIR VALUE ASSUMPTIONS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: justify">Fair value of Common Stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_90D_eus-gaap--SharePrice_iI_c20220331_zF7q7VpvGpw6" title="Fair value of Common Stock">4.62</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20220331_zSqdtGSDLLQh" title="Volatility">63.9</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Expected term (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220331_zT992EkM0iT6" title="Expected term (in years)">6.0</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20220331_zH3Xs70z6CJb" title="Risk-free interest rate">2.20</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp0_uPure_c20220101__20220331_zzlX2rtaUgW5" title="Dividend yield">0</span></td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8AF_z1V3RmuDy7Nf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1100000 1000000.0 <p id="xdx_892_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zZ3TrFhUTOq9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: -0.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has recorded stock-based compensation expense (credit) related to the issuance of stock option awards in the following line items in the accompanying condensed consolidated statement of operations:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: -0.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zr9ErLaY5c7c" style="display: none">SUMMARY OF STOCK-BASED COMPENSATION EXPENSE RECOGNIZED FOR STOCK OPTION AWARDS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20230101__20230331_zhuIzlTMcF9b" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20220101__20220331_zTSCJH91wY5c" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Three Months Ended <br/>March 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_40A_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z72rMgGrApq8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: justify">Research and development</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">11,268</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">4,643</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zkEkycmhO5hl" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">146,345</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">101,404</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AllocatedShareBasedCompensationExpense_zbdPqD7kq0A3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total stock-based compensation expense</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">157,613</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">106,047</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 11268 4643 146345 101404 157613 106047 <p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z2iNMHmWLvm1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes stock option activity under the Plan:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zDcGt59bh8Bi" style="display: none">SUMMARY OF OPTION ACTIVITY</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number of <br/>options</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted-average <br/>exercise price</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted-average <br/>remaining <br/>contractual term <br/>(in years)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Aggregate <br/>intrinsic value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: justify">Outstanding at December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20230331_z7GupXSKACYh" style="width: 10%; text-align: right" title="Options Outstanding, beginning balance">806,392</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20230331_zBtJz1YPHMg4" style="width: 10%; text-align: right" title="Weighted-Average Exercise Price Outstanding, beginning balance">4.33</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20230331_zAN4Lua7Q13e" style="text-align: right" title="Options Granted"><span style="-sec-ix-hidden: xdx2ixbrl0584">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20230331_z9POYYR1ddi6" style="text-align: right" title="Weighted-Average Exercise Price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0586">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20230101__20230331_zXVQyAKp2GL8" style="text-align: right" title="Options Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0588">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20230331_zQ5jkMH9fpt5" style="text-align: right" title="Weighted-Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0590">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_pid_c20230101__20230331_zATSCKgP5w7j" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0592">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20230331_zVnV3eytyAq7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted-Average Exercise Price,Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0594">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Outstanding at March 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20230331_zUhorF8LlQO6" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding, ending balance">806,392</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20230331_zFqXNLS9DeAc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price Outstanding, ending balance">4.33</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20230331_zXZIkC9VdNE6" title="Weighted- Average Remaining Contractual Term, Outstanding">3.8</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20230101__20230331_zbPEESZJh2Bi" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Outstanding, ending balance">271,298</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Vested and exercisable at March 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iE_pid_c20230101__20230331_zLTHYElkZLti" style="border-bottom: Black 2.5pt double; text-align: right" title="Options, Vested and exercisable">803,218</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20230331_z3uqXqTwc0Gi" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price, Vested and exercisable">4.31</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20230331_zDBkFTiaFPml" title="Weighted- Average Remaining Contractual Term, Vested and exercisable">3.7</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iE_c20230101__20230331_zhVBgZvHHI13" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Vested and exercisable">271,298</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 806392 4.33 806392 4.33 P3Y9M18D 271298 803218 4.31 P3Y8M12D 271298 0 0 7142 2.84 64016 82000 14999 16000 <p id="xdx_899_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zfVSkcq8UPl9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes weighted-average assumptions using the Black-Scholes option-pricing model used on the date of the grants issued during the three months ended March 31, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zcuTqXkjL51" style="display: none">SCHEDULE OF FAIR VALUE ASSUMPTIONS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: justify">Fair value of Common Stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_90D_eus-gaap--SharePrice_iI_c20220331_zF7q7VpvGpw6" title="Fair value of Common Stock">4.62</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20220331_zSqdtGSDLLQh" title="Volatility">63.9</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Expected term (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220331_zT992EkM0iT6" title="Expected term (in years)">6.0</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20220331_zH3Xs70z6CJb" title="Risk-free interest rate">2.20</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp0_uPure_c20220101__20220331_zzlX2rtaUgW5" title="Dividend yield">0</span></td><td style="text-align: left">%</td></tr> </table> 4.62 0.639 P6Y 0.0220 0 <p id="xdx_805_ecustom--WarrantsDisclosureTextBlock_zCXoofnvtJ12" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 11. <span id="xdx_824_zM4fgXHmgyo8">WARRANTS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We account for Common Stock warrants as either equity instruments or derivative liabilities depending on the specific terms of the warrant agreement. Warrants are accounted for as derivative liabilities if the warrants allow for cash settlement or provide for modification of the warrant exercise price in the event subsequent sales of Common Stock by the Company are at a lower price per share than the then-current warrant exercise price. We classify derivative warrant liabilities on the condensed consolidated balance sheet at fair value, and changes in fair value during the periods presented in the condensed consolidated statement of operations, which is revalued at each balance sheet date subsequent to the initial issuance of the stock warrant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2023, and December 31, 2022, the Company had <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20230331_zwJWqbw5pudk" title="Warrant outstanding"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231_zRtwKHmp2p9g" title="Warrant outstanding">4,649,952</span></span> warrants outstanding to purchase one share of the Company’s Common Stock for each warrant at a weighted average exercise price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYIs0tIqYmH9" title="Weighted average exercise price"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zEcIz06RmZ08" title="Weighted average exercise price">6.39</span></span> and expire at various dates through September 2027. During the three months ended March 31, 2023 and 2022, <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_do_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZ2UFBNUwPqh" title="Exercise of warrants"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_do_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zr2waMXqz7w1" title="Exercise of warrants">no</span></span> warrants were exercised into an equivalent number of Common Shares.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 4649952 4649952 6.39 6.39 0 0 <p id="xdx_80E_eus-gaap--SubsequentEventsTextBlock_z0hjf6wAKREb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 12. <span id="xdx_824_zMUoZzAGTSg2">SUBSEQUENT EVENTS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the condensed consolidated financial statements were available to be issued. Based upon this review, the Company did not identify any subsequent events that would have required adjustment or disclosure in the condensed consolidated financial statements.</span></p> EXCEL 50 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

\E!J*:TE./H%QK& ,7X.Z/9"_Q:.5'8]R MH(<'E WZS,K9A.C0TG0HKBHYYQU_(-<^P :+P./9CR>M%:P) MDV*E23%<@#[*[%QF)6-,%0^$]$^'[9[K=JU\3?@2*WV)'>=+N?KOSKR#>)E- M2ONIS8'$[]9K;1.\JBYGZ4OL*%_*?O=VUU?-:0U_ K=RXHE5G$UX$BL]B1WE M2>;4!JP(UM6E5%;Y/9!S(^,V]SP!,1#B[P*MO$U($BLEB1TE2;.(AR&Y2!/X M.+&/6CRGZM(87E87K_0@=I0'749"+"7+YH(6Y^+Y_<7!W7ZE# M["@=FJT$#&&L9_&8:KPF),@M)<@]2H( +(+>FVGI_0#ER^[)D,^I!B.*?1C: MUCL0KR0U^9V)75HW2S/W #>C88\.3X?TK+.Q(9;VXQZPGV=L4Z[(-QZF@OQZ MXC@#LH:5.+L'945\);W)$9N0);>4)1?WG+M AR#R"SC+^GW^ELR$ERKH>RLW MGO2\1=?0HAO3HF\(_#O<'$]OK)R M-2%1;BE1+JX\3QT*Z[*WXO%25%Y6/!!T,YY]&-MO'S:A3VZI3RZN/:;G!)_# M*+[GREPX38B69)HJX(7?I/UA:<5^)1G*VZ()M7)+M7)Q)?J9V7P@R=JJZ[Q5 MLTE]H&4G^#?4;8O2PUQ%_:SN/XJ#0Y&SEZG" M-/_1_4$VF*&L-E:5!V5 4,IJ_\N_'P)QI(#IB (Y*)"G*H0'A;!Q=(^L<>L# MMWRUU.H>:2<-UMQ%$YM&&[R1E5O&:ZOAK00]NUJK*H=%$3F"*Z,*F7,+-^]Y MP:M,H&MGV*#77RI>YQ+>O$%OT9?K#^CURS?+A04 SLPB.WSL_?YC9.1C?W!] MAD(\1R0@H4=]/:W^062M.CE57X#;K>^D]9TT]J(QWVNM1641-P:@//&Y_7>%&M,N3IPMTICE@9)LES<'3LTE,.8XC".TE;P!"QMP=)) ML.^R3-6 K0&L[%9HJ!B9 ,@WA3!S5 GK@[TW2D_@!"3N@?9(!30901RUB*-) MQ)^J.PBFT@\^7)$'5QA&/5Q#J2BB@1\6:V&Q25A76NRXS(_BF)WDO \M&^"@ M%/"2'MRA6!3B)!V)8]P"CB@1QRC!+8C_0I 6: M_""RP*3:/C2A==MI!]QF1U,S&< @) I8/S<]8IC2,/%C35NLZ236OYJ5'P]F M.O@J2TG0@^81"H*1],1!QS[!$]9['-I!O;=;&8U8VL/GDR0X(9A$(R"/*!(_ MB2<*R6]D(:T4?K(XF'DFMG@N:Z=.=]R()^FHJ\$[_N#*KM=A,HPY95'83VN/ M7$BC@)*1E>E(#4^S&H#4-;0KXOO.-3'^% J'!2V!^LOZ((=R$86*1D= =F2& MI]GL=\6KR2AZ&(DE-.SO0(\B'?)4G+(P"/MH MO:R7L&1LT3M.P].DMH?[(YA#?O+#',I-P^R8#$]3V5J5I;2.%?9]3*8J*ZM; M464 &;V^%@+]J:Q B;^1GC3NW_W(6T9^W=!I #J&Q,EDV;RV*ONZ544NM'GU M BIQ?-$PI7WP5\])POWIZOE,UDY][Q@73U,N-%X; ?LI1\9%80[[7R/HN&N! M7@9G08 1= _(;+D6%S#.S(%*W=_^">1+;;=*R_]$?H$J]?A4&N.*G=((YG%C M(:D@GQ"W".:J;-L.5O,FW6!8$N4-?,0_,!UB/NG%SV39KQLZ'>&Z#H),=Q!N MFZEJ),SQ<9@QG9,DFL>8^L*.M.*D:UG(=,NR9R\S6AN]T(>M2#@@!. ]QL%K'RX<2=L[8GJZG]02P,$% M @ +V*O5M.@ZM_Z @ \ D !@ !X;"]W;W)K6@I9UQ-G4SKXM)U59*1'*N>* B' MF:60.=;0E2M7%9+@U#KES T\;^CFF'(GGMBQN8PGHM2,,@[7X M1LE&;;61">5!B$?3^9).'<\0$482;20P/-9D1A@S2L#QJQ9UFC6-XW;[6?W6 M!@_!/&!%9H)]IZG.IL[(02E9XI+I.['Y3.J !D8O$4S9?[2I;*.Q@Y)2:9'7 MSD"04UX]\5.=B"T'O[_'(:@=@E,=PMHAM(%69#:L&ZQQ/)%B@Z2Q!C73L+FQ MWA -Y>8U+K2$60I^.IX)GL)+(2F"EA*,IEA#YQHSS!."%D98H;-[CLN4PLPY M.IMC2;C.B*8)9N?H(WJ/7*0R&%435P.347:3>OWK:OU@S_I?L>RAT+] @1>$ M'>ZSP^XW)&G<@[:["YEHTA$TZ0BLWF"/WD)#^%"E&HDENJ4
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c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end XML 51 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 52 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 53 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 68 178 1 false 23 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://bioaffinitytech.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://bioaffinitytech.com/role/BalanceSheets Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://bioaffinitytech.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://bioaffinitytech.com/role/StatementsOfOperations Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) Sheet http://bioaffinitytech.com/role/StatementsOfStockholdersEquityDeficit Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://bioaffinitytech.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - NATURE OF OPERATIONS, ORGANIZATION, AND BASIS OF PRESENTATION Sheet http://bioaffinitytech.com/role/NatureOfOperationsOrganizationAndBasisOfPresentation NATURE OF OPERATIONS, ORGANIZATION, AND BASIS OF PRESENTATION Notes 7 false false R8.htm 00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://bioaffinitytech.com/role/SummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 00000009 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS Sheet http://bioaffinitytech.com/role/PrepaidExpensesAndOtherCurrentAssets PREPAID EXPENSES AND OTHER CURRENT ASSETS Notes 9 false false R10.htm 00000010 - Disclosure - PROPERTY AND EQUIPMENT, NET Sheet http://bioaffinitytech.com/role/PropertyAndEquipmentNet PROPERTY AND EQUIPMENT, NET Notes 10 false false R11.htm 00000011 - Disclosure - ACCRUED EXPENSES Sheet http://bioaffinitytech.com/role/AccruedExpenses ACCRUED EXPENSES Notes 11 false false R12.htm 00000012 - Disclosure - LOAN PAYABLE Sheet http://bioaffinitytech.com/role/LoanPayable LOAN PAYABLE Notes 12 false false R13.htm 00000013 - Disclosure - FAIR VALUE MEASUREMENTS Sheet http://bioaffinitytech.com/role/FairValueMeasurements FAIR VALUE MEASUREMENTS Notes 13 false false R14.htm 00000014 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://bioaffinitytech.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 14 false false R15.htm 00000015 - Disclosure - CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS??? DEFICIT Sheet http://bioaffinitytech.com/role/ConvertiblePreferredStockAndStockholdersDeficit CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS??? DEFICIT Notes 15 false false R16.htm 00000016 - Disclosure - STOCK-BASED COMPENSATION Sheet http://bioaffinitytech.com/role/Stock-basedCompensation STOCK-BASED COMPENSATION Notes 16 false false R17.htm 00000017 - Disclosure - WARRANTS Sheet http://bioaffinitytech.com/role/Warrants WARRANTS Notes 17 false false R18.htm 00000018 - Disclosure - SUBSEQUENT EVENTS Sheet http://bioaffinitytech.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 18 false false R19.htm 00000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://bioaffinitytech.com/role/SummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 19 false false R20.htm 00000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://bioaffinitytech.com/role/SummaryOfSignificantAccountingPoliciesTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://bioaffinitytech.com/role/SummaryOfSignificantAccountingPolicies 20 false false R21.htm 00000021 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables) Sheet http://bioaffinitytech.com/role/PrepaidExpensesAndOtherCurrentAssetsTables PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables) Tables http://bioaffinitytech.com/role/PrepaidExpensesAndOtherCurrentAssets 21 false false R22.htm 00000022 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables) Sheet http://bioaffinitytech.com/role/PropertyAndEquipmentNetTables PROPERTY AND EQUIPMENT, NET (Tables) Tables http://bioaffinitytech.com/role/PropertyAndEquipmentNet 22 false false R23.htm 00000023 - Disclosure - ACCRUED EXPENSES (Tables) Sheet http://bioaffinitytech.com/role/AccruedExpensesTables ACCRUED EXPENSES (Tables) Tables http://bioaffinitytech.com/role/AccruedExpenses 23 false false R24.htm 00000024 - Disclosure - STOCK-BASED COMPENSATION (Tables) Sheet http://bioaffinitytech.com/role/Stock-basedCompensationTables STOCK-BASED COMPENSATION (Tables) Tables http://bioaffinitytech.com/role/Stock-basedCompensation 24 false false R25.htm 00000025 - Disclosure - NATURE OF OPERATIONS, ORGANIZATION, AND BASIS OF PRESENTATION (Details Narrative) Sheet http://bioaffinitytech.com/role/NatureOfOperationsOrganizationAndBasisOfPresentationDetailsNarrative NATURE OF OPERATIONS, ORGANIZATION, AND BASIS OF PRESENTATION (Details Narrative) Details http://bioaffinitytech.com/role/NatureOfOperationsOrganizationAndBasisOfPresentation 25 false false R26.htm 00000026 - Disclosure - SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES (Details) Sheet http://bioaffinitytech.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES (Details) Details 26 false false R27.htm 00000027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://bioaffinitytech.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://bioaffinitytech.com/role/SummaryOfSignificantAccountingPoliciesTables 27 false false R28.htm 00000028 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) Sheet http://bioaffinitytech.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) Details 28 false false R29.htm 00000029 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details) Sheet http://bioaffinitytech.com/role/ScheduleOfPropertyAndEquipmentDetails SCHEDULE OF PROPERTY AND EQUIPMENT (Details) Details 29 false false R30.htm 00000030 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details Narrative) Sheet http://bioaffinitytech.com/role/PropertyAndEquipmentNetDetailsNarrative PROPERTY AND EQUIPMENT, NET (Details Narrative) Details http://bioaffinitytech.com/role/PropertyAndEquipmentNetTables 30 false false R31.htm 00000031 - Disclosure - SCHEDULE OF ACCRUED EXPENSES (Details) Sheet http://bioaffinitytech.com/role/ScheduleOfAccruedExpensesDetails SCHEDULE OF ACCRUED EXPENSES (Details) Details 31 false false R32.htm 00000032 - Disclosure - LOAN PAYABLE (Details Narrative) Sheet http://bioaffinitytech.com/role/LoanPayableDetailsNarrative LOAN PAYABLE (Details Narrative) Details http://bioaffinitytech.com/role/LoanPayable 32 false false R33.htm 00000033 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) Sheet http://bioaffinitytech.com/role/CommitmentsAndContingenciesDetailsNarrative COMMITMENTS AND CONTINGENCIES (Details Narrative) Details http://bioaffinitytech.com/role/CommitmentsAndContingencies 33 false false R34.htm 00000034 - Disclosure - CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS??? DEFICIT (Details Narrative) Sheet http://bioaffinitytech.com/role/ConvertiblePreferredStockAndStockholdersDeficitDetailsNarrative CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS??? DEFICIT (Details Narrative) Details http://bioaffinitytech.com/role/ConvertiblePreferredStockAndStockholdersDeficit 34 false false R35.htm 00000035 - Disclosure - SUMMARY OF STOCK-BASED COMPENSATION EXPENSE RECOGNIZED FOR STOCK OPTION AWARDS (Details) Sheet http://bioaffinitytech.com/role/SummaryOfStock-basedCompensationExpenseRecognizedForStockOptionAwardsDetails SUMMARY OF STOCK-BASED COMPENSATION EXPENSE RECOGNIZED FOR STOCK OPTION AWARDS (Details) Details 35 false false R36.htm 00000036 - Disclosure - SUMMARY OF OPTION ACTIVITY (Details) Sheet http://bioaffinitytech.com/role/SummaryOfOptionActivityDetails SUMMARY OF OPTION ACTIVITY (Details) Details 36 false false R37.htm 00000037 - Disclosure - SCHEDULE OF FAIR VALUE ASSUMPTIONS (Details) Sheet http://bioaffinitytech.com/role/ScheduleOfFairValueAssumptionsDetails SCHEDULE OF FAIR VALUE ASSUMPTIONS (Details) Details 37 false false R38.htm 00000038 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative) Sheet http://bioaffinitytech.com/role/Stock-basedCompensationDetailsNarrative STOCK-BASED COMPENSATION (Details Narrative) Details http://bioaffinitytech.com/role/Stock-basedCompensationTables 38 false false R39.htm 00000039 - Disclosure - WARRANTS (Details Narrative) Sheet http://bioaffinitytech.com/role/WarrantsDetailsNarrative WARRANTS (Details Narrative) Details http://bioaffinitytech.com/role/Warrants 39 false false All Reports Book All Reports form10-q.htm biaf-20230331.xsd biaf-20230331_cal.xml biaf-20230331_def.xml biaf-20230331_lab.xml biaf-20230331_pre.xml ex31-1.htm ex31-2.htm ex32-1.htm http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 55 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form10-q.htm": { "axisCustom": 0, "axisStandard": 10, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 334, "http://xbrl.sec.gov/dei/2023": 34 }, "contextCount": 68, "dts": { "calculationLink": { "local": [ "biaf-20230331_cal.xml" ] }, "definitionLink": { "local": [ "biaf-20230331_def.xml" ] }, "inline": { "local": [ "form10-q.htm" ] }, "labelLink": { "local": [ "biaf-20230331_lab.xml" ] }, "presentationLink": { "local": [ "biaf-20230331_pre.xml" ] }, "schema": { "local": [ "biaf-20230331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 291, "entityCount": 1, "hidden": { "http://bioaffinitytech.com/20230331": 5, "http://fasb.org/us-gaap/2023": 45, "http://xbrl.sec.gov/dei/2023": 4, "total": 54 }, "keyCustom": 11, "keyStandard": 167, "memberCustom": 4, "memberStandard": 17, "nsprefix": "BIAF", "nsuri": "http://bioaffinitytech.com/20230331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://bioaffinitytech.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - PROPERTY AND EQUIPMENT, NET", "menuCat": "Notes", "order": "10", "role": "http://bioaffinitytech.com/role/PropertyAndEquipmentNet", "shortName": "PROPERTY AND EQUIPMENT, NET", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - ACCRUED EXPENSES", "menuCat": "Notes", "order": "11", "role": "http://bioaffinitytech.com/role/AccruedExpenses", "shortName": "ACCRUED EXPENSES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - LOAN PAYABLE", "menuCat": "Notes", "order": "12", "role": "http://bioaffinitytech.com/role/LoanPayable", "shortName": "LOAN PAYABLE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - FAIR VALUE MEASUREMENTS", "menuCat": "Notes", "order": "13", "role": "http://bioaffinitytech.com/role/FairValueMeasurements", "shortName": "FAIR VALUE MEASUREMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - COMMITMENTS AND CONTINGENCIES", "menuCat": "Notes", "order": "14", "role": "http://bioaffinitytech.com/role/CommitmentsAndContingencies", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS\u2019 DEFICIT", "menuCat": "Notes", "order": "15", "role": "http://bioaffinitytech.com/role/ConvertiblePreferredStockAndStockholdersDeficit", "shortName": "CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS\u2019 DEFICIT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - STOCK-BASED COMPENSATION", "menuCat": "Notes", "order": "16", "role": "http://bioaffinitytech.com/role/Stock-basedCompensation", "shortName": "STOCK-BASED COMPENSATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "BIAF:WarrantsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - WARRANTS", "menuCat": "Notes", "order": "17", "role": "http://bioaffinitytech.com/role/Warrants", "shortName": "WARRANTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "BIAF:WarrantsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - SUBSEQUENT EVENTS", "menuCat": "Notes", "order": "18", "role": "http://bioaffinitytech.com/role/SubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "menuCat": "Policies", "order": "19", "role": "http://bioaffinitytech.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)", "menuCat": "Statements", "order": "2", "role": "http://bioaffinitytech.com/role/BalanceSheets", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "lang": null, "name": "us-gaap:AccountsAndOtherReceivablesNetCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "menuCat": "Tables", "order": "20", "role": "http://bioaffinitytech.com/role/SummaryOfSignificantAccountingPoliciesTables", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "BIAF:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "BIAF:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)", "menuCat": "Tables", "order": "21", "role": "http://bioaffinitytech.com/role/PrepaidExpensesAndOtherCurrentAssetsTables", "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "BIAF:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "BIAF:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)", "menuCat": "Tables", "order": "22", "role": "http://bioaffinitytech.com/role/PropertyAndEquipmentNetTables", "shortName": "PROPERTY AND EQUIPMENT, NET (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - ACCRUED EXPENSES (Tables)", "menuCat": "Tables", "order": "23", "role": "http://bioaffinitytech.com/role/AccruedExpensesTables", "shortName": "ACCRUED EXPENSES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - STOCK-BASED COMPENSATION (Tables)", "menuCat": "Tables", "order": "24", "role": "http://bioaffinitytech.com/role/Stock-basedCompensationTables", "shortName": "STOCK-BASED COMPENSATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - NATURE OF OPERATIONS, ORGANIZATION, AND BASIS OF PRESENTATION (Details Narrative)", "menuCat": "Details", "order": "25", "role": "http://bioaffinitytech.com/role/NatureOfOperationsOrganizationAndBasisOfPresentationDetailsNarrative", "shortName": "NATURE OF OPERATIONS, ORGANIZATION, AND BASIS OF PRESENTATION (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "INF", "lang": null, "name": "BIAF:TotalAssetsPercent", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES (Details)", "menuCat": "Details", "order": "26", "role": "http://bioaffinitytech.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails", "shortName": "SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:AdvertisingCostsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AdvertisingExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "menuCat": "Details", "order": "27", "role": "http://bioaffinitytech.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:AdvertisingCostsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AdvertisingExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "BIAF:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "BIAF:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PrepaidInsurance", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)", "menuCat": "Details", "order": "28", "role": "http://bioaffinitytech.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails", "shortName": "SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "BIAF:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "BIAF:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PrepaidInsurance", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details)", "menuCat": "Details", "order": "29", "role": "http://bioaffinitytech.com/role/ScheduleOfPropertyAndEquipmentDetails", "shortName": "SCHEDULE OF PROPERTY AND EQUIPMENT (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://bioaffinitytech.com/role/BalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:CommonStockSharesIssued", "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details Narrative)", "menuCat": "Details", "order": "30", "role": "http://bioaffinitytech.com/role/PropertyAndEquipmentNetDetailsNarrative", "shortName": "PROPERTY AND EQUIPMENT, NET (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - SCHEDULE OF ACCRUED EXPENSES (Details)", "menuCat": "Details", "order": "31", "role": "http://bioaffinitytech.com/role/ScheduleOfAccruedExpensesDetails", "shortName": "SCHEDULE OF ACCRUED EXPENSES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LoansPayableCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - LOAN PAYABLE (Details Narrative)", "menuCat": "Details", "order": "32", "role": "http://bioaffinitytech.com/role/LoanPayableDetailsNarrative", "shortName": "LOAN PAYABLE (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-09-30_us-gaap_ShortTermDebtMember", "decimals": "-5", "lang": null, "name": "us-gaap:LoansPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PaymentsForRent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)", "menuCat": "Details", "order": "33", "role": "http://bioaffinitytech.com/role/CommitmentsAndContingenciesDetailsNarrative", "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PaymentsForRent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-06-012022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityReverseStockSplit", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS\u2019 DEFICIT (Details Narrative)", "menuCat": "Details", "order": "34", "role": "http://bioaffinitytech.com/role/ConvertiblePreferredStockAndStockholdersDeficitDetailsNarrative", "shortName": "CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS\u2019 DEFICIT (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-06-012022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityReverseStockSplit", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - SUMMARY OF STOCK-BASED COMPENSATION EXPENSE RECOGNIZED FOR STOCK OPTION AWARDS (Details)", "menuCat": "Details", "order": "35", "role": "http://bioaffinitytech.com/role/SummaryOfStock-basedCompensationExpenseRecognizedForStockOptionAwardsDetails", "shortName": "SUMMARY OF STOCK-BASED COMPENSATION EXPENSE RECOGNIZED FOR STOCK OPTION AWARDS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - SUMMARY OF OPTION ACTIVITY (Details)", "menuCat": "Details", "order": "36", "role": "http://bioaffinitytech.com/role/SummaryOfOptionActivityDetails", "shortName": "SUMMARY OF OPTION ACTIVITY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharePrice", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000037 - Disclosure - SCHEDULE OF FAIR VALUE ASSUMPTIONS (Details)", "menuCat": "Details", "order": "37", "role": "http://bioaffinitytech.com/role/ScheduleOfFairValueAssumptionsDetails", "shortName": "SCHEDULE OF FAIR VALUE ASSUMPTIONS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharePrice", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000038 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)", "menuCat": "Details", "order": "38", "role": "http://bioaffinitytech.com/role/Stock-basedCompensationDetailsNarrative", "shortName": "STOCK-BASED COMPENSATION (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "span", "span", "p", "BIAF:WarrantsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000039 - Disclosure - WARRANTS (Details Narrative)", "menuCat": "Details", "order": "39", "role": "http://bioaffinitytech.com/role/WarrantsDetailsNarrative", "shortName": "WARRANTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "p", "BIAF:WarrantsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "menuCat": "Statements", "order": "4", "role": "http://bioaffinitytech.com/role/StatementsOfOperations", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited)", "menuCat": "Statements", "order": "5", "role": "http://bioaffinitytech.com/role/StatementsOfStockholdersEquityDeficit", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_ConvertiblePreferredStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "menuCat": "Statements", "order": "6", "role": "http://bioaffinitytech.com/role/StatementsOfCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "lang": null, "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - NATURE OF OPERATIONS, ORGANIZATION, AND BASIS OF PRESENTATION", "menuCat": "Notes", "order": "7", "role": "http://bioaffinitytech.com/role/NatureOfOperationsOrganizationAndBasisOfPresentation", "shortName": "NATURE OF OPERATIONS, ORGANIZATION, AND BASIS OF PRESENTATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "menuCat": "Notes", "order": "8", "role": "http://bioaffinitytech.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "BIAF:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS", "menuCat": "Notes", "order": "9", "role": "http://bioaffinitytech.com/role/PrepaidExpensesAndOtherCurrentAssets", "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "BIAF:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 23, "tag": { "BIAF_AccruedClinicalExpenseCurrent": { "auth_ref": [], "calculation": { "http://bioaffinitytech.com/role/ScheduleOfAccruedExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued clinical expense current.", "label": "Clinical" } } }, "localname": "AccruedClinicalExpenseCurrent", "nsuri": "http://bioaffinitytech.com/20230331", "presentation": [ "http://bioaffinitytech.com/role/ScheduleOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "BIAF_BeneficialConversionFeatureForBridgeNotes": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Beneficial conversion feature for bridge notes.", "label": "BeneficialConversionFeatureForBridgeNotes", "verboseLabel": "Beneficial conversion feature for bridge notes" } } }, "localname": "BeneficialConversionFeatureForBridgeNotes", "nsuri": "http://bioaffinitytech.com/20230331", "presentation": [ "http://bioaffinitytech.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "BIAF_ClinicalDevelopmentExpense": { "auth_ref": [], "calculation": { "http://bioaffinitytech.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Clinical development expense.", "label": "Clinical development" } } }, "localname": "ClinicalDevelopmentExpense", "nsuri": "http://bioaffinitytech.com/20230331", "presentation": [ "http://bioaffinitytech.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "BIAF_CommonStockParValue.007PerShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock, Par Value $.007 per share [Member]", "label": "Common Stock, Par Value $.007 per share" } } }, "localname": "CommonStockParValue.007PerShareMember", "nsuri": "http://bioaffinitytech.com/20230331", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "domainItemType" }, "BIAF_ComputerAndSoftwareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Computer And Software [Member]" } } }, "localname": "ComputerAndSoftwareMember", "nsuri": "http://bioaffinitytech.com/20230331", "presentation": [ "http://bioaffinitytech.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "BIAF_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Prepaid Expenses And Other Current Assets", "verboseLabel": "Schedule Of Prepaid Expenses And Other Current Assets" } } }, "localname": "DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract", "nsuri": "http://bioaffinitytech.com/20230331", "xbrltype": "stringItemType" }, "BIAF_DisclosureWarrantsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants" } } }, "localname": "DisclosureWarrantsAbstract", "nsuri": "http://bioaffinitytech.com/20230331", "xbrltype": "stringItemType" }, "BIAF_FairValueAdjustmentsOnConvertibleNotesPayable": { "auth_ref": [], "calculation": { "http://bioaffinitytech.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://bioaffinitytech.com/role/StatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value adjustments on convertible notes payable.", "label": "Fair value adjustments on convertible notes payable", "negatedLabel": "Fair value adjustments on convertible notes payable" } } }, "localname": "FairValueAdjustmentsOnConvertibleNotesPayable", "nsuri": "http://bioaffinitytech.com/20230331", "presentation": [ "http://bioaffinitytech.com/role/StatementsOfCashFlows", "http://bioaffinitytech.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "BIAF_FairValueOfWarrantsIssued": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of warrants issued.", "label": "Fair value of warrants issued to placement agents" } } }, "localname": "FairValueOfWarrantsIssued", "nsuri": "http://bioaffinitytech.com/20230331", "presentation": [ "http://bioaffinitytech.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "BIAF_LabEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lab Equipment [Member]" } } }, "localname": "LabEquipmentMember", "nsuri": "http://bioaffinitytech.com/20230331", "presentation": [ "http://bioaffinitytech.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "BIAF_PaymentOfDeferredOfferingCosts": { "auth_ref": [], "calculation": { "http://bioaffinitytech.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment of deferred offering costs.", "label": "PaymentOfDeferredOfferingCosts", "negatedLabel": "Payment of deferred offering costs" } } }, "localname": "PaymentOfDeferredOfferingCosts", "nsuri": "http://bioaffinitytech.com/20230331", "presentation": [ "http://bioaffinitytech.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "BIAF_PrepaidExpensesAndOtherCurrentAssetsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prepaid Expenses And Other Current Assets [Text Block]", "label": "PREPAID EXPENSES AND OTHER CURRENT ASSETS" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsTextBlock", "nsuri": "http://bioaffinitytech.com/20230331", "presentation": [ "http://bioaffinitytech.com/role/PrepaidExpensesAndOtherCurrentAssets" ], "xbrltype": "textBlockItemType" }, "BIAF_PrepaidLegalAndProfessional": { "auth_ref": [], "calculation": { "http://bioaffinitytech.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Prepaid legal and professional.", "label": "Legal and professional" } } }, "localname": "PrepaidLegalAndProfessional", "nsuri": "http://bioaffinitytech.com/20230331", "presentation": [ "http://bioaffinitytech.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "BIAF_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Prepaid Expenses And Other Current Assets [Table Text Block]", "label": "SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS" } } }, "localname": "ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "nsuri": "http://bioaffinitytech.com/20230331", "presentation": [ "http://bioaffinitytech.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" ], "xbrltype": "textBlockItemType" }, "BIAF_TotalAssetsPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Total assets, percent.", "label": "Total assets, percent" } } }, "localname": "TotalAssetsPercent", "nsuri": "http://bioaffinitytech.com/20230331", "presentation": [ "http://bioaffinitytech.com/role/NatureOfOperationsOrganizationAndBasisOfPresentationDetailsNarrative" ], "xbrltype": "percentItemType" }, "BIAF_TradeableWarrantsToPurchaseCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tradeable Warrants to Purchase Common Stock [Member]", "label": "Tradeable Warrants to Purchase Common Stock" } } }, "localname": "TradeableWarrantsToPurchaseCommonStockMember", "nsuri": "http://bioaffinitytech.com/20230331", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "domainItemType" }, "BIAF_WarrantsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants Disclosure [Text Block]", "label": "WARRANTS" } } }, "localname": "WarrantsDisclosureTextBlock", "nsuri": "http://bioaffinitytech.com/20230331", "presentation": [ "http://bioaffinitytech.com/role/Warrants" ], "xbrltype": "textBlockItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r496" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r496" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r495" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r493", "r495", "r496" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r494" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r482" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r495" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r495" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r497" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r485" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r488" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r484" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r484" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r501" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r484" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r498" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r496" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r484" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r484" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r484" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r484" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r499" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r495" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r489" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r490" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r483" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r487" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r486" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r491" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r492" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r500" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_MaximumMember": { "auth_ref": [ "r189", "r190", "r191", "r192", "r257", "r334", "r351", "r383", "r384", "r437", "r438", "r439", "r440", "r441", "r449", "r450", "r459", "r467", "r468", "r471", "r529", "r538", "r539", "r540", "r541", "r542", "r543" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://bioaffinitytech.com/role/ConvertiblePreferredStockAndStockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r189", "r190", "r191", "r192", "r257", "r334", "r351", "r383", "r384", "r437", "r438", "r439", "r440", "r441", "r449", "r450", "r459", "r467", "r468", "r471", "r529", "r538", "r539", "r540", "r541", "r542", "r543" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://bioaffinitytech.com/role/ConvertiblePreferredStockAndStockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r189", "r190", "r191", "r192", "r256", "r257", "r284", "r285", "r286", "r333", "r334", "r351", "r383", "r384", "r437", "r438", "r439", "r440", "r441", "r449", "r450", "r459", "r467", "r468", "r471", "r474", "r524", "r529", "r539", "r540", "r541", "r542", "r543" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://bioaffinitytech.com/role/ConvertiblePreferredStockAndStockholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r189", "r190", "r191", "r192", "r256", "r257", "r284", "r285", "r286", "r333", "r334", "r351", "r383", "r384", "r437", "r438", "r439", "r440", "r441", "r449", "r450", "r459", "r467", "r468", "r471", "r474", "r524", "r529", "r539", "r540", "r541", "r542", "r543" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://bioaffinitytech.com/role/ConvertiblePreferredStockAndStockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RestatementAdjustmentMember": { "auth_ref": [ "r137", "r138", "r139", "r148", "r149", "r161", "r316", "r317", "r503", "r504", "r505", "r506", "r507", "r508", "r509" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period, Adjustment [Member]" } } }, "localname": "RestatementAdjustmentMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://bioaffinitytech.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RestatementAxis": { "auth_ref": [ "r107", "r137", "r138", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r147", "r148", "r149", "r150", "r151", "r152", "r161", "r182", "r183", "r302", "r315", "r316", "r317", "r318", "r328", "r329", "r330", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r364" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Axis]" } } }, "localname": "RestatementAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://bioaffinitytech.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_RestatementDomain": { "auth_ref": [ "r107", "r137", "r138", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r147", "r148", "r149", "r150", "r151", "r152", "r161", "r182", "r183", "r302", "r315", "r316", "r317", "r318", "r328", "r329", "r330", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r364" ], "localname": "RestatementDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://bioaffinitytech.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_AccountsAndOtherReceivablesNetCurrent": { "auth_ref": [], "calculation": { "http://bioaffinitytech.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.", "label": "Accounts and other receivables, net" } } }, "localname": "AccountsAndOtherReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "ACCRUED EXPENSES" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/AccruedExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r12", "r470" ], "calculation": { "http://bioaffinitytech.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionExpense": { "auth_ref": [ "r461", "r525" ], "calculation": { "http://bioaffinitytech.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.", "label": "Accretion of debt issuance costs" } } }, "localname": "AccretionExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r16" ], "calculation": { "http://bioaffinitytech.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://bioaffinitytech.com/role/ScheduleOfAccruedExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued expenses", "totalLabel": "Total accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/BalanceSheets", "http://bioaffinitytech.com/role/ScheduleOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r16" ], "calculation": { "http://bioaffinitytech.com/role/ScheduleOfAccruedExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "verboseLabel": "Legal and professional" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/ScheduleOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r37", "r113", "r345" ], "calculation": { "http://bioaffinitytech.com/role/ScheduleOfPropertyAndEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r58", "r470", "r546" ], "calculation": { "http://bioaffinitytech.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r293", "r294", "r295", "r371", "r518", "r519", "r520", "r534", "r547" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature": { "auth_ref": [ "r7", "r83", "r300" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.", "label": "Beneficial conversion feature for bridge notes" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC).", "label": "Debt discount for warrants issued" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalOther", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "auth_ref": [ "r95" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for advertising cost.", "label": "Advertising expense" } } }, "localname": "AdvertisingCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdvertisingExpense": { "auth_ref": [ "r297" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.", "label": "Advertising Expense", "verboseLabel": "Advertising expense" } } }, "localname": "AdvertisingExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r288", "r296" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Total stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/SummaryOfStock-basedCompensationExpenseRecognizedForStockOptionAwardsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r160" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Anti-dilutive securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r31" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r31" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r88", "r115", "r135", "r165", "r171", "r175", "r180", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r304", "r306", "r320", "r339", "r405", "r470", "r481", "r527", "r528", "r536" ], "calculation": { "http://bioaffinitytech.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r109", "r120", "r135", "r180", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r304", "r306", "r320", "r470", "r527", "r528", "r536" ], "calculation": { "http://bioaffinitytech.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r27", "r111", "r452" ], "calculation": { "http://bioaffinitytech.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/BalanceSheets", "http://bioaffinitytech.com/role/NatureOfOperationsOrganizationAndBasisOfPresentationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r27", "r70", "r131" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r1", "r70" ], "calculation": { "http://bioaffinitytech.com/role/StatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net decrease in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash financing activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r105", "r116", "r117", "r118", "r135", "r154", "r155", "r157", "r159", "r163", "r164", "r180", "r193", "r195", "r196", "r197", "r200", "r201", "r229", "r230", "r233", "r236", "r243", "r320", "r366", "r367", "r368", "r369", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r393", "r414", "r432", "r442", "r443", "r444", "r445", "r446", "r502", "r515", "r521" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/ConvertiblePreferredStockAndStockholdersDeficitDetailsNarrative", "http://bioaffinitytech.com/role/Cover", "http://bioaffinitytech.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [ "r116", "r117", "r118", "r163", "r229", "r230", "r231", "r233", "r236", "r241", "r243", "r366", "r367", "r368", "r369", "r467", "r502", "r515" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/ConvertiblePreferredStockAndStockholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r244" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Weighted average exercise price" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/WarrantsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Warrant outstanding" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/WarrantsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r21", "r50", "r340", "r392" ], "calculation": { "http://bioaffinitytech.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and contingencies (See Note 8)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r78", "r187", "r188", "r448", "r526" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Unissued shares" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r472", "r473", "r474", "r476", "r477", "r478", "r479", "r518", "r519", "r534", "r545", "r547" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r57" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/BalanceSheetsParenthetical", "http://bioaffinitytech.com/role/ConvertiblePreferredStockAndStockholdersDeficitDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r57", "r393" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/BalanceSheetsParenthetical", "http://bioaffinitytech.com/role/ConvertiblePreferredStockAndStockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r57" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/BalanceSheetsParenthetical", "http://bioaffinitytech.com/role/ConvertiblePreferredStockAndStockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r7", "r57", "r393", "r411", "r547", "r548" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r57", "r342", "r470" ], "calculation": { "http://bioaffinitytech.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, par value $0.007 per share; 14,285,714 shares authorized; 8,463,052 issued and outstanding at March 31, 2023; and 8,381,324 shares issued and outstanding at December 31, 2022" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r49", "r455" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConvertibleDebtSecuritiesMember": { "auth_ref": [ "r531" ], "lang": { "en-us": { "role": { "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.", "label": "Convertible Debt Securities [Member]" } } }, "localname": "ConvertibleDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertiblePreferredStockMember": { "auth_ref": [ "r229", "r230", "r233", "r476", "r477", "r478", "r479" ], "lang": { "en-us": { "role": { "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.", "label": "Convertible Preferred Stock [Member]" } } }, "localname": "ConvertiblePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails", "http://bioaffinitytech.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r66", "r135", "r180", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r320", "r527" ], "calculation": { "http://bioaffinitytech.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of sales" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r29", "r30" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Number of shares issued in debt conversion" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/ConvertiblePreferredStockAndStockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r79", "r133", "r202", "r208", "r209", "r210", "r211", "r212", "r213", "r218", "r225", "r226", "r227" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "LOAN PAYABLE" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/LoanPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r11", "r54", "r55", "r89", "r90", "r136", "r203", "r204", "r205", "r206", "r207", "r209", "r214", "r215", "r216", "r217", "r219", "r220", "r221", "r222", "r223", "r224", "r327", "r462", "r463", "r464", "r465", "r466", "r516" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/LoanPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r18", "r204" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Loan interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/LoanPayableDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r20", "r136", "r203", "r204", "r205", "r206", "r207", "r209", "r214", "r215", "r216", "r217", "r219", "r220", "r221", "r222", "r223", "r224", "r327", "r462", "r463", "r464", "r465", "r466", "r516" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/LoanPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentPaymentTerms": { "auth_ref": [ "r19", "r51" ], "lang": { "en-us": { "role": { "documentation": "Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment.", "label": "Loan payment term" } } }, "localname": "DebtInstrumentPaymentTerms", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/LoanPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentPeriodicPayment": { "auth_ref": [ "r20", "r51" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments including both interest and principal payments.", "label": "Loan periodic payment amount" } } }, "localname": "DebtInstrumentPeriodicPayment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/LoanPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r5", "r36" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/PropertyAndEquipmentNetDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r5", "r36" ], "calculation": { "http://bioaffinitytech.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r258", "r261", "r289", "r290", "r292", "r469" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "STOCK-BASED COMPENSATION" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/Stock-basedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r126", "r142", "r143", "r145", "r146", "r148", "r153", "r154", "r157", "r158", "r159", "r161", "r317", "r318", "r336", "r349", "r456" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Net loss per common share, basic and diluted" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/StatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r31", "r32" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Loss Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r16" ], "calculation": { "http://bioaffinitytech.com/role/ScheduleOfAccruedExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Compensation" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/ScheduleOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/SummaryOfStock-basedCompensationExpenseRecognizedForStockOptionAwardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r291" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Unrecognized compensation" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r7", "r106", "r123", "r124", "r125", "r137", "r138", "r139", "r141", "r149", "r151", "r162", "r181", "r184", "r245", "r293", "r294", "r295", "r301", "r302", "r308", "r309", "r310", "r311", "r312", "r313", "r316", "r321", "r322", "r323", "r324", "r325", "r326", "r330", "r352", "r353", "r354", "r371", "r432" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/StatementsOfStockholdersEquityDeficit", "http://bioaffinitytech.com/role/WarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r319" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "FAIR VALUE MEASUREMENTS" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedPatentsGross": { "auth_ref": [ "r75" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights.", "label": "Patent and annuity costs" } } }, "localname": "FiniteLivedPatentsGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r65", "r135", "r165", "r170", "r174", "r176", "r180", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r320", "r458", "r527" ], "calculation": { "http://bioaffinitytech.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r0", "r63", "r92", "r165", "r170", "r174", "r176", "r337", "r347", "r458" ], "calculation": { "http://bioaffinitytech.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r185", "r186", "r417" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://bioaffinitytech.com/role/SummaryOfStock-basedCompensationExpenseRecognizedForStockOptionAwardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r186", "r417" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement." } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://bioaffinitytech.com/role/SummaryOfStock-basedCompensationExpenseRecognizedForStockOptionAwardsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r94", "r103", "r150", "r151", "r168", "r299", "r303", "r350" ], "calculation": { "http://bioaffinitytech.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income tax expense" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r28" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income taxes paid in cash" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": { "auth_ref": [ "r4" ], "calculation": { "http://bioaffinitytech.com/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.", "label": "Increase (Decrease) in Accounts and Other Receivables", "negatedLabel": "Accounts and other receivables" } } }, "localname": "IncreaseDecreaseInAccountsAndOtherReceivables", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r4" ], "calculation": { "http://bioaffinitytech.com/role/StatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "verboseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r4" ], "calculation": { "http://bioaffinitytech.com/role/StatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "verboseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInterestPayableNet": { "auth_ref": [ "r4" ], "calculation": { "http://bioaffinitytech.com/role/StatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.", "label": "Accrued interest" } } }, "localname": "IncreaseDecreaseInInterestPayableNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r4" ], "calculation": { "http://bioaffinitytech.com/role/StatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r4" ], "calculation": { "http://bioaffinitytech.com/role/StatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r127", "r129", "r130" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest expense paid in cash" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r119", "r453", "r470" ], "calculation": { "http://bioaffinitytech.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r15", "r135", "r180", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r305", "r306", "r307", "r320", "r391", "r457", "r481", "r527", "r536", "r537" ], "calculation": { "http://bioaffinitytech.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r62", "r91", "r344", "r470", "r517", "r522", "r535" ], "calculation": { "http://bioaffinitytech.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r17", "r110", "r135", "r180", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r305", "r306", "r307", "r320", "r470", "r527", "r536", "r537" ], "calculation": { "http://bioaffinitytech.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LoansPayableCurrent": { "auth_ref": [ "r16" ], "calculation": { "http://bioaffinitytech.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.", "label": "Loan payable" } } }, "localname": "LoansPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/BalanceSheets", "http://bioaffinitytech.com/role/LoanPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r128" ], "calculation": { "http://bioaffinitytech.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash (used in) provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r128" ], "calculation": { "http://bioaffinitytech.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r70", "r71", "r72" ], "calculation": { "http://bioaffinitytech.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r64", "r72", "r93", "r108", "r121", "r122", "r125", "r135", "r140", "r142", "r143", "r145", "r146", "r150", "r151", "r156", "r165", "r170", "r174", "r176", "r180", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r318", "r320", "r348", "r413", "r430", "r431", "r458", "r480", "r527" ], "calculation": { "http://bioaffinitytech.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://bioaffinitytech.com/role/StatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/StatementsOfCashFlows", "http://bioaffinitytech.com/role/StatementsOfOperations", "http://bioaffinitytech.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r68" ], "calculation": { "http://bioaffinitytech.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Interest income (expense), net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other income (expense):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://bioaffinitytech.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r165", "r170", "r174", "r176", "r458" ], "calculation": { "http://bioaffinitytech.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r53", "r87", "r362", "r363" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "NATURE OF OPERATIONS, ORGANIZATION, AND BASIS OF PRESENTATION" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/NatureOfOperationsOrganizationAndBasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r16" ], "calculation": { "http://bioaffinitytech.com/role/ScheduleOfAccruedExpensesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "verboseLabel": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/ScheduleOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r114" ], "calculation": { "http://bioaffinitytech.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherPrepaidExpenseCurrent": { "auth_ref": [ "r513", "r523" ], "calculation": { "http://bioaffinitytech.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Other" } } }, "localname": "OtherPrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_PaymentsForRent": { "auth_ref": [ "r3" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash payments to lessor's for use of assets under operating leases.", "label": "Rent expense" } } }, "localname": "PaymentsForRent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r26" ], "calculation": { "http://bioaffinitytech.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "negatedLabel": "Payment of debt issuance costs" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r69" ], "calculation": { "http://bioaffinitytech.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchase of equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [ "r472", "r473", "r476", "r477", "r478", "r479", "r545", "r547" ], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r56", "r229" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value", "verboseLabel": "Preferred stock par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/BalanceSheetsParenthetical", "http://bioaffinitytech.com/role/ConvertiblePreferredStockAndStockholdersDeficitDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r56", "r393" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/BalanceSheetsParenthetical", "http://bioaffinitytech.com/role/ConvertiblePreferredStockAndStockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r56", "r229" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued", "verboseLabel": "Proceeds from issuance of private placement" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/BalanceSheetsParenthetical", "http://bioaffinitytech.com/role/ConvertiblePreferredStockAndStockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r56", "r393", "r411", "r547", "r548" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/BalanceSheetsParenthetical", "http://bioaffinitytech.com/role/ConvertiblePreferredStockAndStockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r56", "r341", "r470" ], "calculation": { "http://bioaffinitytech.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock, par value $0.001 per share; 20,000,000 shares authorized; no shares issued or outstanding at March 31, 2023, and December 31, 2022" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r514" ], "calculation": { "http://bioaffinitytech.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://bioaffinitytech.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid and other current assets", "totalLabel": "Total prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/BalanceSheets", "http://bioaffinitytech.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidInsurance": { "auth_ref": [ "r454", "r460", "r523" ], "calculation": { "http://bioaffinitytech.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid insurance" } } }, "localname": "PrepaidInsurance", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r510" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.", "label": "Reclassifications" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement [Member]" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/ConvertiblePreferredStockAndStockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r24" ], "calculation": { "http://bioaffinitytech.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds from issuance of convertible notes payable" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [ "r2" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Net proceeds" } } }, "localname": "ProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/ConvertiblePreferredStockAndStockholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r76", "r98", "r101", "r102" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "PROPERTY AND EQUIPMENT, NET" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/PropertyAndEquipmentNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r77", "r112", "r346" ], "calculation": { "http://bioaffinitytech.com/role/ScheduleOfPropertyAndEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r6", "r338", "r346", "r470" ], "calculation": { "http://bioaffinitytech.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://bioaffinitytech.com/role/ScheduleOfPropertyAndEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net", "totalLabel": "Total property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/BalanceSheets", "http://bioaffinitytech.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "SCHEDULE OF PROPERTY AND EQUIPMENT" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/PropertyAndEquipmentNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r77" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RepaymentsOfBankDebt": { "auth_ref": [ "r25" ], "calculation": { "http://bioaffinitytech.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to settle a bank borrowing during the year.", "label": "Repayments of Bank Debt", "negatedLabel": "Payment on loan payable" } } }, "localname": "RepaymentsOfBankDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r52", "r298", "r544" ], "calculation": { "http://bioaffinitytech.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/SummaryOfStock-basedCompensationExpenseRecognizedForStockOptionAwardsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r59", "r83", "r343", "r356", "r361", "r370", "r394", "r470" ], "calculation": { "http://bioaffinitytech.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated undistributed earnings (deficit).", "label": "Accumulated deficit", "negatedLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/BalanceSheets", "http://bioaffinitytech.com/role/NatureOfOperationsOrganizationAndBasisOfPresentationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r106", "r137", "r138", "r139", "r141", "r149", "r151", "r181", "r184", "r293", "r294", "r295", "r301", "r302", "r308", "r310", "r311", "r313", "r316", "r352", "r354", "r371", "r547" ], "lang": { "en-us": { "role": { "documentation": "Accumulated undistributed earnings (deficit).", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r166", "r167", "r169", "r172", "r173", "r177", "r178", "r179", "r254", "r255", "r335" ], "calculation": { "http://bioaffinitytech.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r104", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r451" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/ConvertiblePreferredStockAndStockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "SCHEDULE OF ACCRUED EXPENSES" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/AccruedExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r31" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r31" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/SummaryOfStock-basedCompensationExpenseRecognizedForStockOptionAwardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "SUMMARY OF STOCK-BASED COMPENSATION EXPENSE RECOGNIZED FOR STOCK OPTION AWARDS" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/Stock-basedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r259", "r260", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r9", "r10", "r46" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "SUMMARY OF OPTION ACTIVITY" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/Stock-basedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r86" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "SCHEDULE OF FAIR VALUE ASSUMPTIONS" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/Stock-basedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShortTermDebtTable": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-Term Debt [Table]" } } }, "localname": "ScheduleOfShortTermDebtTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/LoanPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r38", "r39", "r40", "r41", "r42", "r43", "r44", "r81", "r82", "r83", "r116", "r117", "r118", "r163", "r229", "r230", "r231", "r233", "r236", "r241", "r243", "r366", "r367", "r368", "r369", "r467", "r502", "r515" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/ConvertiblePreferredStockAndStockholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r67" ], "calculation": { "http://bioaffinitytech.com/role/StatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://bioaffinitytech.com/role/SummaryOfStock-basedCompensationExpenseRecognizedForStockOptionAwardsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [ "r511", "r512", "r530" ], "lang": { "en-us": { "role": { "documentation": "Series A preferred stock.", "label": "Series A Preferred Stock [Member]" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/ConvertiblePreferredStockAndStockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r4" ], "calculation": { "http://bioaffinitytech.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "verboseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r285" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/ScheduleOfFairValueAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r284" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/ScheduleOfFairValueAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r286" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/ScheduleOfFairValueAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [ "r259", "r260", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Number of non-option equity instruments exercised by participants.", "label": "Exercise of warrants" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/WarrantsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r45" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Grant option, outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r532" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Options, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/SummaryOfOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r532" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Weighted-Average Exercise Price,Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/SummaryOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r269" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Options Granted", "verboseLabel": "Grant date fair value of options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/Stock-basedCompensationDetailsNarrative", "http://bioaffinitytech.com/role/SummaryOfOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r279" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Weighted-average grant date fair value of options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r45" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "periodEndLabel": "Aggregate Intrinsic Value Outstanding, ending balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/SummaryOfOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r265", "r266" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Options Outstanding, ending balance", "periodStartLabel": "Options Outstanding, beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/SummaryOfOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r265", "r266" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted-Average Exercise Price Outstanding, ending balance", "periodStartLabel": "Weighted-Average Exercise Price Outstanding, beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/SummaryOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "auth_ref": [ "r282" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "periodEndLabel": "Aggregate Intrinsic Value, Vested and exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/SummaryOfOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "auth_ref": [ "r282" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "periodEndLabel": "Options, Vested and exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/SummaryOfOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r282" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "periodEndLabel": "Weighted-Average Exercise Price, Vested and exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/SummaryOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": { "auth_ref": [ "r533" ], "lang": { "en-us": { "role": { "documentation": "Number of shares purchased for issuance under share-based payment arrangement.", "label": "Shares reserved" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r270" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Weighted-Average Exercise Price, Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/SummaryOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r269" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Weighted-Average Exercise Price, Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/SummaryOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Fair value of Common Stock" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/ScheduleOfFairValueAssumptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r283" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Expected term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/ScheduleOfFairValueAssumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r85" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted- Average Remaining Contractual Term, Outstanding" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/SummaryOfOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r282" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Weighted- Average Remaining Contractual Term, Vested and exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/SummaryOfOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Short-Term Debt [Line Items]" } } }, "localname": "ShortTermDebtLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/LoanPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt arrangement having an initial term within one year or the normal operating cycle, if longer.", "label": "Short-Term Debt [Member]" } } }, "localname": "ShortTermDebtMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/LoanPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r73", "r132" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r105", "r116", "r117", "r118", "r135", "r154", "r155", "r157", "r159", "r163", "r164", "r180", "r193", "r195", "r196", "r197", "r200", "r201", "r229", "r230", "r233", "r236", "r243", "r320", "r366", "r367", "r368", "r369", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r393", "r414", "r432", "r442", "r443", "r444", "r445", "r446", "r502", "r515", "r521" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/ConvertiblePreferredStockAndStockholdersDeficitDetailsNarrative", "http://bioaffinitytech.com/role/Cover", "http://bioaffinitytech.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r7", "r23", "r106", "r123", "r124", "r125", "r137", "r138", "r139", "r141", "r149", "r151", "r162", "r181", "r184", "r245", "r293", "r294", "r295", "r301", "r302", "r308", "r309", "r310", "r311", "r312", "r313", "r316", "r321", "r322", "r323", "r324", "r325", "r326", "r330", "r352", "r353", "r354", "r371", "r432" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/StatementsOfStockholdersEquityDeficit", "http://bioaffinitytech.com/role/WarrantsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [ "r137", "r138", "r139", "r162", "r335", "r365", "r382", "r385", "r386", "r387", "r388", "r389", "r390", "r393", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r406", "r407", "r408", "r409", "r410", "r412", "r415", "r416", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r432", "r475" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/Cover", "http://bioaffinitytech.com/role/StatementsOfStockholdersEquityDeficit", "http://bioaffinitytech.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://bioaffinitytech.com/role/WarrantsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r137", "r138", "r139", "r162", "r335", "r365", "r382", "r385", "r386", "r387", "r388", "r389", "r390", "r393", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r406", "r407", "r408", "r409", "r410", "r412", "r415", "r416", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r432", "r475" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/Cover", "http://bioaffinitytech.com/role/StatementsOfStockholdersEquityDeficit", "http://bioaffinitytech.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://bioaffinitytech.com/role/WarrantsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r7", "r56", "r57", "r83" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Stock-based compensation expense, shares" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r7", "r56", "r57", "r83", "r270" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Options Exercised", "verboseLabel": "Options exercised, shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/Stock-basedCompensationDetailsNarrative", "http://bioaffinitytech.com/role/SummaryOfOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.", "label": "Shares issued for exchange of notes payable and accrued interest" } } }, "localname": "StockIssuedDuringPeriodValuePurchaseOfAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/ConvertiblePreferredStockAndStockholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r47", "r56", "r57", "r83" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Stock-based compensation expense" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r57", "r60", "r61", "r74", "r395", "r411", "r433", "r434", "r470", "r481", "r517", "r522", "r535", "r547" ], "calculation": { "http://bioaffinitytech.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.", "label": "Equity, Attributable to Parent", "periodEndLabel": "Balance, value", "periodStartLabel": "Balance, value", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/BalanceSheets", "http://bioaffinitytech.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r80", "r134", "r228", "r230", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r242", "r245", "r314", "r435", "r436", "r447" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity.", "label": "CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS\u2019 DEFICIT" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/ConvertiblePreferredStockAndStockholdersDeficit" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityReverseStockSplit": { "auth_ref": [ "r84" ], "lang": { "en-us": { "role": { "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.", "label": "Reverse stock split" } } }, "localname": "StockholdersEquityReverseStockSplit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/ConvertiblePreferredStockAndStockholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r331", "r332" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/ConvertiblePreferredStockAndStockholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowElementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosures of cash flow information:" } } }, "localname": "SupplementalCashFlowElementsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r33", "r34", "r35", "r96", "r97", "r99", "r100" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantMember": { "auth_ref": [ "r472", "r473", "r476", "r477", "r478", "r479" ], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails", "http://bioaffinitytech.com/role/WarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r153", "r159" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted average common shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioaffinitytech.com/role/StatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r104": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org//606/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r105": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org//718/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(b)", "Topic": "720", "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "51", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-51", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(i)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iii)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iv)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org//855/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(21))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(11))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(g)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(h)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(14))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(15))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(16)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(17))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(19))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(1)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "340", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147481639/420-10-35-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r482": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r483": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r484": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r485": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r486": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r487": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r488": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r489": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r491": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r492": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r493": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r494": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r495": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r496": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r497": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r498": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r499": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r501": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(c)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483504/205-10-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r526": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org//450/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r53": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org//205/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(18))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org//235/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org//360/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org//440/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org//470/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org//505/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.C)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org//810/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" } }, "version": "2.2" } ZIP 56 0001493152-23-017083-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-017083-xbrl.zip M4$L#!!0 ( "]BKU;6%/^YY H &E< 1 8FEA9BTR,#(S,#,S,2YX M^&UJB$DXE414E.[DO-Q )2;A0 MA$*0?LFO[P)\T0M)A)2=UE/)'Q*)V%U@]\$"NPL*E[\]+%QT1WQ.F7=5:QX= MUQ#Q;.90;W95&UMUS6H91@W]]NO?_HK@[_+O]3KJ4.(Z%ZC-[+KA3=E[U,<+ MW2#W5 \81WJ$A^UV&+IDH! 0]33!7ISU#S#J%XO(?>&> [S MQT,CE3L/@B6_:#3N[^^//':'[YG_A1_9;%%.H!7@(.2IM..'X_BO''N/7>E_RR)OGY^<-V9J09B@?)KZ;B#YMB.8)YB25#*U404\]'F#/WJ!W M@I1AG?A-(VK<(*6YI&\C4IJ0.F2+CA/[:,;N&M ]">G"6'(ZS.,ERGQ%/.) M%!HW;!!S/\@2PL-MHGKPN"0\ES1JVF!P G^+8<-JT-P0S8+GN'[BTDMNSD^/04&XI(%\8(.\Q=M,L6A"YI\#;%+IY0X M-11@?T8",4OY$MNDG-!DQF//8^ 8X)WQ$_%LN:0P\^'!7R[%%+GPF4M&H 82 M'\ EE5T(FD:+P>I20]2YJD4?A3 0+<4Y1+*(/F,7;**Z<+A0J D?)M ^*=_#8$6MB]JTR +4S&I&K4WNZ"V MWMD_4=0=>A5W^/,!R2R2+M_2+>E+YNBC/D2M\7"H"[PL2Q_M.40,5KC@ M$2PNMO:EV$SZ)$A0R6]4 M$\S@(AUK?19PF _N^Q,>B!\5^COC[:9]/#*N2' M))WSD+= MW_=(!JQZ!SLAA:4#0I4I@;#$D8DQ6'P]0=Y(V:LRJ<%ZDP6K?P/;J@%+DHAU M.CK$-&UDCY^TW6+?Q^END7Y36S:3,]]JPZ&V MYSN"%4XX^1J"5OK=:O_-/%5;-B>EO;8@.!=ID7ZS[YMNN:K!+I6&UZT\'HQ1G&QE:C M)%&#D,G:B[*- Q@['@&V28"IR_LB1PGH'=G]2# C20UM)L=_TA&A.*67W:.T M_[V>"N+%4"=T <(!"T WBEWWL4W=4%C&(G;HPS (CXT6.VHU'C6\V3I!ZZ/> M'G6D%5C6RV0+)NK.6SPH.;KL);3;Z+X2RF%0-7;9XL@%= M7LIPP$F1ON6OIV6)E5B=5GE;X+!B%KG55C)7X%$%5&J ,A61=6?*YG\'-]IX M\R#?=50$:C24;R8<_*/TT7D^+E48U#AE*B7*H_4#<$\Z;B\"\VE"U #GO#NQ M\W'\ ?ZB+"^_3!9O8$-B,\CDOA&GPWQ):BYE*>8>^\[6'OB<$M43(U/#6<\( MBRIU\?Z)AGK+A*3Q=VCOF,-X]I@#2:/=:L/V88?=G"$Q/C;XC/P93![F^31J M%+.EFA6*"1ZMD7%C0*!Z0&0C%DU?!(1L.UQ(VQ<%I"I2-3[9NLM:5+KV%B%D MX>.>Q.O@.:K#B8*264EB-5;92DKA@<5A'\Q[92H?G,)6-1J9XDCR2M7_M_7% M/V(B#\D4R5L?+L15 UIVEKU\JP*@^M457C3VWZ0ONVTDW5U MX^LU&JO[->+OVW=P7(+BS ^0E[G30W4G2W2;3)?94I2"17RK)WQU\:C>/*F? M-H\>N+,::95!K,Q0;1 )WPZ#*+@9)J]_7D0N/LC)5+;3@AMFE)WF\C2(&_#D MR+[E]P4#>=[G/([WVD2R'-/_['*1%AG2;[LAL;J)J%R M0"3T$0CB0EJ0M21GFUM*I/;\A*&+!*U,""^J'*R:7"?-\T*"5Z$ M K#/B1M[VN2.N$P:."[/I1JH*"JH$+5-HBN$H(%,Q$^W(L6B-IB4D!/YC\^@ MUJK6X?P9\NB0P?36BM1]%A">_F UTK0JT^[*VSYQ?J#V,$3QP)RVXTJ\.87_ MJ3=K,2Y^P1*I^UVJ%ZM?"I0Y358W@_-0W#BWA60.P8O5ZIIX\G $N]&4$_=2 M=HA\#[+#_&N?.K-H!B9:5F%XL5JOJB-EWB;2H!@FL7=NW4@RLR/6'#"1(QSPIYXIS%L&8I7AQT:6DP'70& M*#7)"X&EVGM]\FWWC*)/E/%"+#%B 7:C(4(^8$-;&E7GM7QWU%%!(\@.>AG) M>+[UHTMF,#[/&?AL2KC8$,3=D!NK10%)>27^JX%<_!95$H3&TRF>18EFWR/: M6;/ZY(XG"MS[SHB)6;82!&+6[&'DA=# _&"Z1M M$OU_2^AL'A!'@]@ SXC^ +.-&UL[5UK;]M&%OV^P/X'K@H4*5!%?C1MXB1;T!*5$BN+6E%RFGXIQN3( M9D-Q%)*RK?SZO4.1LOB>D47.!-V@J&UI'O?<,W/OG?>[7Q^7KG*/_< AWOO. MZ[JMG7]8X2A,BSD4L\_+[CD*F.TQ!?*!^QA'X7$?ZM<(W=-/R%#Q\6^TB?+E8M##%]L M*[Y07KT\?8V4;I>AW&OLV<2?3_5=N7=AN HN>KV'AX>7'KE'#\3_'+RTR)*M M0#-$X3K8E7;R>!+_VV9_YSK>YPOZOQL48 7TY047CX'SOD/KC:M].'])_-O> MV_WJY%IW>$EZCH>U9N%.TDN6DI1OM,W;][THF^3I+F4CS>^F]1QWDO$ MV94,WSH5Z?W[Z\C&P.XGR M(PWZQ,53O%#H3V!O5^N-0]!BX7A.N FQ=4=YZ]$TO3Z!=@D"1[GO?+QXW[EQ MT (J.3L_.=]6\5TJ4;A90?L,'-J\.DKO>=5?(I=JS+S#. SJQ"A,W)PX$^1C M+[S#H6,AETNVPIQ'%91V)[R$2@)C8:RH"8 V5JO ZER-"6B&Q/I\1UP;#)'V M90UI!WCA6$[((V]M(8V)WT?!W= E#USJS64ZJGAC,*8^WB?1\&^1YWR-_E ] M^Q(%#D@Q\7$ \D2?UDG_G#*/J_OU0 ,(-U C M[68KVI['N+:KUF0[JHA H[_&.]W4B5:2_*@BC0CR)FB#;FA9U>(4)#VJ*$/D M^%&4=851 #TZ,DAU0E5F.JIX$)D%.,;C.LA&'26;"#-J*H\$)UU6ZUZ?#0I_ M26U$ *RR,V1N,AI@$[,R4QL6E[%1LV06/K(8X! Y;C"F!CET[FLCH&/6<5RN MK#MLKUT0;4)"J-E!KKL9..Z:UFAB:^T[(1B16)9:\@XJ38"!Y>7O>:4VQ1B# MT>0GCK_0QN#E[>H!<&H+:<.3\+8WSF(:8B#C,KB57YV_J=$HKZX9LK8U'.05 M_8"B1 X7^>$=I?B&_$MQH!(W]BFV"'B*K]@>$C]*:JPB5_^ ?)NY)S505S/* MB"NT0.W1-#4?O,K<#=FVW?0/N+3U,A* W\ Q%-)&9,T=S? 5T\A3'WT-IVX)L?DG77 M!(5+K)3D+EWX)9FEU601/5K>7:#@)EKC70?=6X16/4IQ#[MAD'P2D1X1'G_P MYS;DC.//I&P7W6 WJO'/.%TF64^(K'0)C#IB^$'#MGOD1JXY[$-KW8!KCFQ% M.0;&[%EL>ZU)]2V%^. 3WW=.DWJ0;Z7:4'ZQ/4[1"ZA!IL5T@>]EDG_ADV65 MJF.UDD.@[%,"4G24!^S.- 4=^HRB6'+RGM#?6 92)H MK[..B6?56:V2Y')XDQ)**B'*Q,7(03>.&ZT8U+J/HK1B \AX2I$Y8LRF%VUH MR[5?$B<6 Y:I0<7ST3SMJB*+:+O+0U U;)DXHK/QS'VG,+%HX\O,2P54J1AY MPL-D?Z4R766J_R;Z0GX#>#D!16F%#0/WEFIJIKP*$XMN/^5ZSX_URJ#*U([H M,B'Q6.C(IQ3MY9BY* ,I$Q&J;3L4,G(GR+%UKX]63OAT7J8@_"C+(-K),=-2 M UDF=J9T:3\_L M#ZCSG?4Y17LD5FSE88Z,C#&<;BAV4:691'NK WEB/N91QYO L0X/WHJ$E3#? M];(H1_!WFTOKQ>=<4^OLY\]=9U=>I&KYH?G= S6G9%/P?F*#]U2D0A;*4Z'B M-Q1\\$D03'RRJ/+GJ42BPI%[[*WQ$/H[3<-;U/ M@4[EPG_V##U6Q2<'%";:ZQ4PE8M4#M:17(XP"(U%#*;*]:62B79V]?04XBI0 M?%?<>L_6,'FWV;.R!6L]^:2B#$. 07UT?\T 5.N2:$$MEJK*!%1F$]W92YG( M=7D&]$?LW 477^CJ\,\^)*'>F8D!FJ,J@^B>7*O[.@#RF503NU#<[?:V(!<: MBVHO0?X@W&X;K>TMK/E%1^"LW89/'S(QN4.H>Q"PXA$X'08CO9]8&M.61Y!A MJ8"2QI..M0>BG@E&42;:G9R2]'6 MQ&Q"YN?YKDQ,S66_.F0N>[^.[]&*!&^5;57*B[BR'U*3W*W.WN4*(D\9_W<>7/:%DYML M9%=HH"3R!0.\\K'E))?VJ$L"P98J,TG@$Y['&8-*9&*0[H7&>WJ3WU)E#GIRTYG(S3B>+>+0D$[LEP&EH$3QS"K.P#$&G0-$F&K3.B&I]63L^+KT)I!PE3QF23GY6 ML)H]2\JM,*FBC!+\0\=#GO6\5EU8AJBMMZN8)F-QB;S/ WQ3>2BP*+6D+;6" MJ=P.W'(E2-4F :*%L9VL4R=39]6D56:2=+J>G3L&E30_&QR;.F.1#*:,!?P$ M\>EY@2+[0'/599)T=IZ!&A9T,O:NG1&@K4HW?5 MJT0J"BG:S!6M4PA7?,<*L1U?X9K^8"_E!-HGL?-1>'SD2GNT[I!WBZ*!< MJJ9NTF23J69JXUGT50O[T?C>H4UA?9W%:LZOKM3I)XK"U#^,]:'>5\WW MC?EXIH\_*!-CI/=US6P>&-<+M2E8;[*P@)&)J@\4[?>)-C8U,^++F/VF397^ M?#K5*$33U&:MH*I^QW8?R.E)'@AM@[-/$0#MOW-]<@7"_ZB,M5GSHI>]CK3FY:M^"S' MOHZ; O4J#VI\#1U2AX9#K6M M,M# K.HM=-BZ5W53T'[.^0(J>A>\FD:YNJ*]MR67EGMY-R5HSD%_5*=3M95. M4/H*;TK J]Z:8*QIFY&NVZGNQ[X^&X*1\Z-LD<'RHNDZ#9VY!_R,N\^TK.< MG^5!NBVX!9P'/-N;0IESS'*N?.***E%)-5/ *<0Y-Q\-FAJ M46RV)X%3XN=\@%# M_S=M,!]%FI@8,T"HJZ/1)V6@C^8S_5I33 W,BCZ+K&9R8_YO\FQ2J[AT#\BARR"U(/92BIZ@YWG$J?#YIQSJ M%E95MS6/\&UTOP^]108'@4.O7BY;4JW*(7I:_P *:C$=G8KCO#>4AEK;YZOR MB%X_.+SCU&M"PDE^OH?F4\XK/Y9-.:^B\8)X3]7\ZV6"D407XJBW\6!A MR"K:%]4_.T=X(4GIBRC(_6'&$+.WQ=)\HOT&+WEL>FA^$!S+D=Q57#NDHIEJ M\H@>4C%3P8!%O@ZT'1_R&_.Z?*+W$O-V(#8]2#@$WMO;PA8^5>YU$1,O56PE M8<.46RZKW%HB"B37=A,VX 5[:@[>?B(H5MXMQA0O,\8F=(HM5\/.KD ^,[Y<#TX '[]Y^/*->XQ M]1WB?3PX?O7ZP,">16S'6WX\N)P?FO/>:'1@^ 'R;.02#W\\\,C!/__WO__+ M8/_]^C^'A\;0P:[]P>@3ZW#DW9!?C#%:X0_&)^QAB@)"?S$^(S?DWY"AXV)J M],CJSL4!9C_$!7\PWKPZ_AD9AX<*^7[&GDWHY6RTR?:_LLA*+<-Y@(+0W^3V^O%U\E^<_%?7\;Y]X/]<(Q\;S%Z>_^'1=SX> M\'*38A].7Q&Z/#IY_?KXZ-\7YW/K%J_0H>-QNUGX8)V*YR)*=_S^_?NCZ->U M:$[R\9JZZS).C]9P-CFS7^U@DR M_.8H_C$MZDBR3H'VG0]^I,DYL5 0U9!" M1 8HP3\=KL4.^5>'QR>'I\>O'GW[8,U39&Q*7#S#-P;_/R-Z4^JU0]#-C>,Y MP5. K5M.\1&7.>H15H49X"CU+<4W'P^N'73#"CDY?7T:%_&WC%#P=,>JLN_P MFGA@'#VO^#/D4"L;[?$M5F?-?@S9+)]?.-83E &;V$FM<'O(?]V MZ)*'4N;-):H4WICUNQ2G29S0)?*?(=]A**84^PQ/]&T1^N?D6:WM MP]4*T2=&N;/T',8Q\@+3LDCH!6QLG1*7L8Z+R2B52Z4*, O=(<<>/-YAS\<^ M,]V$=0:T%U+>+9B^K]#7E5YR. +12J$,D4.C"=D%1CYKT5&'5 1*FJA2>&P* MNW*"*']65WHD:HYLXJS0I!625@S58_.>P&%,L>9X@UG3LZ-AB)6>'HX41[,] MLZMX7&/E'/)II,W7$JQ!*(T-!UZN=3&FT&F6)ZY\IK6IE^]7]U"G,),F M1I*R]:UD-C4QL#-DE#:^/'U=J]&RME9(VM1RL"ST/;)J<[E87KU*LJ]I?!%/ M5)+*/L,682/%7]@>$AJ)3NZBH?X!45NY)=505CW&2 JTF-DC-W4Y]:2I:^K; M-NX?-J2%JPA ^0Y.(9,F9M:E9S/ELJG%UU$6)3)'P@SJQ[TI[- F M*^24!)U/W0#BJ*3#%5Y=\RW94G"S2>O'RM8[Y1!&">K'Y9' + MMG:;1.HEO M4.@&>U?*=?(L9O8U[XF8Q#G[F,&-']DZU<;V&CG/L&0(0> $/$T2!W)L'/*@ MD9!/RMB?L62"9HW')58&A,LC)@C-6\]?JWV#_.M(]] _7")T=\3[QB/L!O[Z MFZBWC*R9?'&UV9ME2N,1^W,S)KGH&KM1L5>)L$CVJ%W4B_1VD01Q(K>+=LNY M2=>XDPJCV"KC6OK!8K-J5DL&;E0:J^EXR?]8([NA9%5HRL1L1*I!VK8,R(%! M*)OB[RUU$*YJ.C4KOR22JE33BD%M&4M3Y M$:2K@*VV>$E#[">#,T2(2+92)O+SA"(:0 N30N00%2>ON\G%U;$ >%5TK$?( MY_9N>_,5:0=1=KHO98+PM)$YO.(.$N)%I4]1O%1[]?KUNRFF\UM$\44R,!!T@[(/BJ W=F^_1E R((B&_,>=[V>6Y!I2*U;MA9-@97R M4B:+*U$?H T]I34!>[I*1AT?6Z^6Y/[(QD[OVL6]1 MYRX=R@,8.279#5OO @8[BV;[BAE>.GX0[WIO%))W'L(D6I-0C!R<\33+ANEY M(7)G^([0 A+2DIVP?0XP9/*?FC7YOT)$ TS=)Q6K[PAWPO BS)#MWS0\46'3 M*C\RE8KQ=Z4[87TA:,C\;YLU__P6NR[?8D*>4NW/RW>" @ V1,*[]DB(0G7[ M3#5U'C9).D=%%CG$QL_-LL'6W@ZQF4Y4@8<=X4XP(,(,V?Y]&[8?>+:JY1/1 M#MD]C5BVH="DV8>.;R$WQC=DWXEV"E**Y,0[87XQZLK=:L^BX"M&5)F C7"' MS)_%#!J_H15P$C.[A2;M>2!IKTP(V!]1A\BMR19^/'W_&3 MS.@[HAVPN@@Q:/:&%K8QLBEU>.#JW+&*.Y9=V0X87@@9M'Q#J]D8V@(]CFQ^ ML(@?P>'V*B8 2-(!'F3(03H:6L[&"$>>1>@=2?F[>_Q(%'WJ$5LZ!$@3=H": M8OP@00VM>6.QS):!.(=( -"#6Z -;3^A="=E*/@I),4G,@I M:&C]"Z$[+4?!:2'NF'\',VC\1I? ";9( MFPF=4G+OQ'?V%3&PDZ([-(B @UPTNDQ>UY-XNJ#2"F+)[M@^#1BT>:/+Y 38 ME/@!6>%(?\JZ4UC86@@7MW-1RE9_#\\'N8?.S MUI;-HH1,NO<9AY(F_4*=@.'AD>2AEWB0@)T_H:C6IH81@V9O:,DYCRX#XA=Q M7# ]J+.]#CEK\[RJ(=*:WM M+@0+VKFA9>:8\*-TTMQV;$NEOGK9I;YZJ=!7-[32 M7(.* _59NYMU^.-*=!6A&K(_Q!0( M1;4V/HP8-'M31V%#VPFP'0,<.A[R++:8VS[D C!0D$IO,E3 @[PTND_Z!;ON M[QYY\.88^<3#=KRPD.U6 $FT9J08.4A'HSNGGXD;>@&B4<@M!=J&4+0#YAZ"9I$E:^&;GB5_=DUA>GZ )$N @%XUNGHZ\ %/$[V;%?12@!*^,"W&* M#G A 0YRT6C@<=10>TR?)9''#F0$.V#Y/%[0X(W&&\]7R'7/0I\IX$O[GXQ@ M!PR>QPL:O-&(XL$*TR7K!C]1\A#<)@=Y9887)N@ 3!ND(A&(X<'C]N+!>)3 MC5(6E"9 @S \EIS4 ;9*&A97+TZDEZ M5A9!X\K( D&*4FG-B!)XD)=&E\GI:QZDPW)*3FO; W!!:S>Z"IZ&UZYC#5V" MI//^E%@';+V+%C1UHRO?,^1]H^%=8#U-*;$PYAM#_J9-*BR^E#+H #WJ>H#$ M-7L4=WMA9W2WJC\) Y]WH0RMU'$A2=:JW):@)2EEMZ_'NTHR(K_MOY-\%,FT_T>73A#+F)8 MV1B9?@@\\_C"B7%H; P2O;[ BO%\;/._?.(Z-E?<2'(RXJR,'RX]%.\0_".E M8 -*3!'OQ&YQX%C;*,&L1J?/UN,FF_V43-=QM_1'?%_,>*BC!^2POZ1T;^5B^Y? MWAAY>6.D3H+B&L]71,3C#4/QG1%QLDKIJ^^M$9G.-5V@O0]'.S"+GKD Q*N= M,95^=41J:Z*B ,1+>X^/5$%,)YX@>2YY];Q$\FS^LD^=@D]A).(BZ:MVEB+R M%D*48&O7S:F\2K)^]"/W9D=+C\.4(4(,&J2A-1Y,VXZ,AMPIZ;K/((6NWKE'9I%RKE-O8TYX$(6+M!OZHKD1G M'NQ^2!G,. HM>J^K.XGTK@"*49S7$EK8AG M669=);I0)XCI2B)V]F%ZC .^P[["YT08+I[(9<2T9R>/%IQ4M.<<^D_H!]'6 MZ8( 'I/4;*F/KX,O#H^ZYE_QV?40HR"DDJW JDK0GNU*%84J2B6Q/W55E"@, M]GDU(FHC![R;X0""3=[N$X7!\S2B3!L--AE';2@= M0#.A2^0Y?T4?3,]F Z+#5&;K/I]!SQN;B<#8S) MT)A,!S-S,9J,YS\:D]DG.%8?9Z MD\OQ8C3^9$PGYZ/>:#"O72]&U!UK5X-'/H/!/F,P:EE)'*OI^V!,V_M=K1@? M4W/4-P;_G@[&\\$\8FNR^&TP,WJ7L]F :SB?#Q9-*$58_0R>F#9\J7O'6PV; M+0CU.'Z=UX-7P,77"/_@7Y>CZ07#_J,Q'BQJ1\ZJ%&6SS34=8L3'NXA9Q9E= M#K:6KQWF.4'>%#UE_-P9B">[$,\GYMB8FE_-L_-![?"&R*'1:NP"(UY^YOZ( M+-#37:!#).I+!N-&.A+0Z<>T2?N>9 &)QV_R.HT_L[8X8K6&]R_# M >M'^L9\,>G]'ND8_?7;Y+P_F,W__K>?3X[?_6+T!ZP_'=7?5B.M#J^A)7)6 ML[>Y,8 C/V2#V8 S=<$;;C,CV1=$^8MA0*W*#[B]"L;2LSGKI/GH,OC<2$M5FPI(IP3'N<%3?4I@_+#.NH'88B55H_U.L:(G MN=&UC*)QQO6KJ3()DBF9&Y"5IT)-ZBB<$\G4R@WBDIE1C]-NA?GD>&F$X6 M3,&1>7[^U>B/SB\7H\\#8SY@/9,IUU B!@LOQZY* ZN.&4[$8I- M\*=28_(VU"GBL3[>=8Z&U*]N_'^+KFQG#+_$Y6>W@42:$^(#+?"4K,-K]LV MTD\A/9T\'_*F'$6]"_QJ,]9W05Q1:W'=.XUG'J_*EM&(_M:\ MUPZZB4A\?7IZ'!%Y-C*'5^?H>@,!7,QRR;Q@2\%G99H+*<)?=?<(6#G>N,>4 M'R\F-\$#HEAJ;%"^+1_RGD:7Z]&0R[B*/JU@-2M/U]8=-GM/(A74TJ0Z6*=V="FKJ$ MI42+9ZDZ1W"A,@J[3BUXMH!3XDH!9*=E;M)I^83NSB%RF=OJ-'>Z/^VVRI\H M;\P3E[J$1XT?Z:4\&H7PW;*.;X'IB@?Y*OC9(/FV?6L97,K^-%$J;7QHU]91SQR/,9!$D 1"(LDM7 $R:Q/BG$K]W<(@M2Y3@@G*(=MY;$S#(^ M]#ZM61TM.CNIGDV=KK%[Z2ZB,$(O+]R2WZJP@>S>OB\$KET7QR=V?C*S2W:2 M838$PFT]4%5J=@#AULX+DJUD#''DHV-:*L\$TFDZP4T!?.T:S [>Z))^QTIP M*[.43=9%H@0:*+@9VN1JQ,9?BOU@AH(XG-IF2ECL![24K);4\^@@BX7J@-.' M5CU'DOMKU;P3N@GM\][[S5A\G3OJQ, 4?#B#>N@N' MXSE[BM"I>W#RB;1QX$AI@?TWD!FT=]]\+T^+*E#Q['=&V[O>XN6=46W\."_O MC!9HIZ'SADW[L6^6NP5+DJBM.;/R^Z)%V$&*VGO4,KSV'=M!]&F.-KUXP3 $ M)^G2,%2DN$8KTQ1"[DJ=?MS]W8=S*(E9PM35D8.FIZ+1 "]6';^ZR34ZZG_! M3+8*5S*[9T2N?F[A.+^@LA()/,BR/S?:_UZ@QT++ID6NWFMGV1P\R++OVUO! MI=S[/#(V>)IA_K!P?)7O_,YU)!N-"HE;NX&SE$=850^(OQ9O"U^MB!?!G"(Z MH?'&6O1&Y/JR3XF?JSAQ)^A3UD,[#W'6U1,A]M+(QM MG]]FS8$BS\(C;E#D3L-KU[$F-TPAQUO**%/,HB,,EM(&(O1-JU/-N,KU0XXS MCNN*^XN06K?(YR>8,D^S W-.Q5PZ06MYA2!FW[89^Q;'$'$/0!)-A.UM[%>Z MNSF6Q[^IY],)=O=1">+WG4[#Y20,_ !Y=D$'+$W8"0:5= !=)AHL#-67%9)$ MG:"J$#_H?]&&IJ)9*)"@F_2HS#_3>K7Z$(GXH>ODI/4,6V3I\8HV)#3U"I;Y M@*@M/X:=>R$Z_3P)]#)V.A>/7_':M:+INJEN0MM:H*:CM(MQJ%E,-[ M*RU.F\#@FJH?&%)< VG:!R-_3X_(U$KDRULTN\E>WJ+I$%U:1@W40ZFFL6(S M[&.&Y-;T[#Z^QRZ)+C)*YJ!%@6,*B5LZ[[[/LS.*VFC7C[X\)]31YX1*<)Q, M"[ MGC44OSZAE+ZMN^.:F5*7L(%"5$:;GH/$$V"QZLN$I+Z MQ)?P'I5WUN, M/H\67UMY&F&('!IM3)B^'ZXBO>3.C?S;JZD[YH;F:&9\-L\O!_RYA\N+2,%& MWWP0^W34SC?G7[B G#7:'%X&FBI_*'R)XSNIMR+);0N1!TO!_5)%WFU[7 IU M\"$E2ER#]\PBM/&L5%>9)/?K5<*']@Z4&/)3T1,5.V(:.$FJ(HC(]-1O"K^W MUEO-/)O?H*MRGUP]I;7C>!$SNWN;67W6U,(7_&IMS%+B,X67MW4-780>2<3 7Z@U3K.SI!UAF'7*MD4/?->[9DX8/T MD-!/+*WL&$A-)39^5JKVF6V=AE+P@G2D(L9:KF,?>41%]'4-%1 HZ:7BJ1A( MNWFYDF-RS$,P?=:CQZ$Y"Q(@-_T[=TZ.2? 5!UNWY3.#3O8I\KNK@O5:"IS> M:Q;L'K>G5("8/WADZV['EU6R\GE]=[5G3Q. L[/.C8F)>M%P[X^\6/V"I\9J M*.S[JU@UV0BJ>:T=IZI6T2_86=[R?OH>4[3$T8]]%.#-!E%3M;(0R$N-K%4+OHXGJ, Q"BM<'Y90BZM6R^NYJU'X6@.K$ MVU9WW;_P+596O]7V<-_O[N%^,6[29Z1F$/5B#;\OW$11NC.W+Z M[&Z"9H]1B!==:J@I(!VVSA"U&LWVY0Z%M[\Z">_^I(['O;* MKIO4*FFEW:QC_TU*XL4NAKC+VEYQH>3CKK%4[6M/[_X/#Y1F MW_P?4$L#!!0 ( "]BKU:5.=#:43L "-2 P 5 8FEA9BTR,#(S,#,S M,5]L86(N>&ULY7W[D^.VE>[OM^K^#]A):LNN4GM>R?J5[)9:K794Z6DIDMI> MQW7+Q28A-3,4*9-43W?^^@N #Y'$DWH I\>IC$<9F$2__75VZ_>O$(X]I,@C-=_?76WN!@N1I/)*Y3E7AQX41+CO[Z*DU?_ M\]__]_\@\K^__,?%!;H.<11\AZX2_V(2KY+OT:VWP=^A'W",4R]/TN_1CUZT MH]\DUV&$4S1*-ML(YYC\4&3\'?KS5V^_\=#%A4&Z/^(X2-*[^:1.]R'/M]EW MKU]_^O3IJSAY]#XEZB_+BJQ"_K5Q=MW%^_??O64!:^JRF$BIE(67" MJ_*[AQ2OQ&"B-'U-]5_'>.WE.* 9?4LS>OM?-*,_E%_?>/H6H).&'M%S? MMM(JE5[;!CO#:9@$X_@PU%UM1_!)WTGS(PK0U+=>A&62>]%!X)N:UF'?XL-J M?*]GOZ;).(\/J^F&YEE@YSSDWM4KKM>(?GE#/K4@XJ><3& XJ$#2)!0C,,N! M30QEVG7JB=]*-Z*C>9+R9:)@?"OT7V=?E')!(*D("VQ%&?)+O5Q MKS9NEL:T5DN$FXAH4(,-QQ=WBU?_S<10LD),$/U"1?_?7U[ODSZ$2_>AMV($ M>?.^F-[_<#D97O]*C+E-$K.,9E[*;*BOWKSYF@SOBPBP53S=UCG_;A?DS7?22Y3.!;#)]BG6<3*$J^,)I5*3@G(%]4'995XBB MO>R)9M2C*38CR> TQ8%\_%.+VB24"FR31R(Y,/11@.NRIA:MK+!"VCUK=%.F M0LXF7Y13H%0(#%-,I[3FG 6'(\,@".G>H!?-O#"8Q"-O&^9>I.2+1L:]NA3P)@ MB'H(ZBYURS0&I:=%A+PX0.UT4)70F0?,+,T;7";_VO.8_(-8&5G5OP0#HU#" M!@<5T"C#!#\[YX\<$V^L/8;4MX8> \W2,$E1<>)^UG&M!P^"?^VRG'X2CEQ: M:1?\D$ 6<:4C"HXW8GRF'!J@?0)P3+%AG(=!&.WHP+? _BXEZUZ5L>I^NJD5,=?YU^2Q.0&'*G35'J_LEYZ^ZUF[+^;)SWM/LE9'; MZ6DHH+T&%$-VO-E&R3/&; $WW=)B*XU6A;S-KJ&%W22V5!@,+74(.2.3DO'B MTLO(TGOF/;,1?TB/7M=L(AF@(@TXLT!Y,*RD5D?&)IV$\)H4:@F H8T(59"+1TN+Y^7)%N%16FD:??4WK@H[4-\K1H8(IIC[9+Q)HG7 M%S?$W K0DGS/2#G,,IR?U^7RQKNO,Q#DCU+BXUO?N M42UYLL%'[F9+%@LX)?Q<)*O\D\ZU5B9LTYU6#;CI0BN6A,$''3R!0P>31T0! M51IPYB8Z:4[B+$]WDNU8E:#-F4<.M#G1\%+.6:.%UF4,LV/VDE 6[(N'),V7 M.-U0?.KS)9&DU5,D.=3661$O!H8M_$MD@1#'R4\ MWHN>":-:VK$G ]WXEODP['^S=CK=A5.?15<_.&]U$1IN@*"G8%D>^EZ$/F O MVZ7X[(:PIJ$_A'&XV6VDS@F=WVTUN!!6U>BM'T$TO A1M_%+&;?]^H/WI&[N M]N_6FEL$JV[NYH\PFEN B&ON0@:.33G\Y*6!9EN^(V/5-4,$K^5,T11P3@,5 M*LYA@=>U2J=<=C M] 71R[Z$,_@0F)C4ZL,P#J[P(XX2=IA0>NWJ:*?7M$P^TZ)T M**A3@T1$0ZP".C)-YJ/=T*T) 2+$31CC"?FH#5[1$'1"# ZHD!RU%#R"=*$I2$)%$9,]+5,R M['^U3AY?!S@L2$(^[+E!_O'K5>*SXRIJOW4*Q/]L@P M]M"OA-V="X3"($AC@E Z6S25]G>;'?%H&,<[+YKC;9*JZ-,6L\T:$<@N69HR MH#@B ":E1B&+"F%'C/C'SDMSG$;/6E)PDK9Y(8':I49'#!0[Q-BD!*G%W7)D MF7IQQB(7:4G"BUI?;DC 8!BI5X-!F_$BM^2/!QL%7]J8; 4ZB(T M9!%30U3/$9,:3UEH.,1)VF:/!&J7-QTQ4(P18Y-RI8QZPN3=DV07< M$*0#4TR/4@@@.=K(=-08TR,Y=\2X#C/?BPHLU^2[[O&*1M8V0:1PNR3A!$$1 M189.2I9"H>(,4W%*F)^QEYK1I2'IABP<5#%5:C& 1.EBT]&$RCLAR6B7IBW4 M\AE'+FJ+)CJP%4]D,\S)_IFXRW.X&GD5C$%C=D MX"I.='\'P04)*.Y!"2:&J!PJ!)VT?'5*$.?T(4QI<;IB=AD@!MEF05L&$!.$ MP"1LV,NR=TF=,&)$1J;4BR9Q@)_^CI^EY>+D[')" K--BHX0(%:(D4EH40HC M)HV(N!-BS-)P0^_[A;YFJN %[5)#!K3-C:X4(')(H$G844JCQ63DD^3 M@! U7(5%]&P-2Z3R=LFB@=WFC$08$'74""4,(DJHK>622#0<>[I-&NX.HV1' M!L#G41+(+12-EEU2&16A32VE"B""F>"4T*RE.BA\4E!"WX)G"2":@A/. M5%16_G43QOBMM/Q"6;OL4L!M17WG MGC3O3$GS#C1IWAU"FN6G! AIWO8@H9>"1I ],. M+H6T2TK,DBSWHG^&6^5"7"SLA!Y"P$*2M"3A444$3T>80@<1)1<+ZY*N]$!# M>)6L\[NUTV81K/J(N?DC"!*($/&QAHO=DT+(=C-3CJ;8DXP([9^M-;( 5-W& MC=]@-#$/B&MAUJ^)C(N.3-_"C&8/22QW$.!%;+6T#%S5VMW?0;2X!!3_L #S M-:-RCG;CGW(<9^+AN_&;M9F]"Z>>R*L?0+1N%PTW35>_6V[-G](P)SF/DLUF M%Y>G/"*_08F0 *S;P$B"H((7%17*I!5$E:9D$LQ13$N*X"*^[Q'& T^EJ)9SM M5<*V2*$'7)%#+@F")%IX?"QD?.$W-%"A@IB.6]I,LFR'TU[D$:@XHI 4O(1( MG#Q$.LE :DE5*+KD5OFDV_/;=_?+,.>"T(E%K,U)$G#UC-3Y'00W)*"Z7&"_ MT4C];]]][7W'VV29>@&9$A?/F_LDDD2?$DK9(H$"8L4#@0@(*LAQ M==EPFZ!2%!6R+J)3M< *BM/YW18!A+"JIF_]"*+118BXSM]J:T=#_OC)?Z"/ M!4@N)(C%; _](I#=X;\I X(""F#\.T"%**ID75Q(V$]9:[T1L'9F!*PU1L : MHA&P-C4"ULZ,@"K;(D0(&9>F]U&X]B3!"972MDFA@-SEAT 4%%7D^*1C1JV" M]CJV(UJR$&>3>)6D&Y;_-?D@**5$SEI,2Q7,.JBE2 @$1U3(N+"61="YAC"B MTK9YL0O"' <%F.LP]F(_]*(Z/*)H1URO8HTMAN!KXFCD87#(#"1'IT*MBF58 M*^Y#7=K>2B\<,'["4?3W./D4+["7)3$.BKT4T4F16MZNQXP&=MMI1B(,@DXF M""6N,U3IXB/50I5:N1/FA$D_)M$NSKV4W25/12.31,XN- M"RU'5RQSG'I^'C[B*R_W2FS2\LK$;5^J5('NWJ84R0*BD!*@]/YDK4-#Q7@5 MIYR%C$E'Q-1:)PHO\8Z4_< Q'$0^=DPM H@>(ER*"#(IJF2=<&&Q\:+H% M,<[D$U%'RBX7A!#;7&B) .*"")>$"TP45;).N##>X'1-IK=H'%"^B+,I+*A"U3!LIV YG M.#E(A)&!X]@28?:2YFV2HV6"[C*,\@>,F#MK0+YO1((OTG'UTHCOTPL1A54> M!UXJHI!*V/JK(U+ W-LCG"0((FGAR=\AJ350I6*9-5/"X;2YCF,@Z%MZTML. M>A5;##(%7_%()P^"388@NYQB:NW%-5-D[R*ZC&;4#&XO-_%:0I8M8P' CF'< MD #!$2DLF5GR\W7T4^M=1XLEW65HREB/F\? ZP?+V H 8P*.2A[/*,S* $FWP57*ED^7C H0.>0 M0:$!B'H&,&4'#DP3,=4!*I110]O1^BS;1P'$P>7S'*]P2N\=+/%3?DDR^JA8 M81CHVEZ]&1>GNYC3*H(@85^TLJ5>AIH)H'OJ(U8F@7ZAB2"6"J"7[J>KVJ5D MEA0;&\-[&IO;[\[3_51M$/20PE!^]M%S3L\#P'(.BY4J=77=>Q!5VNB72M\] M+X=9AO-,P\"ND$VNB0$V6=66 ,,?(2S.VVRQ&"\70%A06HI&9.!D[7-" I>G M1D<0&$/$Z&1/NWA,YSOGC!EYV<,P#NA?X]]VX:,7T=EXF(^\-'TF5N"/7K3K MWJOHJ6N34;V*TV28D2(8QO5!RS&0*"%BXB.??L![=>=<++?[,U*RHR/B9LBS[=JP]0C$^[WW$( M*R.N%P?AIB^,, M5R1O3?F28AIIVB1+CZ(T.62@!H9:YE@%,2ZH9F,D\ENFFG,BFE#.(;FT-')' MF#S)O>C&U("777FEB4#CQ"Q-MCC-GV<$:D[83HW!+=VPD,]5:A6[PY$>?'L< MDLL#&H"T(/F1IU!A0P^NY&$8/XWA\Y:TJ'+PD?1B%>8CINH^=(3XD48#3C YX^;-F M[]%XK:0AL";=(<#OA/(2RN3M\P> M->P.@<3"D#BD1"B@$95'N-A2 F!Z)5YL-O8():U.8'*HK9F+%P-#%SDV_CT& M+P8SUA@/,JY'%[-AQ?%XHEVX&8\F[5W$AED#B3'Z0CKCB(8<8%FAI ,D&E"O MX#!G+IG4P2!AM^]P[,MIH=2PZONAA][R^)"+@YE]]!CYU[YJC<+)HZF#OEA@ M3&_H8O3-E\ZIUGO7",H^4;^=H1>P%]1[]Z>I4.WV8*;H?GD^2ZGG>(J+/2V5 M_YI0TO*!O QJYP"^*P:&.G)L@@/V0A)EQ963K9>B1ZJ _OCFJS=OWJ(M3E%& M[Z%\C]Z]&;QYP_X4WY#!;)<_)&GX;QQ\C^*D^C:DX?<"^B9NLK^Y@KPOQT@2I !&PNOL(_I/=_JZW?.N=JXO:-TM.3$;,^K(I#=R;0I X:?$F"B M:3.))#-W]^5S&3N9.HJ/D]$_EF M\/Z;MX/W[_[4(;9 '1Z+AT' [D-XT"?N#!.RR?AT-\'6 1SA"M=FN.V6* Z=A>BC!16T?CO9.!@QO#\?>Y729DG/^ MCI(LGZY*--+QOR5C=SX5P&M/H T!,#P1H>*GR(P%(\V\"("S^ ]IDF6S-%E) M73-:$C8Y((#69$#C9UBGE3RP+@68!-HR$><,F&YQZE$'\S+BDBX"K4+>:IP0 M'>Q6K!"9,)B10X>0BQE2R=>W&MV[;<]QAJECY# .KL@0&"4L"DY9(.G,JM2Q M:^<8P&];- H%,,PR0OW_+N',Y&5[_.B(B MH>]%6M9HI6WPQ1 R98I&U#E'S/!Q%DRI<$IF'.\#B*.(OHJ)8S(P1H3LPV!# M8-)!E+ZFK!Z%3)6M^@KV*E#+?]!(TSGY#H++76,JE =H7:BS$"0 MCP]!EFVT$BKF)+%[QMPF<=(N014Z5[V.,]"SR2;C8C2YI54",\F9(A7'A@R+ MG? ORF'J2_=K/6EY^I8?",MZL0L^JZ0G*CDF&'*.4"<)52M9W5U[87@?81K-H K0(UJ@]$S VAKPH(+5R\)>VLX9=S#D+@5I M&N7-7&^?"DIB&N>B2@?%-"$PH9CVAD%U A3&.]+EIK45<(E728H+N:7WA+/Q M$QG5DS0(8R]]I@]4LS# ].PH80N6JB)5M-'3I,%TCM)$NM3LR5BU6$;R6E=H4@#5(B:!U&4%D4$1^=LZ#ZB9\Y>5]Z66A M+RF81-8F+Y1PF_P0"H(9/E3H9%1AL5S\TM.0*@W0/54K3JO":)<#<&?]"8?K M!P)D2&Q:;XUO=S3@RW3%.5*J:-8S#9OT.ZAX35KV2@ ,70]!W:5QE0;RBD1: M5#;VECWGR=.A42K>66TG,@J$2;#(O31734(*G-V6N?3(/WTRG,"XN6/J!N_8 M]]W(X=VME[LI50R]W&N>%%W6/5$HQ8N+'U>[E.">L?*RK9IJ5L7!*-E0BYNM M#E5]I6="UN/G'%10;N3JE0J8^>=@Z,+PGQ?W5)K./[4XF&69I*1%%ST%J=4I M 6"U25$-:*U*!CJO#;#W);;)H UG.6_7HE(>-0EQ@5W--TXHEHDDOF+CX.(* MWQX.IOD4/^Q7OC]ZO@+?\=[%7I*MY*4CX M&P#E%>GI:N1E#]=1\DEWC4NM8G?YHP??[L9R>3 CK0%(?N52W7-/5H@J(:8% MZ=8[,>\IL%F:/(8!#BZ?[\@R:Q+7'K1#/P\?BSBM&N?3 Q*R?.IZ8$$[:[F> MJ8#A[\'0N$OPAVQ'C]X4VR1D]?UOU>ZO4L-FMS& WF2_0AP,B?48^07D7J.XJM?0 M<& ;CK0[06ZY$)^ MDN6V-^^M>_M;6AQ_6S18C-^3 M#&NW9#Z;,VUBVZ68P+O"Q=\-:Z[\^"=5S<#;7!S&.](7/+ MX@?R+QI\M65I9QDN'_UMO%KCWNKF2TLF:'H$0)_C8><%9 6#PT"2!_)\3BB$E&\C?1-3IN^2F MK^9C0P$^_WBP_#6B0L+]DUT\^EF*Z;.<5^7#%-4U_[(O#=D0;UP59HFY)6.? M JM9:I(2?/KV*(7@.1.J6H>C:8RGA6T D._5V"^^P-]##\:4+UC &RM!6SV9 M I9.YU#6X<*"I#O2,_=FINK8I9871F99=/<"K="E8&?O"4L$Y^\P/Y(\^T8?J:G&< MBP6XJ_']<(L\[;4'ME!92]=OV2DS!TG<-06*4 MB==D_JB\J/W?=F&*2;E)_\N?9Z0L.5GK4<]=%AA94EU]$K#ZPFCO@K4>&S76 MAK:,[XV<6[H34 _$QJ GUKB2=&.MX>-\Z^"*M!CEMK-8 <727% MO YC+_9/8#4H$P+ 8H."&K!9D0ITJT$/76'EH,WN"HSH:Z7( 5"G82WBLAGTVNE2+0YED#*'*AVKJ)-LH48^%WIZ1UFK"V5: ML/M\4M)>Q#0C#1=+805TT=I7( Z%:>90E4SKY8X-;,%PM!T*=8%PW,+@12QS MY;BER]PORG7NE_2U3988NG^&N3B@):9_Z$;3HQ?1_CDG2_,T]$EOIC\,XZ#] M14.R")?$GW>5[Q*/GWSF;SHG(\.83!#2!;-M$%;?%'92P:U'BZTB@-6GG91= M-"X$I3;=_6)C!/6Q8A_P/L.7/1K4%7,59MLD\Z(?TF2WI0^ TM M[*D 8F#6 M+P6C>[P.8QJ6G-J[19D< M!=?Y73$58$@@)^7OQ55,/81-6&KGPN1NNXU8$!LOJN+>C(LOM &)C%2M7J;L M49C6U4H#/3 [F3W QQ S:Y6D&T9Q$#?9JN>0 M:- [I<GZSMU=0I M*J%K=QZ3)AB6GZ@@W$9&D9QP)_/H65;WCNMT]5,9];6(V"XZSU((VW^?50:8 MC\[2E73.(R-XBE KQ!3KA.BET;ZVD><7H2:]]2FVNR2,V<>XYJ)B7R?I)8MO MS6+'B K=0]D:HWH7J&:8L2:4&UP'H7[A0KZ*T;4[L)ZV.YNQ^DH2=#\WG*$VW S73'J!6ZFQ' MJ)D^'>OK'- ^"T@!A(^JJ[UUM,1/^25!^/$<32+,YL7T.T4EG:P+"O+X/'JC MO&"< 3Y,;1"U6*%@.?JD!W@F#*9$&0UC(:W2S0SX>0*C?]W-KY=C!?,BIPN M_S:>H]'=?#ZFH^IB,5X>/9">XD:2^(:TQI8TT+-\.\FL&)T[2FHEYX3LBU1P M7XGI#1#39+L-M2XDBU-:0//M@GY)@""GX3*_CSY\RIHOSV=SNBQ?_LQ&S_$_ M[B:S#V3D'*#;\=(]88O;?71Z8%&FO$BW^E9J6+X2I8/>N1(E$X=#-BU&P5TH MIL&&Q$H'THC8"?)8E:P5=,]\<#PX-0?[0H<66;!IU#_& M>W/4.;GIC45C1QJ9L-UWGU2 VT\^B23!$$L)3_A2\%X:TO#8+H=N^)-*N^.0 MO\YR4ZO8I) )^":/5/)@R&0 M4N@;Q70:PQ,H\TU4*-THI=%Q333EB*54 $TUW>AU/9S,T8_#F[LQ^C >+N[F M8[H*=6]#C9+-)BS>7R/FX8A=15KCV._EH]PO#:L.R8<4K^5]W"ME(!:L\9E5LW@/9-!!R?E4-LOQ1>%J-U@_!H^N'#9,D&7K8;.)JR M ^GQ[2E.HX\F+]W;S)\U8VU7R";YQ ";Y&I+@"&/$%:7'(40I-&,/6+YD$0! M3K,"'76P-A_(>NA;=:/I6ZR6)XVI,ACR]47,#UJW/X[GRPE9]E+/P>OQ?#Z^ M0HOE=/1W-HBQ3W^;WER-YXO__,,W[]Y^_3VZ&E]/1A/WYQO[4DY7S5=;YSBB M@I@-:FSE$I@ND5)RD&YWI&%2[8&\&H M"E,WI#>>UAC:4;5Q^2^;Y=?N4!Z;*LB^H:Z"@SJ'.,F7USN4Y>"Z!YTI+BZ' MBS$U?3_04YR3^*!K_3"KFXIFOI:\M -_2AED@<]D5]0YB\SP==E1B9V)#57R M>O-5+VZ-#P:@:T(H9&$P0@^0H\1P/A]"V*5<[.XS_-N.#'+C1Z/X03)QNS&# MU*#;<8+$LLZ98PB0CP=4B:-"'I+MU2V+=ATMEW?))_4Z628,EE'Z>R67B_$_ M[JC7\_A'$&R'VZB(7==*P#G!A@%[ M'22KWH(PXYA6RZIWIED16EZ8:A4P9#/#R7E5[K6JP&;.>3;V4AKREL;:9KL, M9CS3:ED]JS(K0NOP2JT"AF=F.#GWN23+$%%!3,:8&'T[7#Z:Q!8&/X7Y MPVB7Y=!L+ML+1-!<^PGZS@$,?L2RR!) MB^<'"*S(RS)V1YX%% G^18K'[B7AS$_#+?U24C_]D[%[R^RP0K9OFO5+ PQU M#P3.D[>MZWYE2#BMD^YFD?FF H>Z! MP 7498>FC<@RK;2<,WGA/^!@%^'I:DCP!6&TR\-'O,#^+F77F<9/-- ^#HKI M9[/=52&>NE:3=M/O#!E9W2T\6T6UMAE/G@N8'G6VHG$;FZ._C:_N;E@$L=ET M.;Y=3H8W-S^CJ\G-W7+RXQ@MQJ.[^61YOH@Y^Z(:A:V@=PF5AW?'I6?M=.\4 MQ:Z/_XY)S#GG3U4");5??C23@X-'0 L9<5B@"#A\[0U534Q1@ CG+&S,/]RE M;>40?$@"CBP3PX))+ Z--AB6]H:L8BNX6_C[THTWVRAYQL1&2A]#'^\=U)HN M;,.(P6"64KF[\V\<%(MNMFUN3NN3Y^>F%YRIVL2=YL29 >QCYRFA*LJEQ*VR MZJ)H/AY-?[B=_)/\?CV=EZ[[TQF3&?XTG%]!ZL3B^F*7&*9LTRLKWRAY[CD) M'9ZPFVYY;$6(^]^AJ0+L:$<61=&CJKXQ(LO?R?)GD+VC=+H>?O+2H%EF>C&\ M&&*R;+M>>Y')RSQP:5;0>0Y;: [.>\59B\7-@64FU*FS MF0W:YX.JC!!M6-3(BKD9EYGM?:C0+RQ#]_<9CJRV&S(Q37*\D7FPGRYYJXZF M)ZZ4ED?JB=(&TP5/7"#.A#E5AZ,9(9;3B^]UPPWUL#A/>U1IOZ#^UJZ.$W:V M(N'/I:>U2B/J9A=U/\OJU-UWE;V/>WFF+*L=@:"CVPD=H)(+":44E)=:M0A? MPNV#ZS .P[*TY63X6O.1A9"NGJ8K9.V-K!/X\3"DDYC4@Q?[ MLDF'%[/KHR,&V?;(:$W403AM\X5Q,AO_0;'TR MHY1V/B@90^1&HU+8^4A4["YSUZ<-SF042M;/9;0%X,YFI!K01B(CM)".:GJU MA;Q@P%8]>J"2ZR:%7GT8X[S#-V_&D?7V$J<;^EZXV3F+2,75?4@9>-GMQJZ\ M\\FC!TC5K0NF=$&U$%4#$02@6/?]NM0Y\; M0&<=%-$DSO)T1S>*R@N\%*N,1RH%NQLV.N#M[1N9-!A.:2'R<;&]&&W+QP)S M(@B-3"PF2>B713$K=E?'(:7$\!6L:BM )980I9A;I6A-,H_=X0!<E,N(^S M?.[E>)'3':ORDK*WEIE;?1)P1T"3@LG9J-(&2DT#R$*>AJ4>2HF. M)^E MP]%J4 9=LACLBH,AD!ZC.DT+@X]&"L/5E7&Q M'X^))IP[C0?B%MQ#*]3+QMMZ*7JDFB :D&'/)EFVPX&^T9K2T!M*B%7@8.IC M'&1%,)"0"-.;@G2PWZ;A(VEDM(V\XAD2YV-]A97&:YB42"?TF2HOFNWNH]"? MKDCQPW@MK1YC?S_V*U?$--%,&,P?T1=QE["W.J0<%2\,Y)5E'*[K8U8Z" M+K:HBH&1U-J#1]_4+>YGJ>9$XR2L&R0]"\=9)H;Z8.AY &C^T(0.O&PPI5&6 MDI0LYXE>O&;C:ISDY,>M]TR77T4,A_(4N-H+0!ZHUVODZ:UXM^'D&_VW;"C,#TLG.63CC97+ T4;G!C(9I2F>;XOI$ MZ7$8L*EFY&W#W(MH^@-4A#4#LQ%XFKK2;2&>/!<7WOLGKB*1K_^)L@#3)\]3 MKC/T1DB[JV5]X$!<79JP@H;*5F\F]"I0RQ?52!,,W7O!%3NGLMVZBWO&9;^A M"^=P4MR']]WM\EG\OD/YM,-TEV8M%*/N9/G8]=S\4S5U'9Z/'$F M5GM2X2VTR+TT5^VOGJN0G(-^(8X:\@-TC]=A3,/2HGLO.D4X-TC][R<+,@&C%U[OK+))F&F@0/X M_2SK5?1SS+BG1 "J7YZ^:GOUU]-E_W+Z\*DIOE4856 M0%;G!R0$X+S9H* &I\Z*5.!TBD.AR^:N6LX]B8_M[U51G$Y@/4&\J#GLH H^ MZ336"P&<3NNBV+TGLQ*CP+T^QD@SF % M&(TI@*GLZ"32[CV/XLQB'"L#)I^OD$9GD9C];7($\3+8!/6L[/-FGE'1CSHM M,^>I/4OJ7E]W][WK;HXW7DB/!4=)S!X5W'D1C;_S3M6*MI%8MYK<5#4W4-B% M @6APQ>?C3_!&U]"/.Z%C'5H78)Q^7 M"?VJ-'3H98VSNJN:9_^2NG3?2CUE#S?-^_/K\#U++MT-+=(I7H;9Z_X.>KJ# MO=%C07U>HX+MK8'C$/T>1Y!S')="'F^.6%+UKDS92DMVZ1\2P)>TW7#ZACGE M+L3IT'TVFQ,GKY+C]BP@CU=G'?SK%:*5[8TC\'Q>5I&FVNT:1!(POT=;2%T5 MQMLKL <4[>+'U4)$O2@ Z+^@LI&OO;",TT@C_1#";I*XB +@P6']"-:)D;P M89;M-I7[9=&7?DPBDDQ$8Y*2'G'J'MPGYQSVPDJ&O7.$O@AC](R] M-/L21I\\U< T#[./URG&S8=0; R(XGQ?[!2JJL:S3:"B3&'U5PLEY2+.$]&+ M%9$%]D;/6F[>JGW)-4B>];WJ,3A=*83ETC]8+!71[!LYM$, M8YG15Z2:@G6H2YH3F("R!X]!-]KWB(]/^$7,=5Q%G&0RNP$7'/9D15'%@Y7U M)DUGN@$4#_;@>BJ\O,KQ*QL^>F%$QXCK)&515D[=+-KL7D3O,ZRTD_1)35XO MOZ>:%;#;?]EO*&%FZ EG\/-@*("JJ=, E(![.M3U[/1RWZ\ M(I50;UE;:1H#%"_"Q#ZNBL_7O[40P-@(;LHM=53W2C_U]4L9'0J?1C:%EB\Q M%9/JO%R*D(7+]8Y&:*J>J96TPP'IV.RA!Q>SV<=Z)P*FEQR*G+>0RV4]?'XSYKEBU@$]*B\TQQSZ?,#T_LL%))W52[[)+'6 M/Y4=V_+>T.5D>/WK,O4"S"[1EB"6276RK\&B6^ML4E>K!E8 M.W8:_5#DW-.=51*H2@/E":I2:5WC0K\4*2G="L[5PHWRS+QB??G5FS=?DZ4H MX[2D:8VT8+5I'\C=QFRVU@ 1]3+XU1]I"FB+TV(MXK0A9RG>>F%0/BB;#>-@ MFC_@=+1+4SH>91DF-,9/^269MC]R#=I+&U;#'@*]V\!E&M6KT!DBJ2"6#"K3 M045"Z!>:%&)I.6GFO0NB4;GI""1O]6,2@T6"$Y1$Y8S9AQ]LT'?,DA+O#5Y[ M$8$Z2Y,5SC)2=UXDZ_HB65AMK %#O)+I>I%<^07:DY:J"K!%7[$4;*EA18\1Z\1 MA=4V6IR,1];M(\Y"&+TQRG)'%5_U[J2L)I%!U,=A:7:DT'%4923WG*)8[P* M_9"ZFM%>3(V::^S1$[3K)+U,PV!=# Y<$QEKPFJROK"[3;C7+\<]F@!:%2F@ M59*B>Y9&,1(Z:=-R]W"ZNL(K3$R@8+HB?[-@=5G.-Z1:'%;K&6'E#/CR"@[I MJ01B:*39F(.GL6";X9)10DL=UX$5G-(\7$;F500>4QR0/>Z?)UA M;G),=!]Z*W;V\^;]^[?L_*=8QA^PU5[OLC>CVA>N-)/83S$1O<+%WSV".+N' M8^/!!X/=PS@P M:Q"=#LQ^H(:JZ!SLI*D0=]1([-H0/2 +A8-^XV= 52]"Q=]X(C*H$')4MU-B MM!+#-UY7A\&B&N:$ -6S'!M_3[&4K ^^7=A/&.@"M1DE7=)5XE*2[DEMX3SL9/>>HE*5GE M>>DSBYI#5J<^?2\CB:+BV4$6RU'4C&?,#A =;)2R2ZL6F1!M9+3/&.US1O&JMQ<7EK.-'=4.*%?WX,A@!R;.#2'\8NXYZYT;EM*6O.<)*#^ MIP&HBB!61P;;[WP5OC-)X-KWH+,P]?]UO$MSD?$/)NE"0U, M'EP^WQ%+;A+7"^VAGX>/TJ8TUP;4H > [C8K20+1-%"5"#WA_8*F0UKW2[3? MIMBGY:A]2YL\6R9#_[==2-]42PBZ_'E&"I33M_K(M\R16=2^YMJ VO< T!(' M*W8YL4P$5:D,$$MG4&]GLZ1@==\)"[QW:/<5: -JW@- ]^R^=5+NN^\][)-+4P='*DXHO(OW_'4_1Y;'Y22,5&BYGAZ MHZCN\RI$$MHL)2NF,1;H,U4*5&G+9/)*Q^CJ,";1#IR>!-J#&.P!T MS^FI3LK]]$11TC_4#'KT(DK .9DZTY ^AT1_(-96^XN&I-@%D_P[V@7L&-9_ MH-O(]#6E,1EJ?.'$9Q]$.:[+9$@]YN*\X>R0Q;GSR>G/H] M\P=@NS@M]OEHOZ=V!0DQ3$RSB:IQ#OVYWJMS3[(# MVTDTP/!2@.8_!3C.WWPOZO@8>NC[N\TN\NACD7B;8L(0VJ')YPBSBRQQ,-PD M!.N_V?>]]NI.E3:D-CYUD021-JH,4#.' :KS8.-P,YO/DZQ& M);9&X3JZ=0D'U9%T9[KHUB^#VY.8K+#C+/3/]@J+-#- L^_YRVB-L77^14S9 M%\K0'XOG[V+FP$GQ%_>Q?YG'0NP!1KPQ(.=2>A M7P]0 ](+-S#T=6[;[C@.T>^J.QA5!(Q.\GF:,/HF&J[7*5Y[.3Z_B7,PF-]5 MG]'5 8SN4J,TL*2:7]V03^3KZBOR'QJRB'SS_P%02P,$% @ +V*O5MH< MO@R_*@ Y9T" !4 !B:6%F+3(P,C,P,S,Q7W!R92YX;6SM76USVSB2_GY5 M]Q]TV:JMV:KU)(YWWG=N2]9+1K6VI)7D9&>_3-$49/-"D1J^./;\^@- 4J)( M FA0I!I2=7=_.+[KPW&KWJA)'E+2W7]\C/KSS_U3_^][__JT/_Y^__N.2B- _)!_^ ML?/-UY??6YV+"\"X[XFW](.[V6@[[F,4;<(?7[_^].G3UY[_9'WR@X_AU[:_ MA@TXCZPH#K>CO7E^D_Y/TOWOKN-]_)']OWLK)!TJ+R_\\3ET?G[%OIM^]M/5 MUW[P\/KMFS>7K_]]>S.W'\G:NG \)C>;O,IZL5&J^EW^\,,/K_E?LZ:EEL_W M@9M]X^IU1LYV9/I71](^1TGH_!AR\FY\VXHX[,K/=(0MV+\NLF87[%<7EV\O MKBZ_?@Z7KS+A M4H)Y[\> K'Y^=>]8*_J1MU=OKI)/_&FO4?2RH?H9.DR]7G5>'_;Y:\ME$IL_ M$A*%*C(J&[='SM0*B!<]DLBQ+5>+MLJ>C1+*IA-9TX^$D]5DPY8 JF-* #WF+;MDY5C.Y$.O4J=&R1O3 MQ30@>1 GP8/E.7_P?W2]Y;45.I2*:4!"2@__K8KZ0\9L5O;Q>FT%+Q1RY\%S M*,:6%W5MVX^]B&Z84]^EJ!,U&%JC-,H E=#&*$DW MON5-K1?KGHTE)Z>B::.D#"TGX%;6+;%".J/Y@J0B2MJI4?*H7;IV(CX^U96> MSZE[[@Q^^*_PT9M"S' HJD/G/Z@K;%77E=KL*,HVA,-U%??8:&;ZE_:7:4$F5?49LG^X4?Y#E MT ]XT\F&;_6?K& )GDDM?*L=8:0?M*G8>9A:CSUI[Y;6MFWXAVYI\9H3H+_ M 08YAF6M;$]/[2- MPXL'R]HDI!$W"K/?[&A,?_';]LQHD0\(YPA-&Q;;%:G-H]H-]BFW CL;F/ZX M!VGYK#EM\7K#SS O[$?'W6K#*O#7(O&E'_2E5/L!W:%^?G7YY@VZO*GJDQ'] M,03(/-<66>X"N"M 0#T7"O,SG6[SPX$AW*74X2CS,5V6F"!DB>I M[Z\MQQ.C4=76,!A$JE5 I(J3%(JZ2%0DAHRZP]^8:^)[_$-3*S&2OG[SYKLI M">:/E+-;LK[?;: YD;/.P+XJ"+8SOR7ABU4HD[H&,R5]:1*,16 M"9NHF16U M\*=Q8#]2"S!'GA03O2& T%SA0E-'+(3/S472'BO)?:J MKB?H"B:15H@9>7"89\)(V?(@7S($7; 7;ZU%1,HV$A1=SXLM=T8V?J! 8+\E M4/!_,T+P54PBR?M?L15$)'!?("(O-09*_1LCI"Y@%E_5'BC_[XR0OYAA Q#@.7!]R@TQX( ,6U6;@45-JX[*^(.1J]2/E%D M/@TE)N"Y4ZKL\JYQ1%[ OK>;2D9//L=28MM?2%7: @X#JL(+Y1 ML!AYMA]L_%S4NL>N$@0O/7\I7?85':&XX'JR&C) 0:>[7%*YA>E_&">7,DPJ MFX-/L0Q 0L*O(?)_JR?_MW#YXWJX2GX-D?^5GOROX/+']7*5_&+*OT=_G 0+ M_Y/@^%S8&"I[7"]7P2NFY#G]DV :^$].4MQ*)?Y2#R@&)CB_L&5?!U;M@SJ@%ABA=YO 94LKFM;Q=61!7OCLT.91]^3AH7+K: "QO51 M1=P=>W%FE]-"X:J0^S,X:0]WZ2WRZCH<;U(-<>X$(S",":!+A 5O:!PX#J44.Z/O00EI8=>+M_> M+]A=;<$"5&H%%3JN,RGB[LA"'OOL/A5=!.#9_O1\AZ(.!FCNB54TK@^I(Q+M/7Y ;0^/VBN MS[B^I(@[)"$GN?-TCDWN7>=AKZIMM;PK.X#O*ADA>@G/Q[X>R:]-L7="@C6G M8TA_J):_H"E4\LA7465\'EOF\=*)R#(A:>AXEF=3'VWW=H% _,I>4"20[ZH" MN4?GO_)FQ,K]#VR3%P&V=&#L L4#A/./15\HV#QWG=C*JZ 9\,& M@EDA: J5O0GGG0(^<1)0DUSO[?Z4/!HE$[VH!Q0!$PX^Y5PCI>1%A)7U4"!,. 25?/G)?Z$A5.PF) 97\H@B[?G:421]F!-@@>ZWKT+_$_18WJ'5B9U00>H]$W(\Y7R MC(/"\^XJ?W*K4 I!16MPR0@3Y"_D%JLZRK9N_IR__AD(Q"]K#P7 C NL8HZ/ M# $OY9^WNC@QC'Q9#H>Z%Q0.7$<8RCW.1IRKJB#=A_?:005O@LM;Q2'.!;3X MWG7LH>M;4OM^KQE4T";XMQ7\HHVOZH8]R4PK0'0J4&36AP/*HP.OOKTL,TD]^S/Y:^<>]T>J] M'%#]I/?>"P)O.Q>=K1CX$P+T,UY(ENRGT'>=)6.WDX[428;J?'7G64FH_R^' M/S=P4)WSR6I[S##U$\]#\BY!$7=I;YQBXBNU,J<8+ *10*+R:XT97 MO?I 9(^1 ?$H-<>NY2L0;A4" E;1@6"/O;,GI^A_V -E3Y;+5N-NU+."X(7N MD[S.N1@88'?L6L!R#/PZ+!F"7QJ2V+[O-R,VH32S1S;')!+;YIE@8-VQ*PGK MX*T#Q)N%:2"$G+_(CR^4M\>9:\@+JU&5/ M[>X_@RJ;9+)>V.6.078?A''T^92;ZF/?LU7S2M L&5S/'I1^[/P$5C=$K0VNC(N$9'P^-J7+('&DMZ*"/!F1RG+!U",+/ M@ +4S9D)9X ?RQIP(GXHS8X!?)[O1ZC=*\-3V@F]U/6!^ (D@KYXUO'"FO"[ M6HMI'(C9"7A;TVQAX+0J#AHK&QM0)EL3%@G/Z'CDTJ54I[ZEE@:4R:ZQJ%5Q MBPY#=[GDP17+G5K.?K%CM,#%,D+X&5-O61 PN$73PRKSIF 9&E.,^V @X _M< M91C5C[H;4.V[.4],*IM&X3VT40MZX.=_]LP8ONB,!(M^64O"6]U;GNU?RNU&=S: MOO]U8-1%?\L#=<9.%SX 1 WAF 0D?*N3=L).(FX&.&,WN1*-JAU.V $[O[A) MH S;VS1O,8NXJK.KM7\SM@&X8%L:DHN^JTTY64TV)"@\7['GGO\-YI[OANSX MJ\YN4/Q;L^P&\YILZ5/[XL(.6+'M)^+%9$BUE1WQ,E(^.-%C+PXC2F8P>+;= MF*D92^.E_[M<6,^R8'>-P9 =427_+O #\-IX*]D)T5[C;!=9SVI5_!WPD<-Z?;B/:1WXP"5 R1=L)UI/225 MO*//I1D5'_T\NZS=I]/<]?GMJI1%O/=J$'86 Q,]ZR#I@>[M@P:L8,61ZS(GKLG*=Q*-\N50]NLLU M)9KQQ,H$*^<)M#^V\ZL[8?3D@@YCB3V-O0??U=4%1\CM.5@1R09\XU<6:"X* M(-\8^WYM;13+')\PCF/?\_<9RTHF**U"0%?LB[UZUB%8%NCKIY#2&F@9#W?>R)!Y-R[9.Q')+N1); :-<= OW6K MC5$-)@V97;L%/@N$.5[,GN?:!F:OR.%U(5DY M!A9"\[EAQI^R(*$R<-K21]$O NLMQ$< X(2W["W7Z02\ID:_-/0F[(!^ ;F. M6@@91U\WQB2"6,.%9NCWC36-I"HF3W@V93G^6>K%M14ZMA@\07/T:\IZ($J9 M1I]''XCS\,@>!:16@O5 DO1HF$GR,_?V\7&8!$ M@=B[,[['2Q$\.Q LJKN=(BS5G.2R+I"LPGVR^O[:(L_LJ>KFA@$B4[:B M@5C-4.ZXTH1; ;=$\"Y8VKRZ-7;*3QT\9'RCV^NY_$T5(A5-L7.!ZL AY!@= M"T&Q 14NBF[863YU, )) AVO8JD!%5"B]M@9/G40DO..#LV6I9YKA9F;"C30 MRET,LP5 QEF9B]QBC+37Y$A26655;0V#0:1:Q?VF@A-T6RQWC*=GEBD[8F=? M:<,#DX0!*]I1BL4@OFLL(?[ DXH-?YV:4A!$J.<5&A?&ZM\20WP*64S[N0#( M=#.YD-B/ \I9\NXY3Y/(#F/(DAE0Q LY,(I)JCF6,;8\:!+7$I09"VV9]$2I M&P)9/I@Q_D!-E"&B0H>YU0-_Q >A@4?]6!&.;2K9PA=)@:I$-@WTAH%.<]L: #>9C/\MM; M_(L&!W@MC/Q&S-Z!MSQ9KT4#P_9?"-/V6UJ$T(#4'?:@\-#U/PGJ7WQ;)U6' MC=GA@QJ5D;-E52L1IZ(7FJW*:)D&_I-#(;]^N:,PC+SMK::N'3E/29%5]3J<'"P[=49,1Y8HNAQ/W3' 8[CEH#*!72 +&=]"92YGA$=TR/ M?DCZ\*>B&W8PM@5%J!#+F0$_#1R]3U_(B:NZR M%"5>)%H,L\X8Z/5W#L#*K\WU&;@)<+DUL1[ %:6UX&1CBJ(ON?/;/M+'HAK9 M/J1C0=6F_3S0@[O&GHK$)66:%6O,7!"1F@:P3.,7(>- !LFDI$R&U0":K+$@Y6='_,N_5 M#RO#O*R7JA,4F&/G!VH V'S'";E=JUANL8NUU$!$1'V!:NULA,4^V,G_M68 ME&K9G#3V<$$U85[!-:.U6%UCFJ$ON1.VQAFG[/^8*_IDN6Q&S*C3$3@V56#V M!^JF[O\BUS*YHEN.<::O0PZ>[4?+>R S.AD&='&56?+'I@.JKL=X.!SJ!>!@ M];DJ]U8T?2?<^*'EO@O\>,->HG-".WF*@-H,I8=_&U9M;2J@BFU2=!0#IY.O M'_+Y*;?&!="WQWB.WD3U/I^;PO%FXW)!6VXFZ$'R"\C-2U!OJ#*U?U\?KDPZ MYF&E!50I :6V4(#:B]7J2%OP2DV)=P-@R7(0E)@4&D(!:>\"_B& M5'*-CD;&!GNHBOZX._7QEA4^)UOV73^, \#+C(>/#+[O9R#>3"L*RD/12E]@HRUD!)P5.KLD]>#+.=K)A1KG+1T ^N V?YD-PD M$V"AT1^*37NE%FMBHRVCAM,9D:J:C#F'D]7.I)X$#Y:7WORE:P=[2"FWJM!_C+N+N]F@,QEV)M/!K+L83<;SOW8FLW?=\>@__)]_ M[73'_H!H: M'NGIZT.(WRG&@NKI-:7P8TMBJOP2 M/(>NT2R;++EQP.IF4H;M_.'$WJ+T?7%1FM_=WG9GO[+E9CYZ-QX-1[WN>-'I M]GJ3N_%B-'[7F4YN1KW18(ZS I49 ]0\D?1!BF;(D *L -#^R/-:#58QFJ$E M%W.F8'KW*[WSM;TWVHL#)J7"W:^]"?A#<0+237[:'?4[@W]/!^/Y8,Y-@,GB ME\<[N;S09L,L[G@T6]^2&%AS M[1"15Z3!U!&<21,Q2:G.9U/G@SOYN7?YICSWF"6^^)7/N<&_[D;36SK?_MH9 M#Q8XNYTP0UR]Z0&ZHJ4&5A.F90/KC8*\#X)A+&<*:HO*G+F8WG3,EI+J.7A9 MG(/4TIS=#7;[']+$2Z[CL?6/LV&Y #M3V@FM(EC^YG%&V=[]4ZUY5WM ["FH M!K1<)>P0T9DS#V]\RRO>/-^;@V^+<_!FTAUWIMU?N]Z^UFP@[(LT8.0ZE"HI1KR.9IWWW9N[ M0>=VT)W?S0;,1$3:I;:,[$@$;%/R7C@SIHHFP+Q1=$.>/1!X"G,() =S9A)[ M\-9)ZK'1_;''\X\>B">,-U[^K3B?>I/;V]&"SR'N=?4F/,HX&..%&"5,:9VV MZPV#]T:SDDC 1-0=!WEFUH*XXK%G?=&9-'<%KU-2;O)/CO3YL:\@A/)->3Z/ MWP]FBQ&U'%DHO_D\YO_],ODIC^8S?_\I^_?7G[W4Z<_&(YZ M(Z002_*BBGHZ%]N9\NP-.W/7FJH:0R#/TFIHE*_C*"1BS@SDI%_<"RO3[LVT M;TLG=6PF75QWYP.V:]ZR: EB9L".M,DJS\R,N.SN&[](QPOQZ2'N8<6HGDG'^9 [ N#D:/(_O0_)[3$<=/(FC M*Q79)]?SP;_NV"'WX#U>7*5(/>2"B:@'UG69?7H@=J&X"_8C70HX2E=B%+R; M-$T@J5O2%*[+4@8)/(6K\U4V--([>N>1S7474L-C$$;.VJK.$4\;%MN=6G96 M-9_X%V;R69VI9'5B^ N%!@R94?TM^-T(0.* AVR&:%F3TS2\F*<(_XH>QQ&_IH$ M8 1UQT%_04X7T'J"0L=W&CA^D-1OF1';M<*06XYZX^$_CB<+LIUA75JGN!B_PVJ MO!_XMI3-K.,')@-_\0(/";G8CV09N]1%ZE*ZEHX;1\X3F1,[#GBNX."956XA MRV2[66_B[-Y9T:Z Q&I:^-:I>:/MR=N<50%T&T.R)I2RJ\&WBPY;$CZ7:T8[ M'00CI3JM.&Q(,XXS#KV$U(1839K$E7>29/.VE)$MN9F$O'E_5E>4#KF89, L MA(]UQ6,T27XPF/*X;IJ7] M7O1WF/IC8Y\BMZQ6APK=2/U)I=#]9 7+/"OL5E8"7!C&Z^1WA^C2(=_!/NT^ MFEX=#H8YEE&=2H)]$EF.&XY9ZB>+;E8;4*5+. =5%NQ\E7ZUL_TLDL'UI=J@ M[)"?8N11QS8-9E-/(5['?/H5+FQ5'>RK^YYQ14"XZ$[ZQ:?T)8'"^P'=J$=G M]0OEFU\SEN3'P;ICFSAM*HJ6!%LJ3;Q@K^8D<6YJBMND\EEEUK*J(;:=T HX M(F9-V^]SAQ@^[1]1YMR7?NF8,MULJW?V\J6_WB^#_MT-W]NGDP7=LT?=FYM? M._W1S=UB]'[0F0]Z=[/1@A_JIT-_.=4WXE0_7W^GS1/]Y#NJJ5^:+>=VJ)^( M8;O]O$'+>3Z,#[H8D1%=$277"IK[@AE*T\Z4*^9?-R:T_,/#)ZEBUR_5 W2? MG?:T3O[1+XK8C!QSUK=)JCFVUJ3OKZD7IJM?^9YF*,D1)A](8_*2V3GG:#>R MJDO+W)+U/0G$H"L[8KN;4'TNW\Z"" 0](+X]*-K%6E602;J@W_"I!Y92".@P MI:4 5- 4FJ'?W:@'1R6SZ!#D9C2K>[GC1V.)J^X(A*FU1R@/7^)D D$'[L#] MNKMF#FUK9G$V/'8R?L-.:[,V[SX&!D7\0'=X8&=ZI2(_.K=Y3#G .Y,08!:2 M5H7P"NT,\4^T0W %-O!#:%N* ,&PJK9F %&M1B+A&Q5@2MXNWM&6YHG) T32 M3B<$B90/] "+@#I5=$71S0QX &H'P\J4N,B7PBKPJ9]_)WU"_,A/FK ( ;FA MN]5R:K$$H/!=X(<2@UG8 ?O0 XRD@F6#(C5:%\RE*5KE&K;Y%"UXN86#DK7. MKMY" U>X.8TCCQ)L>;9DZ2RW//TB"D+6FMG:Y(_NWI ';K)/ W]%PI *S7(% M.B7M@;;LM?*BKDPJZ*8&YVB?T90_\;R1]4%+/&Y\"JDE@P[>/G49DPEW2A1! MG=&L^;961(BL:AN?$4M.+YB>!M@YY2(T4KNF7%9\SZZI*D>#G7%^CJ5HR@B6 MJZ] ,\M5(Y@1E*I;G0;.)_Z)EI#"DH>EH:HWQIUX:>HNM-S0C4EG8T(JKU\6 M]+/R,S)0Y_,&,\\I^FF:F#7Z4=69&JBS&6!J*"VX!EB.R0/CUP+WDII4VZ\) M ].L955#[!B:AF;EG47<7T6?*&]264O:8Y\[UA2Y4@(& M.'P"QA0!9E4_[$)I8*,(NB:IHL]'SX;;U1F@LK6=M,;'QB7II>CNV@^B],*T MD"MI[EQ#7S!VN53I0M-"/ND2$$+NQJ2.+\Q[8=<4:'Z5R GC'&(^@G+#H+3C MJ](C M+"PZ;D&9]CX">_>HG)WV]EZ@:N>K^W@E43SXH+M81EX=.K4N7]?/BT M7%@8.7!Z)I6%LYM[:1VZ7-EHRT=VW*5I\BLDZ(/NJD)1P_ C2%3+3GP+-45AQWW M2_JA1WNTIQI,$B>=@U@#Y\,A;NV!Q]JK:0OH&N3PW?B6EXH&YN257I>YF73' MG6GWU^XUM4^-\>K8-?(=F8 Z^H+VV ?W\T<_B!8D6#,"P8?U5;W,.#R2XR*I MZEQF"/\D?H^J4@BI B!!>S.@@2A=$2 !0_@GZXR@D4>U*Y99B CUB\I'B85VMI3*>6UT:K&V!ZR2JUDJY5AQ[+,#@M3 M0TQI9ELN?S D'$ ]>GNBH]EMF;W-Z.%NQP.+GEV)OPJE2#L5DE MJ62,:\0:-(=!2O]('UX:^L%,NK"6&B(;(K5 *J9[5#-OTA04U(1EB8?LOX^^ M2Z4#X6 V&_23%S;Y-.4__3*YZ0]F\S__ MZ?NWE]_]U.D/AJ/>R*#\#I9($+VH9V6Q'7KDC\%X_=)SK3"$!_[*G #TK%BCM9H=_%#?ML)$GD)YQ$_2Y53AD;"$ M'O[+DZ0*_%6U-003E9Y))HPQ,3_J*Y*PJU=87]H)^UQ7K%NEJG!*UM%=YGE\ M'SI+QPI>YM9V\BN6,G$70Z:-_E(F9JF=$G(Z".TH8O'FR6H16%Y(31I W4Q( M7T,P4^EA$3$ 9]A+WS1PGN@"/G4MFTAO 68^H* ]]DL(< TLW6&0"0"G_J5% M77-)YE5/>;@(_3$,1:Q0R^39D+!R91F!EY MHC\G3Q3--Z[LM6]09^R KRPL4_*2P<) !XX%LGV/$S:U@DF0' SQ=Z.SQTSD M9PS*SMA'TSK(:4@#';E]'Y/3%G;CZ-$/G#]VD?[*>FK2?MB'U#IXP61@&%3Z M\PS:'_MPNCYT&K/M].XX5&GI* QCW5F:]3$I&E9GAN[S?N+0^C8ARY"]",;8 M8C5L1YX3.98[C>]=QYZL*$>.]R!#&CP$=E1 #WA-R:"OTIRM1#?[,:,LR7E* MUJ,XL!^MD%VQYI4X%<8L>!0@HM^:@&@=^:"#RE*@DCP&=E4US6@@RUU65'Y) MNI3GB.F,@_U&I@ZP]62$#FW5UC*)HS"RO*5BQ55T!(+WO0G@ :6 CE;.M8+[ M*M).:*&OPQQ+8[V4$HTJ&U78 2]\U@0T0O,4N\S+]O%61NO%/=UNEZP4(/%" M_IGT.O^,V/Z#QS1KZ >Y%\*[GZQ@*2\)\XWL25>6AG=QW9T/6.;L+2L+TUV, M)N.L1$QG-NA-WHU'_Z%_'TYF:0+?9,K;=#]T9WWT(C([UB:KO.#2ZB,]/XQ" MK@)'&X(K!F5(I7 8]=;]LD3<7U>D#$U9E7Y4Z#.V">0=9X7UI * MNN/XY=%H**H&/1JM@6^Z4Y!E]4:B?OH5V!\YQ:,EL[18\$M+F 9&'])H@DT5 MEC:2QA.^E<03LLA ;S%Z/UK\^B4V8%1LH%KW@X"EIB6OL.R:I$3S^%*B'/D M]#A6U7QI_%/(ZT@[P8"V$*E]_+[A:Q[=_X((]0B^0Z M'9/ =D(R#1S9\[Q'(P#;CC5=L2'P??;J_HXVC,*1EY@LBO=X6OD8=H*AD6HL M@07=_E?R%FHQU](JVR01V+XECHHV#R.^ZE;G+"4'O;G#T3 C7W+<76'0.9"QA+V::=*!G3EJYH)6"TSS=5C!]= /5L2)XH#7J1\\;YR MC["50GOV(.#3V!FQ1EJ'8,C.7SEQ?/0#R<+.!CY-I?XL5F/,4.EO;_%SG8U4 MS4I)-1) &GBX#ZY^+M%2#=5N+4'<=-56R>]\%+Z4*UV6U[VVO&:$G?33W[/R MKPRQV')99>:W"N4_-C'HV?CMS0,<7,_)YAA1%ATO=&Q^C>\HRW;QDU#]_&S/ MM:HQ.H=U^0#YO".07XH7=#)<6:';4=!^QRFS $VGK801::?I#" 231"I]*)'3<:).$S<0#4 M(ND^/ 3D@8)V+ ?A )*@:G]FIYMM8]SXYH&5N;Z]%S>TG("SV W#>)V(29K M_ETI@;WWRZ!_=S-@&>S#[FC6>=^]N1MTNO/YW2U/:/]RR=V\1':( :QGC)[> M0G(FAV95,SA;W][[5$B.R\JM4F&UL%/I?/Q+KO9AL)FAHG6L3AFO;?D2@&^> M;]9UJR"9H8=-S;F9$WXG/,]&Z*Z7?EUQ 42$T8QXC_>(""AX[K9TO#G\:]=!/ MF%%DIN5Z9@=+";^&6>UE]$9=MJR)LTA4U[#Y1IX*MD$,_X#>P M6S A7$NT*[(G5KL5/8A^9M*9_K<.$KH@G M4O>CM7.-]I:N)FI_G-X[;X[HFFGK5QJ"&2[#>L2'KPQ.W@83#@N''[ MS #@^+"BK1DA_VH=$@G_QJ0SNBU5@]]CN@JQE=CW^*&W],Q.T>T48:GF!/U@ MKD"6ZF1-T-PP0&3*5HSI5#.$?=:5KKBJLZU",^SPB529"H*OY!#?9$Y>0$V) MFP0S9NN#7D=6]\0^#!+NA47[%B@#,\':N]"]_6.8_C647".H.1SZ<Z+X2]7O<>/NB\&YWW\S>A?=W@YO!KTNLWP M&Y\VJ\?=BU?]W]F;X>]7@Y\.,JUZT+KJ)P(V)OP(CL M "MBU>NZGH-WKL&E&*DV2T Y,!U6<#,2JN'TN,U.9I>Q=DX7>.>@]T3%=MSI M-J^7C'TJB-HF&L.BL_\=MHC&B%'N#GK=YZ]>#A=?T,AX(>2T_;%7^+)6_ ,! M$5JZZ W>Y2(6[O&CT]9QJ]N\P&XE\[VOW)30L1MN2ST(_UY;S6V &;@5,D)!<+BQ>C;5Q ;16#$FLP.*-7YG.6"ST>98))=R4#2')E99Z M).@5ERHY9H=/9/JVU!T#(V&=XQ0_#'ZVV9!5_1V[9ZZ%>QWM=1 M>;HCSGC!+;H@>EPQ93=*3R2D(X@"W@7'9*E<H[9%3EN%",JRDKE3,E,.NX M@P+E)3DKQT4'58?@DF4\P5N&Z4(X')I0;J6 @@2LY69*10I^ XS$R\RF#5@* MGD+$\+V2%#F]B$HEPB1E@645VD X2/YLD@O4-[:D'S,C; (&*B/4BD)8"3P5 M:H1\[')LI1U#XE&2W7$03(G&"8;=$T]]7P0DH4,>Q"3>4\LVCLKIO: 68+BB MH]\2#\S]-$)>P3KXV"P\%RI#/>"C,_R=<4WFXO?OJ@ 8Y+15D/:)BI<122# :6<"_LT*5<)NS3.J)K>EGKC@8IYNA M'&*-%EC$UI!6,#^(V;KGD&T[]&%12R!/),!DDTLAG@ 0":8"!/CUXE^1?JU/GSRLD9;0%0.=116 M"E#&G+REE)R$&3;0(YF'5U@M!&N+@29^BH$*HFK"^I ^B/5X@_ZZI;#VXFT; M1V6C;![O")O_B8*/F$HKC!"G/CV%K/?7?N[<"UA[HMG&4=DHT20[0C2#6RY+ MKZA(]4"60>+$+2BP=0B[G$>J(]Q/T8KA*]BA1%WV@71Y#26N\X!>!$/H$P35(>-[-[H/L/:$<_N! MQ%88,2"F7DH<&M6'-@HQX;6$[(A@,P2R&WSI)2D.\MQ#AKK%: M:.OP/AW#"U@R1(K6WH9C6NSP/?4RI'*7+Y>NT"?(K7[7E39D53D#=Q2@Y=S. ML@.H=+FG?DA]9F*^G\DM*N$8GTMQ [+:AUVJ%'UQ9WV [O<9S@>0X=QT\O#L M06QA^*-2:6>_'+N<'9_[-RU0X;8(2I#+^!MHM M?-@,']"PL>;&:\14($AOY!")!]6B)4F*ORE365%FP %O2X$-H09EI4K\[NO1 M?E_DX;+&?E]DF[GM7$I&6Q7^\#SZ+&V,)@*08\#6@BN=G\&8 +^AJ!-LK5_" M3H<_)%:?MO@L^JHV$,)&[QH=PU.L:/&B0N.US'NI+A:2SIAB/>0K])(HA+X6 M>\"6!3($-MVWJ(ILUYY0V8>U]P;6/JS=QE%YD'L6YQBX9@:U5X24!UXV(FDJ M[>KCL8%BHQ#W"76KY2U0\*?XJ#J;:RJY"<58ZBG@TTFN@\#D=U@<"?>SP^,Z MI%UAZ.-M$&^;_^[;CG_UJ(_SI4W?/IJRUEG]3; -M64+QV4OJ^\ /COY_G_F M]JISZHD02Y[?H'^9K#N#L5^ M&+X1K&N#@5H*U6'59[F C W>05+21B)[%;)6#VBEQ]9\UVBPYP)DVF;7J+$Z M:.!MB:$O5>RP5V.?NVJS*VX=:S3J8>Q?_E:C6FK*C]24)9Z\6.9);-A\+5M< MNY;7MKN\N[HH+2U>JW0X=ZLUSK(V-3:?H0NFY_U73XIZ0G2;V!=UMRQT9I-Z M,_38SLZ9.[.EVZ2_D1'^: ;];8U_ 5!+ P04 " O8J]6PQ(?=\0' 9 M0P "@ &5X,S$M,BYH=&WM7.]OV[86_1X@_P-?@!4)(,=QLKP/MF<@J=TM M0-IFK3%@>-@'6J(L+I3HBE1<[Z_?N:1DN[;;IJ].8R)/>BT7[U]TY]_02WFJ523YM=>X_OV42P MWPN>8\35A-V@M(Y8+XM$Q%[S/$S862-@IR>G9UO=VFKV;2G\JV!_[[4,$RX4 MZ^IBF& :3@(X*LW&";,)M\VM;=SJL>E?7%[WV,O>]?7[FXN75V]^_>7@Y,!= MWUQTN]7U-S=Q+".;4-&3GUILH/-(Y+50*\5'!H"J3P=N.6OWWWW["^YH3$*N MJ@[#LG10+H[M?O?_!GQR?'HNLW5V>^-XVN7][O<@?.BYSQ)^)U@N[J08@Y5L M(@VN1CJW'K3.&)@L1?':[TS';"#U11S+3-H)ZXLPR;320TFON,K"8W;X0D4? M"MW*Q5 :F_/,OLC=C:/6?(?@Q[M-F04/Z&T;/?3+6)_JJ)QNB3-><@,7A,>E M$W:;Z;$2T5 $'N^<8[)(PVRF+1@ULUQFC&<35F0V+P0SEEN10F.2LW(L.I > MDBL6\Q"W3ZA(RF\%(P4SM6D\EI1'(F!XKR)93B^B M4J',PR)%V0PV ?DS\8)UE5F"OHQ-<+&(A>E$6I%*HT2/)+9$'QL$[32C$3H M4)+=D5=-H<8$0_<,)JXO/!+?(<]B$N^H91-'Y>Q)4(M@6-'AM\0#,S\-P"NH M@\?YW'.9Q= #+D3#YU 5%,R "^8(*@"92 IX1G!EHB*B**5F7%-ZN/GTU1X- M."V29#V@8H5"*1",!@NX=Y:H0FX2%BL]-A7]S!0'XW33EP/68(Y%3 5I"?.S MF*T[#MG$4?EY2SBD_XF7O<@-Z?IR(?8L48;,M))K! FX/#1'S@^O&,^%\WNX ML!PH09[)!,AFH*1)J 852Z%F2-'0=21-J+0I4(]T3JZ5<65&N0Y%A-N&'<+3 M(P$"$9&' 9_N?40DGPT%NX"$>%[^8,F+0WZT'8S4%0:F ML9:["&-&&%,EL8HU @J#0EZ8Y7J?)1J$(@,!JBE?YX,;7>0P &%Q)XW3*R@E M,F>'2D@? #):R8A;AW9@9"1Y[O(M MD"X40SDYEY&EPE!PY)C8N$C**1QM!%!92"I4\E!&G+RE4)PT&AKHD,PB+53S M<=M\S(E/ T$%(:!07T3/8FE>H[]N**R=CMO$45DKFP^VA,W_!^U'3*4S!(L3 MEZD"Z_VUFSM/ M:.:#9Q5-9*-.&6$$WOCJO"*2I2/2*.16CEGS>1ROZR]59)J<941$2CR0C"@]T8;\"X^OO#'S*R]NAG%W\A7!T9%=/CI*]^8GG1+Q6H]X[C*[0L?P"!4-+DHT3LM\ENH&4M%Q4]0#7\%+ A_Z M&O2 *5(P!)KN6E1&MBL/J^S"VB<#:Q?6;N*H/,L]BPL$KG$.[16 \H23C2#- M3-OJI*RGV,#'?3*[T^I.4/"7\6%Y3# M5R'M$D,?/Q_QMC5_J]/%;&GN[[WF$]8XK_XN;$O;LM/1]P!\?O+3#R;SLG,J MCQPH'MZRQO$Y(+MS)M[J8S:B?=6IF[H'OO17>>WZ56>W+#\:K!7CL1N+1X+U MAPS+Y,Q-CFB-#HJZ&.AE(D7,7DU7_+<^=?6HQUD??&%! _Y3JZ'50D5-=@-M MU8*!#P5"7JK88F]'+F?59-?<6%:K56/8O?JC0K4@5OY+8F6!+B\7Z1(-FRUI M\TO8XA+W*?TNKTT+:]@R*\Y\:H6GK%15L^DY9WK6?]4\J.9 NXZ^J+IEKC/K MU)N^QWZ0*IQ^0X(;W':=OMK"?]<%?27&OU!+ P04 " O8J]6\M4['< $ M !J) "@ &5X,S(M,2YH=&WM6N]OVC@8_H[$_^!#6M5*0(!>JPTR) IT M0V(M:W.3=M],XA#?'#NUG;7<7W^OG00815IW1TO14;6EB>W7S_O[B1OWH_=I MW"V7W(_#W@ ^D?ERO9$W'G9=)_N$42= TS.N-MY!.NB>R@&,L9Y34M MDC9J+"ZG0FL1PYU*]XA/5=)QG"*&2",)BZ^.F@5322SB)=Z;J7UU?> MZ@:U$,>4S=L_V\+.5?1ODB$"21?=X4-$IU272Z>M>M-U+L"L1GSWF57)#+ME M70HGO)02?Z5*TW"^92WZ1()4ZF--!2^7)JE4*>8::;'OFC7?EDM_U&_K_3K, M\HUZJ'EZUMAWM7JJ7.H%(M$D0"O>6NCXKG&.1(AT1- MEE/,B:I=/S R1SU? MFY%6H]'::R,4B;>G\$>09K[@//?7/=61]=;G%$NH4FR.;D@B)/B*HTLA8UA6 M^VP<-Z6B%X:44SU''O$C+IB84;/5B/OU*L)H0!B^QY*@OI @PN8T.CYBP5TJ M.GT1)YC/CZ2].JF62Z&0=N<$D(H $1Y 3'W"TH_0:;,*@=(Z!:D*A93!P (H M1%HJJ8:=$>8!&C[X$>8SLVD<4Z7,GO!M9@98$Q0120!] 2-3;@4%P;!?'K$I M0) *+ _["=#5AZMB+,=OY4WG4--MX0(0R4H6--^B#3EOM%X?#OI M]4=7']Y7&A5[/>D-!L7U+ZMX3P,=F:F--QTT%1+"H.8+QG"B %#Q5\62,M>[ M^?4-OIMP\3$K# ;DJI)3/-<;_&O C?H9Y<]H=6^P%9"M+:-LGFP)X3/'L,G3 MO)KZ4#Z8*1>FCF6(S:@D=RF5) :&:"O-LFP M()KO3G_OF(*X:AGX=?-:8O:51NDKA?72Y?40+"\-J[5'-8QRX&IQQN> .VI, M@2%ED&E&M?(J%V)J&&0BB3(5K6J&,6- (8!:4LR@WJD$2IRJVE7 )C'WS7V0 M&E KWW ZF)6RK" *8(=VXT=$#-L[EB]F4 K2B([--(:!'UD&F*_+::8O(%2! MAP&'6P(_J6_.!,?RC>Y_X4WY.4JB'Y^DF'NKWF,DW.J)QX%"/0'P6>/-"U>; MW#A%&$P9]K^A9OT,("O!:)!)W:42[JCK*"<##@E&,?H3PQ.C/X@?_[ S6 )I^&^K6'!Z> M,D9P<,8K@O4_=L#V.O^S=7OJ1Y@P-!#I+ )3SP\M?[*1L*"-)GA&.B#@+B7< MAX6M\PZZ3NR!2AN-S1E)K58X;3#Z4L!:T^7-RPEDFT(34VGJDLXW%%]-* 1504$>$Z8(O"+"O6=(PY,XMM M\7]I6VWFZ\%@D3KF7:'LY2'SCM$_4$L#!!0 ( "]BKU8<_!4'%L( );L M!P , 9F]R;3$P+7$N:'1M[+UK<]K*LC_\WE7^#MH^9Y]*JL!!XNYD^?]@ M# DK-C@&Y_:&$M( BH5$=#'&G_[IGI% @+A+7&SMO=:R#=),3T_W;[I[>GH^ M_;_GGLH]$<-4=.V?,_X\<<813=)E1>O\7M3E[JD)\85 MS;1$32*CEU1%>YS?/GX[>K1EJ,K$H_B)VTGRPTS3\*T\?L'[<.8#^W+B4:883DY]7]S?AQR__Y\:,?+$/4S+9N M]$0+YA!;2L<30ES(>!J)FT2:: C^/N_H3TO;R<63O-O.S.1,CA2_;HGFB.,R MF6*WVR=\ 6\(2?=!@[3G-IOY -^Z#]IFO".*_='#;=%LT0>=+R9:A<\,726F M[]/TFXG'9X./"B"V2;FN6,?0?J_/E1%>F82WJ,/)Y(P.U0[B2C#3P[_]\E2+)5< M?OK ?L*W/6*)'#85)W]MY>F?LZ*N642SX@T8T1DGL;_^.;/(L_6!*?$'?.^# MT^RG_\3C7%DAJGS!U8GUD:N*/7+!//K_J^4&P^U.&]SX7"'?S X:WQ=C+51(XU?3C5=#FU1G.I GN+3_"; MO)Y.-@E(.0P#_BEI,!'#(G#8$-6*)I/GKV383 29GDAFQ'6:3?O:;?0(YH, M_UIE5>PTVZ)JDG6:XCU-%6W#P(844Q+57T0T2II\+5JDR;Z^J2>>;Y7$R^VW M?_Y9IXNRIXMK7;)[HS[NB*'H:=;9!FRMM*'SYQVFCI\I S MK:%*_CEK@P)?<'RB;W$-I0?=5,F N]=[HA9C'\2@'T-I4ZB0E2?W/5DQ^ZHX MO. T72/T2^7Y G6>& @F]"]%EHE&H07_A >K,(V&(C'4>+;N$;S+AMY#-4%@ M3/"6SGY/TK5#@\%!5T2Y\%6$L\NQ)GSZ,-%%,+U.J,G9)=634#J:IT1GE_$X M+\##H?0Z5Z_.+K\MZK%LB!*N\TY3S@IZ4=1[/<7"!LV")N,Z 88@&(0*,<\F MJ"N8M;:7(D7^YPP$5U!07!.)?.J,LP&%Z;.@"["LF1>:HL(B8]C $IB&83 ME&N:TY MJ6BWI-*D2 MJZ*!#T5N &9"F8[\0=&,-H:N+2)8"'ZIWH;@@BPKV"28?J(B5[2BV%V$H8C&9P=O)=Z.91@:B.XC)/5N2&3SXCX%)D>>ATG)IS 4G MC9/(7VO_$ T#0,AD#O7&K MP>X]2>$4TTE8DQ75V/)Y-63>N#$7NL.5IX#&:1GGA\(&.%;, MLTOJ :W$A$\??/OSTOK!G]@W*5@-0Y0)!@A=K[>AWP$F= $X9^/:KUR^UN%% M)&838C9.84G'>>'(U@9V#LZZ' ]@U(7S3=!,.L(%=)))7DD*A4ENSO71,DEP M#S2$P:2Y8=+C8M<$J F;@)JP U!;*=/MM2R-+#\1O2I=H\=(Z/+H?V)B/ROA MKG1LSNR_7JMH\=3OW0+:\[PO3IIX&S*PD =O3![FY&&]#4'P'_PKEP!^!3M@ MY4W(MR$GF]D+ ?GTXY5KX53L46KY/4AM9+^\S7F/[)?#M5_V(0^1_7)(]LL. M)>#(8D2[8M)F9W7?AKH<@METX!L@&QR;?ANRLW>[Z]@%)S+<#LQP.W:!BBR_ MO5M^QR%"(1WG?!N"%H6^EHC]X>WW;G#2]VW(\F'9<$TXBS(*0AV( ;/G>8_LCP.S/_8L#Y'YL'?S8>?Y M]%$$)XK@!)MRMWNIC>R7MSGOD?URN/;+/N0ALE\.R7[9H00<;_+2/M2D3E05 M).0ST8@AJ@5-+L@]15-,"\N7/!&G^J8C0$W3L$"Q3%<(QR4P7X=VL7*I(QV[ MT256-&1"M];B6##&(+#]PLMV2L_TAU-S\5J5?>O:;D="1"+YND7R\+9VEJ)DJ==7]2$AGE)>D3"N+(QSN138'LU45@+@O>%@I$DG"0DK";>GV)?#R9&.^%=W7# M:A"CA^;4ZQ ">LT;\,ZPQQO'XQLR9H:[WTUCG(Q0-XUI'ZX_$DW]7J=^VEW( M;^(N>"4F+ \V,Y*8#/1V9-E%TUS.;,+E3&A<'@/Q$?)V$KPRH8'7G ,:=6B, MF(77F%"P0M+[@M&_;ON5S\83VV;K=,159$8U@75>(K M OX#W]_LNS,3I@G#^L %:48.(CPX$#SPKKGN?*VUYDX+4AAK;B0^ARH^NP*4 M<.>]9I7C1>\CA.DYX8UQ[- X?7NYM/\?EUSJ=W7*]U M/E!7K.$XY/MBT8,S1)OQJ!_LCL=FK MV.S*7URA0E0D"8<#( >;,A&)S8&)S<$X1DD;B]#G$[/'2; MX]2_JA-%*Q:YV>N9H#TE+4;SO?_Y#C4U<;VCJGF!3_-".A* R Q9Z\QI)#=O MV9ZP-84)S4/]>D8$>D0T;8-<*J:>$OCL!3SC-N9^-=D%MC:G?7J8S9S;A<,$ M^M#&?0!]=W/ZD94GD+U9WN*[5;L'QJ>E^Y3B6H,'TS3ZM>KI])IH.EBZR[I= MSI?I?OT:=K^?X,(*#+V#;I9,61]^77'"/GU0GB]@'+IM2,3$C^@G72+*5.D^ M?0#ZX"?^_U.?,ZVA"N#2!K&]X/A$W^(:H/8F5R4#[E[OB5J,?1#C,&.C_9'K MB49'T2XX?'3T[T<.A3XNJDH'OI) 8=%(^F3V1+&L#_JLJ;P0 M1M+9Y?_]#Y])?/ST 1N\_/2A?[D+ZMUN_A./HB"8G_GDU\T=(-X'OJ0C%)P1 M_A#-KJ)U+%V+G9Y*32(3 M)1Z_UB5ZL ;W"IL2FO<)/L$WF_2W)!C>+^9]MZX,2KKY587V8-'3=(T:"(K$ M.7;9/6E/NWR6/G85SCA-1%L;.KSP]G=VR2?BW^A".FYS+"B[DADL.*JTA^.I MWDUOP8GHNUO1>#P]J6GD_8XY%K::66)+): 6J@J?2X L_YPESNC??5&6W;_7 M'J+'KAB9!Y*NJF+?!(+4&.KPGO1UP_+'L9XA\LIO^9FT.QOC6%LW>J+U MSYGR;%VT=%TEX(\;-O$#N"F:D-7Y;"KS<2[/ 8FJ 5<3Q2:YVS_'I=_)[KE;F&E]*W-B8 M&MM1A6(#O^;SR=3,\D%9>C3<\8'#XQH &AZZP:BVNH3[ZZH#ZA#]A 5Z.*+) M1.:F-3PUI>%W].$2BQGYZ_?/2NJA2+JI)RL7B'[+&)2#][JR.!P2T2":GYI/ M$'9V>8M)#ER2C\V,:-K@*BLF+!"_H.$R?&+ZCRG7>C*-EG#[9_@8H.TUU?49 MC>K.Q:55K#,*6_ ?XU"6S -=(P^4K%W#620LNR9K&HT2T^Z?(6HFO71GD0F5 M?*I5VCG2_7I#@C2AVJ)J^MI0TU0Y1E0J5"-J%TMCX[Y0K5>H:3-E]3"R@S-] M)E3M _6G+H\C?K&#Z,LY^"FA3SK',=C3DW+EIL15'VZO2O<7,X9EY84F.A,]GMVV5+T0KNM:/#5Z4F#2%U-5_6.@F.K:-+YWF.S MP0O6N]*S*%FG)\@93F]SQH@CG&AR9I](F.,A75X35<3BBZN 1R !9^&_!^K! M[5FZ^ GI:HC/%2>%C66S+S);?M6*_8IA:2^_@P@\+23@[#*5B:<%GD^D,RN* M3+#!@P! ).0EB^H8+E83FO?^X*(,H86D0N!IY?S^O'[..7Q^Y&_O17D-@EEYWR6=Y2HG1GVXF4F)FRSE:EQ=,OQ=-0T;.Y 1R%F39(*;I M_+A1-,+[HZ9]WWKBRSE)4,3 4-.G\[-+00"\Y'Z< R 8^B"#8.9@YXQ9Q;F M;*+.ZT;P'V/F<_[?NQ\_Q!>K'>(8A;/+NJW@J(3$O%5A=H\E[3>D(OQ:,QKZ M0)NSU%4^_\ZF5/G/]>;[1G,&-.X:A@.4%C1+UQ1]Y?$(?N.ABT'-N ,#3=&D M.7:A\KM2^%9,*:W*YNOWVG:A/X%GEPWR+)J1-;AG3/,5ICL=9E7]K?3GNQA/ MU6JI]U/6I&)P$2R_WL\NLSDAG8U,0%]SQ>$8&H%] ]1*Z8LJ1YZ)1._6873K M;3!?B!G9A=LP&J210W'T,_RB+92=4[_ .,/5M6 0<3YTI6^[9=*[^S'04P% ME[<_$!2!3[R? U:SZ;;7#LUXDER]Z^K:PDV#TM=.Z2O_[[-R(P= ]W2?9Y>9 M?"Z>3N).X>L+[XXCW/_W/SF!SWXT3T\LHI(^,H#3* =B'""H:J-#Q8DPH\!4 M>5>YLY&"SRAX5;=.3PI]/,>(X'K4XE<&HYD8;'LA1DUH8G"BLWB+FNQ^U*8Y M6!PFEH$TMG&?0>L06 [19.94T;0X@^8\1&*YGP3&\3V$IR=LCX@8,#]]VS!M MW"RR='A5HKOYO/"N]1XM,]SE+TC6Q>N:LN,,2OD8\U,' 5O3!P$91]8+["=V M$=AO*)8ZLO$Y(DI=3L(:X*_ >0YA3H3=S(DAHNRS =6'O9:N1M/A-X9D9A?3 M@>D,DQI"GMF:R@%"#[H*?#*&\2"C"0<<-9@7 G+6MB$OM"BT^'HA;LD->'S> MQ0--Y_9!\,7T7@_W@N&+.]'X+JHV.4\DLNY-P*PX1?.EV*XFGVKYQ!=^G5BK MIWS,^+;#Y=UY?:#I$9]=LB8XVD:,ZXL&]X3-L+G\7VP-L_0X6KX@Y#,[;S'. M,B^KSH%5!J@[DTOY>E#[8S_+M^W,;N5R8KCL'LM(V (7M@;8Y=,"EYW"PI*S M7,S-QPM%[GH_!M;7EW]%99V$^HWE;GI'!Y?(V DU6<%_A')WDZ6X.M0E^#UQ/!7H7%35J\>G^5U=KFW%<.#6)## MWM+<6;60HR&_HLF89PBK7FO(25T",P6$/'*#+K&ZA!V/]YQ+>,>_YT" N+:B M$ID35=79&C#AYU];P; T+*4MXCP ;8XBTTE.-YS#@TY\>AS7YEQY.CTI2!9^ MCZ<'.1F^UCKLB+Y!)$)WR7B!HV?A3>X=-(A'^$U;ZH)WK./I"/<\F]45K6GB M!^(DF4@C>]D9Q/L8W1=Y)[P_/<%1MD#ZX8'6'Q@#OH#MP4M(A=,.ZKTYKB. M>R7Y!">+0_-\KIG/\DZ*MF' R^PT*:(^P,B\L_?9I\[SO]];/_-WP:5 ^_=_ M=OF+S,N/XIRR(5Q5YT:'7X]4[-^6UJ(L@QCW%,L"R2%"7,X.&N14OD\&3?M%*/V_#N/6%-PM.35"*->GM/.K8J4HVOQQO<.V1T M]B,G)(5SYPFKJ]"S3'T\RQ2PBI^>3.LX(YF]C_INOI]5S.34T9<1)Y 1CI[X M*V;]0?GRW$WQ"?(G,,7T[S]2S*,@?TW%!$T0.14H)9PH2:"8AHC:A8)JX%KD M^RD'$A#W_<+L@49#+X8+ZJ[!@(5LZ7,?0!U:7<[X^AP$1 M2IQ,Z!%,T%^:X(>)*T+BXSP2Z=?\1_>QN0^:LHQM#?RM(_E'O=0J)^W)MG2VKQ2<\ MV)4 5$HDIW._&CECN.8G9HJ^=V6;BD;,.8[D MC]^W?^O=!ZLO=8.LFC1=>-*'GG6*3D80$)%%R2KY&X S>C!YNMQ]ZS-]J M\=>'N]^#="=5O/ZWD0Y?'WSIVDPOHCCISAV[]NG)?/\)L_B9X\=-^GU*VR\6 M0R,PL#QI.@V@V";SO6 $K 2I3WDN<-^P+W5(O;J! GVC)F@P !V7BB?%I.N= M)FJ2(JIH(6(A#"05+].214,V.3PQJ/JI7+]1V;7!Z[6FT0+S&[X/&.UH)WH$\T M:,$*)2V."+P_YWX!?8XLS"WUZ]@OV,_"Y://&^W'[N?2[U(P=7X72[67'C1U M5[5KCTTFCERD&UV09G:X"T6073KE"J-BFC8QW.-@*,2896+2'5+=MBA4TZ-@ M](U;<0BR'.-07F)T^VJQQ'JV==D%7K5QDTVETNPK+CRG>0'$]_>OZT&/Y*P; M922^91IZ!IIF]HL6M'TV(>V%T86JZ3@O3$HX\$76+9E("C@'9YSSB_G/6:5: M/N/PCBO:A'O]6"Z6YG.Q?(YW9=TESQ7VUQ;B"_@JJIET^:6748TNKSJ8JZ@B MA)D)V$P2/BDV.",?X=6_-M$D?(5-#_7F9F5E[DUD,Q6",K3G<0C:&W*>#DE/ M]C$;2YZ*.<\.<.SW^Y37GN2O2MKT#=E7/=R9=KTGUW-R+\F;88M!Q,=XBP!F M 35]RDMOY23&A9&D>.;?6T!IHG6OSFRK+DL+.Z%>3Y=V&L?X(MV!U=G0[4X7 MUEJLA SVY.AR%(ZE0N 9'3PYR^&%4-P[^HRS'S7]J+,1]3Y&EW;XIC=ZU%/, M='J3S/,5-U'F='JO;$"F7[7-Z4]TVW _T0WW0Z2F.+E79I V6M,Z-[=W6F05 M-Q'=FHFX=S@J\,828[ *Z:"K8]: /D"#V[1;IB(KH@$><$V3]#KU;#^9=A_E M)$LC^_ [!S:1(?:)#:H,/=W<%+T=<:K24] =5A6QI:A(F;LM^;I.KQX+]9]: ME\7" Y9\+]S_.CVIUAHE[K[TN7!_7:E^YLJU^Q_P:_RF5ON*?]/[$&]+U<:Q MWHGX.F!-,4]/9K ,S7)1T6B&&JB:'%=U_=&)"5E.\AK&DL!Q1M#H@?.)WSK. M2AM\"T-4.7.P%DWN$4?8VQ.' M,U@JZ;8J3X-G7P7.3G]FZ)CM-_LQ'=',QQA'FX'I%E$5&,_TQ^2Y[VEY1!H! M80#_:.9Q$<:)M95FOU$TC!-.?VKASO ,A28ACS-4ZQ8R$;._9A<=154!B!\) M"!&X8+8ZTR(LG3CO,X.V9>Q^]!1-FE1FN6 97MHQM0O07Q4-#MB#E2EPXD]/ M0 +%&:%E@D2% L53(QV1RAC8B*:;L$)EP=/4.:X],RTI&G-*T=%U=(2%C^AR MSS;>.-2H#M%0!8 9JB[1+45;DYVX%-ZXC(TY [L5-;#N4 M&[OVU8DHVI8,2 M7=!$=6@JE,[R*%);=.6=/G-/>4X?J?4)6WS-T22U; L 9D@3;'5;HR3K-%!& MR:-, $48@#WN/W"/IDZ-=CQ2 ]9EB[CYKJ@DK%S(:$J!+QB/=C17'Y&)1"^V M+T8*W1(Q7(U08!LPHAG.@1ENZAIU-ES]H,T[?3+)1#F!J4"!@GDNJ%8733L8 M/>=H( [ 7,@$D3;F]A6C&D_G'F[5.L3+ M.__O?_*9;/Y(+BKSP(9W9X\1W-?-\9KA(J3,2:+9Y5JVH7&8_W*PMYP=DS@> M*%EO_)Z\MRM!1X9@8^O-8Z8@P6C":":^/K+IP 6T7:-)$ON*):H3YZPB:3PX M:8SP+)*@-X-GZ#>9MB01$QZ2=-.B4.5<+*WTG,@9HIZD*O1X'3BG8+)%P'5X M8A6<>\BRR[0Y;F" \C"7HS>$BS6MP4J%$5*4:O,4Z_8?NO)#ZRYBC^39IV MXV.?U.YCI9I\(1&/JCD;'4L0T[$P9V 3\UHP#00SNA"5'0>_TSS:[NUAAB]^@KGX*AYZLL$H!*.M#Z(RQ+*G-">\> M$G+45G;3W969B)/8')_81<$82]%:!TX$]YSX\^*YRQQE* MIVN9HW,\8U\<@=&F(4=% W"DQTLMD7V'^38FUS;T'CV$9BOLUA:")WDDZOHZ M74WV$@GSP0ES!(>1!+T9.&0 9YJ*"XD8;A2=G$'<4*9[R4,:V9-44>EAF,^Q M#^GWDQVK;6#>?R#&NIYATMZ9O*/0,B.M"#Q23<$^*KM)/ MX1-E%GQ%!YB=T.(\U,6'6Y.W ZQJWNOIN-'A"1LZM=@I"NI@X+E; M-9QH65@OEGLD0RRD;NJ:1M0Y CLJJ>\M@;*TWN)LM45O'L/V: C2QW"2"+=]'%WNL=%0D?;0&ZDT9ZW MIT1#D-Y=(TG$.S?85A.M/CK. %W]'.,7Z3U M>$:;YYRN=70$O&+M>^4ZSNSV44*# $YTE?<;]DE!2WG(O.8 M7XD?]J%[M!&]SXXA]DP73R5Z*PH-T.\NT&D M-RQ%&_.'IPP1G$82]&;@U+D.AL.-%3ZU:W6!!O;'4J6IN9E%AVB-[58QO.$W@;"[V+QP+3TK3H10;PS:A/4]4' MLC[0W 0!0%V)W?43C/HAG[OV(UU;[ER,EU,4Y?8 M*6UJ^K4(/2CMPIISZ_E'--XB&3PT&8Q0+)*@-X-B;"_$O8)89O=8$R=1CJ@F M&: _.;I#>OKB^?,E9VR._9+AHR'_%M83>ILZN_/9(&P3;/Y]U>SR-7U 3VC9V(A!8DY2$5YL'8-54(066KCPG9ZTAB.YHGGYHCFQ M/R?I6AL60PM>M :$:-S#HX'7L[/;T?$V=3'F#?*Z<=W1\\6NHHGTZ8:H#)!' MSG),HRA.&/GT9#RH(7UX7D@::2-/NOKDN8'>X>?,5N+H^ 'I$:-#G(1;#6;K M2<%@.MX7#I[/.)_U] 3H,>EY,(L; $N(YMPBY]D<='<>67C;C8-[XD'G5"!< MIK*^F>]D@730B]SA)^M4P7OM.4VWG*HT*A4+8(?)JG41&7DO@@C0R7$:/>?J M7=U6\<9V>I:XIX^YP.0$*W=-B(D,)R7W7MJ+2P\[4,,)VZP0$ MC 6OD/#2L]05-1A84>_U%!KPY][AI7NL)B,;GP/CR^[U MV?X$#82I0RH_W447Q ,]F/W[2#C$.^=8H>7\CE*YM9YO (BL%Z1:^I5LD MJ@A]2I0264'?E<-=:MPY!F:PB:)IQF MHN QGM%TYTG"3D_&E)US/P@;AX7D M:5BC$F!$=(]*VGUV2I*:ENK0KSG/.&,< #J=![H%S:AWA5?!&FL]VK)[6^OI M"=[6:K&-[%&Y(=1T3#6G\.$6"VK1DSKG.X50YT,%+^^QPDD-.^IEX9=N@RPQ MW0!HE.)&FDNE$D]SR4S!1,NK&:/K M?JF"Q$Y/^L2@\@6M.5MX5+18O7W%@*Y->GC!=-83K_(P=4+TI&HT<,A#MTNR M=BUS+5%Z[!@Z#!^/2NK&!="C6.3(Y6XGX_K4NOQ!6B:T>GJ"\UY'/UGE;F$Y M$KEK,#]5'=?C3Q]:EZ]R\.Z\OL;A_2!H7K K,@9LDDWNW6 P.&\INMAN8W!W M:!&I>RZ!"E,CQ?#[ZKUSII]:,Z:3Z6X 4.$ZUP#TL7#YDF"=!3AX]_]!"P6G M!?;FC:(]$KFB@82Y#R$1*OU8T;"+#TX(YL-4]QJPI@.6R'MZ!>:1U#&7 M;RKCX HT8LXJ9;E(3<&PPS(T9 )53,HYN"CI(BDR8JT!] M$J]NP;0!V5C!C;DCWG9/3Z:#$<=FIOFN]HM+BB2CDB*OK:2(4VJF;\T6F\'/ M9FO4^(C@!6?V (CC$LS':G'/W=LD@1+O@>[3$R]VQP!FI/,#&-4QF8NA#*)< MN[\]/>$3\6]'/I!&X>JF='I2*W/%6K51JC;JQSR@5U]FR,_I,3JM=T(B%1.2 MN9B03K_W[F_!(\B+?\Z2:P_0NWB$,^TBUP73ZI^S_ZGSS42"#UBR[PKWC=.3 MRH0XBY=LS0MC6]%O:GXP?S20^=@+$\N5:J%:K!1NN$H5,:_0J-2J,RP-G)W, M2-BML!_L%O8*8A6,_(X.(V<#CCA7&J5;CN?B0>UK3\J\$"2I11WC[NA&PF_4 MO:!>8%G11(UZC_71O@/W[D$3;1F/B;R?5H< I\;5A='LS!QR=[$@&8JP+=*X M8-(Q#C5]8E+,DCL0LRM1I'0@>BS"F@B1T!&/<'+'T M8)[>YFI]8K"XW]$+:"I, 8V D\EJ>H^R6K=TZ;&KJ[BIB^%L/ON1*_VU,2C^ M[IJT%4FQ=K%VARO%Z0AF0Q+=S!Y%MRB:7:ZLZH/CA]E,!+/ARVHV2$*K.FZ: M63JW5&C]/*.C%]ALA*B'F(0>X#&&_LU/N]8CX>/QCF(C", MP# "PUV 82HD,.0#O?H*3$#+T)UDY#LL#R(C]D5(%R'=JZ#U..%OO[E5J^3R M\&$D1'&5V82H'6;O[#H?*G >UAI?2O>[S87:>=;?P>KL$:X2H68^\8%F/MV0 MCJ@R P6/E'5>@862C\SER"T[+KOD:#&N$!;(!9IWAS$FKLP*@T3X%N%;A&\1 MOJV$;V%M4_(!9W(:I*.8>/V S-7I!7EZVTUXFRI*]L^>.P1>A882&$1I& M:+C?;4@^T%SA:](6:;[%0U_7X"E-T0T/"D:(%R%>A'@1XJV$>*'M-0::8GZ+ MQ4;K[$H5;^6Q".@BH(N +@*Z%8 N'1;0!7H^H4;KO7I*@T48%V%EYZ[24E[!:2HA$4%;!&T1M!V5<$T"6Z#' ^HP>GH9Q2N -GX_ MM\7LJ'3>XGJMJ8][@60\S739^ MY!K#/O1?,,26(GWDJF*/,%97=62@,%&5U7T+OXE*Q;ZBNJ2*_,_9J(*?TW_0 MR;_3U1"/K+BGMQSAZ4F]40!3_G46+#V:(M\P)5/B*_B++Z5#)I+.#CU?.+<8 M*1IA+MGI"7^.%6BO2]5ZZ1I_J]=N*M,ZY=P_5PL,UO'K]?EPC M_7CE8._X,]'#NB6K)T4@.1:!8ZAEO4F%[E$ME-,3W_I]IE._;^^#"ZV2\B(C M#"7A67YN)A.I)L_SS9?;&S[9K6K&CRNPT.P>#&A(G[@8UXSAXO,*S$S61/06 MW=S@R,AJAN%,S69_Y\+C#$Y4[Y]T7^(#HG2Z%KZDRA-E_GT.; AC[J7RN::0 M$)*)9!)8V/OWN?#\.?WO9ZES-K=U?Z&X%0VIRR7YV'K4!3:, @Y#X 42ZP[@F$NFUB+'!2'PB 8'-Z$?.4861N4I]F14XM+(_M"*#4%BF MR?6ES:?%E6?^H(8K!#/<3<1C91U:F3%^8YRH,#S;WJ;-&TCN(D(G6#+2Y$2Z M26PSWA'%?CQ>,$V XT++M Q1LIK*5?/EE_BG4?CQU>@5Q;/%C-PBCCO%[$*] M7D(78#/ 6@V!F*._LH(LY708W;Z. ?J+769&[(KL^MZQ]"5XD+_6SVX6_]][ M2F\@?_/BN[,4.[WCK:Q R\5B59S;BC_+5N;ML@8/B1K_:4UZIA6+718T&7]@ MMOJ3J&(=P8)5% T#K[JE(4689J'2[(F%XDNYIC5?TL0N)KZV[@HY-1R\<9<3 M'!&S+T=F8B;U7S]AID4[Z>6?^ L9#V6:84XSPG\7*ZYKE/IV]K]S&N6G:7.F M[I/R?*'I6AE5!DN2:6(/7G+FX&*E*3BC5[!!T_>X-U P:VVT.N*)9#S)GW$L M&^.?,^79NM#LGJQ;X/(KX%V=<NSRWPLF\G'$KG'YQ(\OA>2,\8TQSB-6&%C M[&(!6HFC82@J"%!"R"X5GGVM3&%Q;5NU2\12N>4JMXF>Y3UZAA=0:I9N#&$T MT^K4$VZ^#??R)22E2";31ZH42YFSI>RG8^E4(A31 M%SRB?V>0OJC(I><^A@]=!9_P%*8U0BZE[QO/5^FJN(E&;+/ S V@.*/P+#O2 MA)^Q4JQCL96S//:RJJ2MU])*LKC"+(:AOZD4'^.3PE(AG1-:6I5AT6P% RA) M/I;++U]--YJME>. :ZZ2!^R9'Q8U_E!?G!?^05!O(*H77W[D_C1[EHONGY5> MG>0,["'/>AH5NB.@>Z]V3YA@VA8.$*22&6SBU'T<,T@T*'+3 2 M\QD^ELEMZSU%$'60$)68L$;U/DS)\$X5-0L61@SR]'&+FSEF_!BP7FQ%K+>^ M:XU!3PXU8.V21&U+XM)S *&,1;P* ZD$(1U+9(XUA+$VM[9$+8%/Q5+)Y6'9 M330FZ]$8C^E8U35IM+A[5:61*JFD.DC^:H44ZU_93V-'#]^&3^8[,V$H9B:6 M%Y8'"B(?;,/9V1((,K%$(J39VN MK7+"L*NU;'(7861_#VL6EP6FQLSQ6@V7A0TUG[['R;K=4LE*.X5KMK*&MQ*2 M(Y?*I&+IS/H!%F$[*'ZM$[*MWRC$^!S\*RS?8-AH0B+T/1ST37G0]T816XI* MJY2!G>^]Q)C5E^_KHYN5O#Y7&KT._[F[Y MPGU[D\#S!E[J.!E1'=,6921N.-=IG[RE.W&(22)3^\C%%[T^@/F^%2WC7DOF M>YW]Y2GU&84;LGG&0MHXLV:24Z'8IZE,+)W<>?ANIRS:TF),IM*Q1&K;C9CE M46X8D6$3>181IS2DHK?OI;_%\G-WDTR^#7-T?94%R>4(VZ_>]X[GIMP M9#&41K1.7/>;+_IS\;ER=Y5*?PTCWVA*KC9)0_(XAZ\>''9B5&7SF5@RD8R0 M.Y3)V39J'N,!&#,KI*-%T/UZH)OWAVZ,S#F8C5C=$V\*]=++G7G;?*DVOGTO M#\J9O[?2CM-$YQK9#+;?)EQ'.'TTLQ(!](%!XF%1L]RV+NJ]GF+U"#N0600) M@UDFFN0 =F4"IW_IO>^D\\7H_@X2IWVV4L9$L3/\7K*X=W5"N*IN$2[G6XPE MT)B8MXZ7K)A]51Q><* HQ"EFLW&=.6_#<9-(<>4YWE5DF4#G,$V"\MPRU$0B MGSJ['-=(]U2XW;] [I\WZ2UY$^'30>*3=Z=W4GEA^5T*RN;Y=(F21>K M8Y*7$#>-@E""HEW>#>>Y-'ETN$W $64Y-A-59F#UJ4NP^O#DYNK7<^&;]C6_ MN\/S([K@(2 L!OZ"P3TA>=S_CLMMXGCR4X=/O..Y$XV:04LLRG1H=\2H=T4# MAEAI2N/:@M+/O-JJ#/ZM?P>SS5(L)&H^ =YZGXR W,8$.%4!?XJ/O9]M\YM] M_;@: 1J5:GK1L[VC+9H@$KF=XSR ( M7ZW^( V3]U;JW\QZ!*PQQ],D!"Y\FPC>2D1M(W N44("SP_,.4.P6.)F^#XK M>?R2B:^8ILTFO:_(35GW"E^=;U^__&[]SF87()]#@T+;F16\^J7S^WN4B+T<6.SE)0W MIL1AQV]2_78EE;_K][DU*5E;[-FLK*R'Z Z@V ]T0S:)%H8B+J#(3PEW0)%G MO@Z)4"K@[ M\;;G.\5\(H&-@G\B?#SD>,&B$?#;C6"Y4XGQ)5V;[VFDOEWGGGK#5O?;X\ZS M21EM:WH;G@$MLO01Z+V++GG^.?B5NE%+X@CEO=TO?OYY>$I> MR]5N?GGOBPLY+N]_CT[&IM0%Z6'X9>IN[&',$3P_ZWY*X/[]?E4L]1L#)9'V MG?*5_ MA_>Y=!Z-8,!ND8F1:W36Z7W5R#\2U6)>B(/P*/A43ZV6[._//<43J+^U[# M=IXS\D.1LDU,U'5)RL52F60LD?;;K5PL98YI1ROZ+;+M/M)'IB4AOYX .FC# M/_Q]^)GL#(34XV8"N!#HY@B@T_>W0NG[E=!]S%=:>Q' ($ E8 $,@J1<+(DY M_,+&,#=?#G?O3ZS*WM#*C:?S,2'E%_L\$'=E>P9M>PHB%\NL4 %@$V_(6_6G M &X)-BRJ=Z(B5[2BV%38+$B2W;-5]/:N25N1%&M:I=)?^6H[+S_74IOB).D]:!1O$.0TW4)8- B'D7WHLF/0N)5A<7J; ML[K$)"ALSFWKDO>V];:BB9JD4-O8N9K=/ ^407%+[U,FC3YP16[&@I_+K@O. M!(E7XY+8-U?H&EIHC>:Z-3T4&,Q_XG&NK!!5ON#NQ YH=QW6#J))P.;T1XY& M6D$CN'C5K=^IL:9H;.&U48&*&J.II'U1?_!N(D]^_)/I9<6^\G'O,M M+Y@&/_6>LR2SJ9CH#I[U\,WEV$>N,>Q#_P4#X$[ZR%4!!!E7JSHR,.E]Z8/[ M%GXSAA073CY] #[[L=P@XF.\10 4H>T^G3&O<#$.CR34HYAC^.I/MNXE"HEE M<[V9G/OQ;079#UO.=X)I:'#6^68BD3H;]1_$J%J*7F@#.,%">7K2(%)7 \NR MH^!#%4TZW]=PMQS5Z'KWTY/B"(^+7CRNCU 8H;O6)X:(R[=Y />>,UR)722 M^M4 T75HDHETD^>3S9?'064@286;/S_P<*C=@Q$-Z2,78]YQ<6Y-]G+O1E/S M_FQ]MJZ&UV?3SO'4:49__VJ^2[Q), 0(PVGXYTP8\S:5OVK2K!(^P3>;X_P2 MN=%ZZOP1[Y4[,KTRK1C[<&4)VUR?ZD"'6,:!":,A"FR(PO6?+^4OP]]#,;7] M$(4-AL@LZJ4!DY"$(+/EH!M=@Q#N%O2D:W(ET#B9^]0RN ^7HWR7C5FR0A0I M/,TX3F'?G_QN-5DK#VQIO&PW#2^_ _V>/!'-)F5#[V&I W3!?RA6MVB;P AB ME)XEU4;&XD4"\(_<$)]I<;$RR35?S$%1Z-E&^C:5"2?RYJQ(F93K0'A+O9]= M.L1/RX+SEO#?Q?&8A3?)S\1=W*=3_]T@P+(!ER=C+O@F"X_Q\(^E![#_(2Q/ M-%K((7] V OO5SQ&D5YZC&+E 2\_OEW43:O6=B:^V3,=E5%N5/Y+,G$E&V$< MI)A"/Z0!C4=35%]_N:8)AH>M/2OD?/?ZW[;.BF>6?H M;;E>9A6.@*E=RV MMO7^C^FEL\$=TXOVI/>[)^T]NN[$7K2.07>HW;]R M754*Y8OYS M;K7C0*F%;X3@&G@6F3VDAEEZAS.\FZN0M6UHG*@RP\YEH8 BH M@!L%N0<#1D/%4IZ(KV[Q]LUCOL]+W9OLH9RV<(81XSIL('1%$R>&\@H\Y<4) MMBO-9.B*'N-A!4VGU\^D>_V!CK"F+S#,2>93L4P^JF']EMR6\B*/E:9-TX@7 M C]&HVG$ZS'1R/-I.VT_;G)M^CK7#*S@Q"XY$*//>+BO'4EF9C%\S$^G<[%< M8GDH+L+\#68J,'C/"ED\'1/!^QN"]RL_>*]HDMXC-[KI 7@$]IY8N2D7:R^Y M5+_Y\NW/34?*JMI/T@T0Y%>[>1UW,MH@_2YZT_3 <%F^Y)2L#^^"A]4Y1V01 M7[.Q?';YM8ISC\(>/-^V +DY7%L5[>;R+$*T@T0T;YR]JFOZI( Y*^G$5DOK M]^>'Q,_G[GH"K54@G=' MN=<6.R%BC_+INO+SY]S7\*($:X:)<41.&6!Q/"8.9E<:C\HY;/AZ+@9? M,0\EEPPEP>JH63=_7V@MY0C7KT_!&L7G0XJ^1%;P01I'WBKL8]?*S117-!LF M>GSXZXH>+&7/-<1G8I:>P3P&C5 TT1A6+-(S84%#&35TN@WA6BPTX5$LOCPD M4\V>Y0%WH7=;MI_-ZM_K(/< 5X\.L*.RKD%EX9CV;!&$. N[C#0(B5@^NTDQ MT7U'&G;-_S!LNE0F'\MEMN!^A-8'B=;%&;0&^7,;?B#937*75@U7S+61*R-(=7?,7JL=-XD<,S,2^K89'\OQ49Y$B),57')C MC \KHR5"[(-$[*0W^$@L[XX9VR^C4/VCUVK=??EN_6D%>2QOHZ0'IY(8T,JI M0.8RV3SPPF/+HF_>&=FE=9P48MG\\GVXE4N/+2TO_-KG*10K.BO$$D+PLQ1! M]4%"M??XM%O$VKT0[$HT%:GY0J2'_$TK;U7E4#< 7?"EEWY)SC4Q2$8,F@5" MV#D;1;4M(F_(WQF]75\I?7D4,(C2:U]\%=1SG1J_R8& 3<,,.V7R[B=@;.*:J_UN6Z_%I3# S>]2M60RELD=[I9VV!S="O5F[U@'7O(Q M885Z,RMJ7%31]]@J^MINQ<)=5_3=4;U,=VK7*-Z;B8KWCN<@@.*]J==?O/= MBU0?O'9.E?]-C\O_1L5[6779NL\5%:ST/_?.N3OJ_0&P8L]E??DFSZ>:+X/A M[U_*W3#_[:6[=5G?"<:+?=V)5M>BXE?.6I?OJBHG:J)]74_G#XWOXY%>KSW2.1>,NJ/6;X5"=?@\,"WU-8UZ^DI$ M=[BUX>//U&_+Y"O=PQTNWWQ1!O542^3;3R^IH.D,K)JWSR;G9E6AUZGPO61G MU;4@RKJ!'BCG4_Q[\IK[%3, ?&H0;Y0"<* UTD+XOZL=5 MNE=(('%)]MS>S>K1W[$[O(^%_/$ELT="L8^OLP'E^U;U;6OHL^#L/J=L,[H+ M/7 V-KB >]]T1_S>+=V.?7M\A%]O>L7\O@DO;7@Y=1!0NO+0O(3C:2^E/5QD MOD=-1TTO:=HW#R#)-R6?:ZH6WU=?;[YQ_SRZO1%7$ M+1+1XJZ)1#UCUQ^:N5XGB&L]YCBZ^9PW[VMFEQKYTE=D7WZN&@]8%FO[ELHJ M!2F;'DCJ&6JNK2(3$TE+Q!W;WRK;C#>[JE1T)96%W M0ND3A90Z7WIVY@L_P*LHMI/(Q<4JIT>VZ*IGE^+F#,%;YMLD=BF16N1W_#K%X8*M_X:'\VEDD+,2&UO,['<;!^28KM MAKSW#]AO?90@F0&AS\92F>6)R@MY-'/*X\AE?HL3CXE4,I9:H2K;1E>JK6WZ M1K??1-1$U+Q9:N;>-C+I<%=,TR;RM6W TG)'#$67:0JF>P:$R&BB$\VD52:: M+X.[]._G3CDGRZUPO/'905$RXRVD!1/V1\1,G^ /C_F.CW88LK"J>\DO=2]W MLVF?S^66RQSS>^8(7:A>9=\>?F_?*K_YW\K(JUPF<3/NYF8FR7IL6'3.8WS* M(RQ_E(]EC^Z*FR7,7H!S.^+UK".:W:3DX9O@<2@>*)_&,LK;'L(Y *Q/[1?K M#T-J JE; Q*1X8.\FBKRVR)J(FHB:K;SV\IS2_:\V-GVC^KC'_/KPXY7.LBT1H/1$2$I$(;-\>ZH&JL M^7BB(>W';5Z ;>YD+BW ]G;F\4!JY2V;JLAQC*B)J(FH"'*['O;%V[_'AU M>W>5M(7'I;F1FQ5#7=463:YMB\ZM3+J:+7K@1617MN'3KX1OK&2E,+= MYWTH5Y]T_GOK2[(SUA#2432TX0'" M65 /*+0][/C:4RR5@BO7R[\4BD+BAM M#2*1,+SMX7Q,6&&W,IJRK:6O>PJ#R9O>49P&3=I$ LS: MY>DP;Z92?I#SMZEVY6.9#$Q-)A..EM[A%%UM5W$#K8I >7K M0\XV4E1%$U23/C1=(VQT$ZB_/_JG4NXUI'\_"[:\*$ER,\9-814^XA-.7HR6 M1SO;@11T^U(S;S)7#Y^S4N UM/8IUTL*NCTHLE!\*O_Y(8<@E/L;];R";G\[ M#Y4[N21=__MXN,/EFR^W0OWGX.9;-E66HH)N(19TFRE@\#8+NGG6+K>Z6( E MWA:O21M*350"+BH!%Y6 BTJ2A5J2+!3DBN;CN.B.2L0=#^%OMD;<5O[_H0\N M:GJ%I)82W2<61OO$PFJEY,CC0R7Y;^7?U/>0DEI6+"7'3TMRJ%6[TJLFITSS M,Z#DE%4BBVN$%OM&ZC8M77,;:L=_6PZ$TNOL"=U M')64 ME0VL/&48A!BV40RELLOW[\_ M#M8'D]0RS?N0DEJ$7"S-)V/)%:[?/OAB@($R?ONS0FD\*!3+\EO6%_4Y(#3V MAX3-_*&O3_S@JTG^E)/MT6(92AK&:&5^PLH>P>XA+DTL/C8'1Q7:O-DK\-U6 M_5 RETS\Z_^;_ZQN+Q _BMW.UZ+]NW: MAW@M?-NW0[ '/KY6ZWZ!27_H7-REJ;[$/H^.[^^6FC>8$1Q1\S:I":>L=_+; MC[_$[N>E03>7GA,_"+"K:3KDG+^J%87?:1"<^6B6C9!FF^I%)/_?2OS-=AD>S*,[PB&DV*%U6$ M>X<@KLTH0FSG6H8B=PBGZ=;X<$CD)TX8!9GD4?B)KX_OJ>,TQH)"C$,P[ 4^ M&<1W3E9,"<]$4_M](!J&",1R"HW^1":\__*_]%*=@P?)H^1[ M=NE--,=K=E$4. P;/1O+9[>]:/$ A$6(A&4K(SP(,8B,\,@(/U(61M0'.XP%/5.1]1M[GD;(PHN8X MJ%ETM^=Z93]*S1>!;P]+Y;_7[6(J',]TS;L]A8.^VW-)G;/2D547>4BU?A9O MJI7!W^7E$_=W^^&T\7;P!4C>UH5M@1S;WL,<;U'[9,L)7C=0;R4OQ/)\="?K#L FR%(ON?3Z/F4T96M/63AG M )-XI6XLFXJ6^+4B.!O.85@%;O*Q?"X=2V:7%[AY,W>R!CJ!VT??,K&LD(IE ML\N/5ZX[0_Z^<7$SW_B/./C;^_'OK]]7F5!+8J[F*D\5S#P8GWB'QN(N?.*4 M\D=4U"^%ST0Y(NLS\HD/"F\CG_C5^<1+"HR&[!,_E^[E?+WXF07&3L<@@EA[4J!V,=TAS;44#NP\KHIBN06F>'P"#+C@3 MI%R-2V+?7*$S:*$UFMW6-/% _G_B<:ZL$%6^X.[$#BAQG?RU"5B\%USV(TB)#)TIJB(P0E5UE(RJ+/X-Q$GNWY-]2+JJPHB! M%O>WT65K?"+Q7S^!F)\;9NE]/TV>DQO"IF*B.WC6PS>78Q^YQK /_1<,L:5( M'[DJ0!WC:E5'!J:]+WUPW\)OQA#B LBG#\!G/Y8;1'R,MP@ (;3=IS/F,!E& MY7)X)),>21NO$?W)UKU$(;%LKK>1;$9* O%R2@ 2\RY##U?.#U]):0OH!]?Y M9B*1.1N-H'794O1"&^ (%L?3DP:1NIJNZAT%WZYHTOE1#K=U.I5P)G:1^-4!THR3)Q'63YX7F2T>U>M__ M=.SJ/:"EW8,!#>D3%V/6<7%N3>YZ,\/.UN?J:G!]-IV]NU+ ?W[.[L3<# B: MGOB2NN9Y&._MR:-]C7P9HTS)4;PI2>--+S_;WXHIJ_5O4)-L^L3B7B3^;]OJJ86_E6XHO!&"X*P\?.](5KGK/L2F M_4\O%R9/+^.R>V?H3PKHY=7P 1;IBE;K$T.T@,\%R5*>% L,O4++M#!.T52N MFB_7!=+2$L_JUU1(N>1+)(3Y2M1@:%.#H6WH/4YWJ>;$$=F'F-9_6-2L)"2> M(^X*K+,]L?C"?ZLT7Y+5;\^ZT&^W'SH;",+T*:AI)6=[A#QUV!S++9/RO2=U MWF'W,"^BY:=)">H47)*=@K-T]GM Y^#220$ONCJBFWY#8_ ^CQEN?-UO@I]7 M^NV>P!@E1243(V_H:R-[@@=L__ZC^-Q*\HWD]URXYX2\VCW+"L\(.4OG#'>, MG.:H.GZ*OTNX"MCH6RJ:[Q)P<8BH>UC4^ M$CIUY3(BR5OVY20&4U58$88[,>(GD1$WF1 ^98?-],2@MX%_P M:\!TL:U8)K?)'9"[D==@^1;/?FXQ4J0J[@.)Y:C4B$J-T,I;UQ *>]%"GI)M6Z#;VBI4UDOS6Q>_W(^/3 M0A"N8.>S( Y\D/?=3!3&DF#5UGOQ>%E4#+ISYUG(:YHG>;&*^Z)WXA#CSBCV MU::L-'NF(_K68/#Y[_6=I*K2SI<1))VE8'.BQPJ!>9/&Y#O[NGTV@(-1@8.M M'3_':+^J%,H7:\E*N-H!\!SC\ZEMKP*>5HR9U/G9&P\GD+]]I[X\FO C+IM)HF@94&71=5 M$5N*&CFP004Q9X4#S"XL36^"6T%+'M\3B2A/N,1@D#,Y:8_\?D[VAS;A'P5U MSZ8XI9F*B(Y48V3$)7M/:[B++6NQ.&R83B>7YS$OB&\>+0L#0^UT+)GD@[:# MR@LUL@(&GV;IAN*G@;G4_=-3[[;1'VZB@:M[!&>7+AG#@Q,&#X-"UY]8-K]) MT.CP-&@9TP+4F%QB$[MPH<:4%FK,G4'ZHB)?.^< G0""BQ4%:D[,JE(V^]1M METO%Q^>0BE2OMI@YQ+O.A'=18X;0?DWES;B]LQV]7#Z6V]JH?@6\#6$SCX_Q MJ2 OIQAKI0'(-INB(7@U_BA'PLD]ID>W/E*+>?'6X1@YB6 M S!58DVJGI)5A'+QEW"WD>IML\#-37EUU5!Q2)_FS_&5:%]U(RFU]#:\-W=+ MP?I^Y[2\A[RF9O*Q9"+ 0O=AI1)CHEFCV;.8WH/^%TOWQ1>-_]Y\N:DGOV:_ MW)&J*.]B^4WXYHZO 1#551+0CE_TEV=P8PNZ AJ'H,W M4S+)9"R?6;]00G1WQR%2L]QHG". &,$U%QQ'$8V?7_Y^K32R85UML-%Q%,6E M.CJ.$NA.+MA3[@6VTE];,0B("R"4-03'0;,*FHQ%7/KX"!H:3N2[6KR[>G@9 M/O::+T*)9/O:MY2:S(>\ZS]G@;BS#:D+)B*F4Q*7UE>_N*P^;6%O;26%6))? M'GQZ2X;!JFYA.ARW[&&O\A(?14Y-_OI>N2B;_9V]KQ>KNQ*(U MY'BE;3,SU&>N=^9.1)"Q.60LSY M_RTI9 _(A&^[5$J =8>Q^>W'N[ MYEP2EK_,(6ZYK;P*Y;<[&+-5S^SSD+5+LQ.P<$_U@5]Z\">=,ORA MGG1:X@;/%Y.03S9ET['$"MM#F^A!:GSNSP'-6MO-Y*JUX2<>P<"CHOX@_WC? M3>=^_ASD"MW]@3P>;644P^^,Y,,ZWII)':K$+SK;MU@>0MX1Y;.Q?&Z+=6MY M2N[=:"U&#:XX"+I UO\6R&_U>]X>YC>IF!,0\L\/37JU8>Y![]?OM&:R4?K# M9N%='T4(.>L^'WAE^M"Y\8*LF1*(''( M=TX@\CW7=X;)M88+W>)7*^"K3_?NC@"LYI:]J:ADF',8&&8E$WPLF5E^Q&#W MD=$%!L8!1YP.BYKE6]@HA/@O;GD^B2JNF_?$M Q%LHB,7Q0T>?(#SY-W8#[K M\FR^H:3:*"RE9XD>+;\7+5("6QL#K#3;;KS@D%I*R?ZY:N6TW:XW;&&1'8IQ M?XLN,GCLB_Y"QH/<N%;.OFZ+Z&;"@#V_ W\@@1;/!HV?Y@;H&AFZ]^=).V47QVXV>^/P8 MCH>[LAE;G(,I]UF^^\?L."@@K MH"G!H_NKXNB!WQ=XX*JTY5YN/I;-Y&.)7'3-YU'-^O;E;(5<+)%LJVO]:^9^6?G2 ++:T4'O#2 MR,F@'*INV@:AUX-);FX6IVA,!T!ZH])X :3LL3L#&N(SUEA59'8PFV^^W'VN MJJ7RWQ^-ZYW4O)NW0\_(XRRDCZ,%@YS T8;M%1/I;CMRU' M?KB<"BRP+L3X%9S#311FLJR(>[+;HRW/;463=;/RZV?85^'XJ0@CR*T7?CUT^*W:VV$X*4KOS MNT[?VQS )XOR3T]_R"LXYNQEPZF^EQ@+]Q712%N1%/"%:!*N"7V4B6@!V)5U MX\I0Y Z[=8 )>R;QD'WY-]>1?^[D)I9YZ+!LVWM;K$Q#Q;]Z9TR7M3NF/CP./FZ,[TB_8(@M1?K(50'F&%>K.C(PXWWI@_L6?C.&#QJ$- M>*18P].3!I&Z&A@Y'07?KFC2^9$.ER[J,!Z=*XX0N.A%X/((@>LC!#Z L6Z^ M0K5PD7IG:Z(M@RLFOV>KR:X&-+J^/&R+@5E05;L';TDK1Z"("<*#P&O8Y&PJ MK%4S.J+FW$$Y%A%V/^6= 8NX9M$_:^V1S(Q%9AQ3:0 =5ZHN/5* =)V47"+O MB=<$W57S12PWA*>?_1^M[KC\R:%/K*.>IR?\.3?1*NW7 M?41#/[@K/[?6)( MHDG.//!%N2KDFR^\8'].\95^JP0LKQ8:#_E^T*C4JO68USM_G.A M6OE-_XQQA>HU=U6H5^KXV-U]J5ZJ-NA7(QES?KPZI3D:\AF*78.Z&DH?->'T M!$SI*]M4-(*WP;]*2#L:\I>8"C%.Y*Z)*@[0)9)THZ^S! CN'?A"'(8-A,3' M(O.?8O1/_J/[\8",/M$-]T/=-IP/WT/;L@P(B=>*8&L:02]*-TY/8#50M"?1 M5)X()RMB1]--A6XP$]%0AW'PK\#FE/#PFD&SG63%Q%QAT_'1.-76.N=A>HL>I\')J^8G%K$]/\'H+6&ML< GH MEK<.[H%"J18M:-)696S!5BWOK?5MEZ2XP+AG<(0M(H-HKNBR7F;/+F-U6 M#-.:)C'&%8=WHM7]9-I]5)9L"I4%?N=N8)9B."DBYQTBOD3C9'2"@"U=X/F].\/T AO H9ZS9N,[ M()1>EF-HVL+EBI(!X 6S^J18ALXA6HW'1WD%9'BGD.D)%3*GVC"TK8HMU!MZ MOQ%FXC6 \ =-H<$KD &@ )9_D7Y5![TN:!;P0S_G?A#:GB,6- \:*76I\W9\ M>@("3N<8^D3&M&V,B,7P]R$XHC"?+6@-W6A+=Y@:XWK0#Y 5HURA(NJK2YY; M?QA[,;!QI(!WY'C-5E.OT1FMH/LEGP81W75F %J,NLF6D%N*.$(FQ@D)/@5: M9LY;3@>*U>44A&+G0\2RMB(!)> 4B Z6>, AQB #@%?C_K4UPO%I0$3H)D-5 M?K3P.<2(W*"K(^3K PU!VVZ9"@"9,02#6I/T.E$!#SP0S3&,;GB6E!AWA#CDGF!H!Q%X!X@K64I,NU5X?].BA@@W.G:$C'\SL[L,HTK/. M'@/7%<%J:A&BH7G7%PV&%=BP(=/"(!1<.D0#748(@&]('UL3V752U,0%VP<: M[JOLNF.+&2CX$ U6F-P[QW[_7"CI[Q .6Z@:2<@QO276N3A=I((]8Q6P;& %, ICT^07+X/ON8\P7;"#)ZHGIZ8A#)-FBA(<^#M L1+YX! MOR(&C@O@M(F&(XY-Y-J8^M#WZ)T[?.8DT!6"_NVR@1W),-UWB RP/KJDPGGI M],1]:^9IR@!-MT:$@#AZ+/;IWJF5V!.':!!B,AJU5-W&V^#> '>'8"SC@1'X MYAH:[;7 ]$ORN(X)25AG<)BXN% ;TR'H',U:DVPHQ&:7NE$M)%-D>7&Z]L?6 MI/'RB.2Y38N:9N/TK" <,%5L5\^9==D5<&>)'$E'&6UJ/A'_"@VI\-BH4Y3: MT6KN^B@6(^0JU!]&P(7F6!PLIHG5 M$?7$;PN!ABYX_B/W6<<.BCIZ0!KWKFZW+$ 4"#]I>77!4B*8 $5E M<] EU'_"_Y"1EZ@P=$09)4^T+ZJXW-H]VPWJ M8 (03;+OZ5GR4A7.]<_,F>@B-?O&_HS$&P1 M,$YF9JT\E0%=T*8/Z!6LHF@8:";3#).FXLZ;9]+*F6_DMIIJW/:DT:3-/1*[ MRG'"I60$/GM3!T'/_8Z 3LQ9#$UGMHHAT$\SEA_G4S9T2U39+B$^GW6U I>FK6V$!6,0A+@\4CRYR>Y( U M'(^_36)6BZ@*/&^RD X*'G33I5[#C'ZQ3"_*BVC>%8'ZITC2WG M'I!F+@+NS4@*J#O.UYXCV%>JVM2@X*F$(V<-4\Y819.W]X=I8 ! M-CR:%)-,09>#[O% Y\S":=N&$U3N*S@U5M?0[4Z7D6+"+-,!RS%> M;K#*ER;Z9O0L 7[$XM.L)*9FXMX+\^GP6(1%.HK$T3T!9%I7Z=-7.C1E.C9^ MFR91,Z?1I+:4:??1+Z7SZ'@[8]Z?GJ!BU/ M?0#B1HR>Z7CA;D#>PZ>8W\R#I^,(I+,90!/G^ZJHN9X>N"?%L%U;=Q3K YD'KTQ/XAJZWS(%6P;\D?5H>!)9P3,/2@2-MZ$8W)H)B%)8I M%V&\-FO[JC28/0>I)KZ_J0X*\EE1%PZ1>#GB/\@!+&^OA M] 2<;UE_==N:++>./-.XU^6BQ.U\E+@=:.)V]G@2MZG)[,I(H$(?K48C\@LF M,VI'F#U",#>*0D,J!-#^B25M<+9J47=Y3>CSN 9@C7:53A?6(ANC?QB)8+$9 M< 3^P*I&@SBTJ"*%V:F%P#%W/?8FC&_05<#@3@^7AL>["4>[H,RQ\LA!U,L-+8V5"ZY'H6 N<#SA(?B>:&H6!D MGN70]3T@9- ^P J7!J M[?=UBSBQ6' CAM1_8$V;4U,QO="8L7%^&5@1X'3TX*,N$56K*V'LU!R:X#R9 M;%\%&W(,%F8#@'5O6Y-BXJ3ML/48_$_&7LPDAHEX96N8Z]$[Z>&7(62+U\=V MUW@CX0Y6-7#(S7DYX-[ZG:LUT'RIW3]_R18ZJEA5CR^S6SCGIC.VL\V7YT;O MCY17LF43&%1_N+TMW/_"7.QZY7.U4JX4"]4&5R@6:P_51J7ZF;NKW52*E5+] M->1E+SP^%+R4/IBDUBZ9;%$P)Z4QY8V?3C[8?$E4S$/G>>_>]63+*:.5?9T.1[?ZCAXH> M)=WA?3BOGW.8? )K*;V:VO0D>- U$>P!CKB"P#(T3-/NT:TK:GV)EN/-.]D0 M&-C#5((> C9-46&A8?JNF]"F.&V-*YTY@T&(IP;*_]_>FS>GK2S_P_]3Q7M0 MY;GG5\FWL"\[YIQS4X4Q3DB\!>QL_[@$$J!82$2+;7CU3W?/C#0"L=E@P*'J MUCV.+8UZMM[[TU/>\<)X*M=[Y'DG$U.3%:81YV"$V.?DYVEJ76,1UT+'A'KT(F B/!%C&]Z MMU=[EA4HD6HUTE:&4Y2=O Q2..NUV]'-[T^YZ\QU\?A\QV4-Z#;Z3]7N#G_\ MO.H5L0^C2)"C\QI9A;W8V0KR)Q,JEQ,Z85(@9S8\03)(7PRJB=#C";^>EE.= M3"R55 V,VC0CWE]*#&R+8*)J(H_ET@%+*84-'&9^ZIB(;>'D=I%LQBAC=,YY\W9T5OT?R@O7DO MS3R9X*K)GB=N!?F1Q+! :V2)S\&FL=:1BI0V!BQ)^K. K,3JECF)/,?Q%Z+& M1N!I)IETYO8V3#@I'5_N3#=8GR]:G,?)^G5]][7S^47Z!]5E=![69JR-R ;V>H^LB0X4RSI.) M:(8,+2220WY43,M(DDQ"O=:?941Y\MVN1$RCEOWHZT;Q?I;Q\_ MFD>?"CLNV_+ C[+7M4^_1^;PL??F_1E%[V'B"LU\+]:V@GRL;VN#KL'/I?(6 M4X_?H>-#<7LL'YTJ$7V/M4/5C'N#U?7HJ%T36CE_1_4\QVCY02H6_ VX$5 ) M!QOT>TUW7!P!>16#N]6U ]"['0R? C-LZ0XW".DU.B1@,/@>YN[3)R47C7#, MG!@F41;0OQ3A\10G$W$DNWY?6"]3J%>6(S[PS&;$.4ON[U@A6<]06P!*G(HC]P#,KSQ+R; QCQ ![7Q7#V@(<7 MI_J56.0QP*]MR4FC8N9L+/A06^?(!1CJHZDD$_.FLK-W\*7 G)KMGJ[YIG[9 MJ5B>(8Y6,TC^K+'>G MXLX(1[(;.C8Z>,FC+*+?B,@AKIZ4?RMY(O@"L6H2YK(-EHD\*8)QA-=GDNVH M]"3I@S+8HN?W$ 2B<;7^]R;[)L2K M+I=NXRS:3R>GI>K)6;%WGAO/;ENP9:! $\0QEZ=Z]5.<,$I[N>J%>?3SI/Y= M?_X4LT^8(H-.GMO-:@,'I/C,!:F$S ^-X">OS0*]OC9S?7;S1FSND,_J'?Q, M-:5" 6:J NNM:LSC8?P E4?#O;V5 XE"Y;YR>*"XB9KQ.>7@WXZ&GWH?AN63 MQH=OG?4@^G/I4\S_-46P2R1R[#0JJ44BQS>3CY7]:W;[1"'P_HK+2HX_K^*5 M<2J7P_G/9^47&>;^<KV1>!5^I\8H/6OQ+,O %1^G^_#V\^'XU&)0+*VR($\LZN"\% M7M<=<\B*-KD)%-HYZVXZM*E;D@MN26[LEDS=G&?=CZ-T,94K/[<9Q^O;A^G< M:DW[<)1/I^M1<1;D38%_\X]F M3I'->=9%R*>*^7*J7-BSI,59TNI6/YM*%TJI4CXN^OQ\1E1[%8Q(4E=/])87 M/B=8T\_BV2,PIU_7QT]A34OH2O\H4PSA238U$:5YCFW_)'M^UBU;;J0ES;=< M;I[Y%COWQ:G?P:7;.A8VYU(]DZD5,IE4+C^_?^Z3#L+\[O2KXW6C.__1U.YJ MVGVQO-Y>C6()LNPP1R[;6'SA>?6]%6S3[QK]!Z! YKZ,R_;]*&V M0UU[0KY>_#TJI H%L!;S\ZV4V%UZ.D/=;_(2+/596UQ,9=/E5"E76L\6QS;M M'$_?DQ(,*MG;T8>[XXMT\2&3/C9V)@?@F9@BF?0>5&2EH")'>U"1U8**;$?% M28,5=C+V:7G(JKX97J_*,8QF9^E6(G"GRPQT.VJ[=]5B_>JDTMB=O*2I!2EV MZ::A9JQ/]V;QS7N^$LE$0V_;7)8XX] M5$U*+1.% N.UQ4_J-D5C,^RVUA#1O]N&2RWI\"76* L(O\?&*]CZK%JY.D"< M?YVW%JB>U2L'"*7#<&H"G)=!\';0ZFD8),J.$PZW$(LO".9'112=+L(;BU8J MR03LRYWNP4B^U>X)L'H7P6 TY;>O.A[+V45=";-_![[9MUD;*-<+NC..0/)A0+Z$S#\-^/5KRZK=&?*O[60"NXLY?3Q@'+, _ANPX> (R5BK[";();;!&.RL M( :$N EM>T"GI-*L*L5T,:5PEL(NMY!\<&8(.$)(OS&$7HZ Z'(\9L=>UK"6$PF[!:LN"IZ MZ45&@U=S[\+Y\DSQH,J7I97#0_EWA+?0%@C]$\^(>R&#.T:_RS#(Q(?IKK\M MO!.[,PKWZZ&G6\I;!-*"J>([."]O")S3,]P.X5M,^J,"N1EA[H=%0;U7X^7S:]U+[?C*N#)[:CH#$== MQ[LQO#SJ&=$%V&,#;0?Y50%$.,##ROJ/! @'81F!$VP?TU@X'A#]R)&PZ56Y MS5*D5T%T!- G!)J[)5I@8 \AZIG"JI]1[YA=VUR2KMHIMF_5ST!<:%F(V"7E=6%'X/)?@ ME'6(Q?H?CY8L-UV8U^V,:3VU2CF?G5VF3,:(W#Q6!F!'A'@VB91HL,:6,#*1 M&;7.8R4NKZ;$>3L\*T"OA,?H@)6$0*BD<3)GR.*^E66'NAU=?;P\N_]]]+70 MVW6XC\KMJ/]P4S%RGT>/)A.MA)LJ==V*KLA>U&X%^1'LCU@ 641<#[M HO4L M[2+OZ24JBQ]Q&<_, T/!'87GQ.N^G0ZPP(= MLZ)!A=/;4>[>./Y0N/('9F:7>,-TN-/U\7)J)G2%6)*&)C0"4!4N$<>YRC1! MUF5H!E"OZ("TU#"WHX]7>O?4-W6K?;1+N\3@>G.3<+W9VY'V^TNC.&Q8=;/U MYOU5HW95J9\HM>]7M8MFK:E4+DZ4R^N/M892O6DT:@C=VVS6KE\%6N^ZJ]7I MG(;5XPL=-8S432M*+X7']CFCWHX^E(Z;=K-3 LUV9TXQGV< )L8,-M:C29A_ M GC5(9 +H!/>QU)PTWY86_WW2F_J6)%W[7;D]W+56B9S]7C4FU?DG4Q@E??2 M%WB;Z[V?5*$JZBO75?Q8X"7&VXOKM&5=V9+$XQ M.SPN#?M'I]VJ]LPICK>-?F[UZQK*F!URF5E9%ZF;T<55:UX&%C1[D,D^!Y$PGTZE2VLO MHYVT.,[T+CDXKQR[H[LN=;R9N)O-QZ-J[?O/!R^?6V'!1=R%C+V$1"/I60.) MRLV4(.V8>EB:7[&Z';5:SUIH9YYBTK95#H__Q(]Y>;(Z+%DV40- M'F[G3-R'WS\2EEW4^4:LM4,M%<7GO!S?0-6\=US>3RJ5PFKN'S MOBIJ=9OT3%:1R913I=*:-BF>A>0FU6$^3^$M86Z2@)=< S/Q)&:2+HYJGQ^' M]9N\^=)UC[Q"A#5;'W"E>*X+9%-U)Q/ZWSI*3A;8PG5PEWP^D\KDYJO>.U(B MM-5;]4P>4\AE4D?E\I:4^F2 @7S,G)@?>XW"C^S..%PWE_R&_4J]X96)O1,M MK?;;-RBUXB3HMS4MKG,<8?2+#W,[LH]^7V1[?M4V=F>#@KA.?C*N4[L=#J\=G&=4BYJU_M(S@K.YK2036&1$RF= MP^O^R8^SMG4ULLL[E!4,S<7>0+TC\"=Y'8^:&*O)2-"9_?%;OW!QES*/G8NQN530F)T5C M2L.SFO.0KM?OV_MHS&Y$8_*+R( @5;@W_]GC(18%L]1>X54^4UO!WT52[ZF? M=C\5K4]#)[LAL%2@*A0(NQ!PF+4[LXQ*O@^WD]OP9'/SZ"A5RJPP,/'*%IZ; MB&M8^&(VE2G,A]1Y9D2H_!)<@6%O@,5M:4V[XSV 2B:8@_FS\2-S\MGJ?'L* MWLXJL+P$<CTK'8[ZGSY<-&S/A2'WXW5:B?K@_02,U0BAFY*Z>($ MQW"]-@/2^73N\F1?:Z:0*B_@%M^N(/GS+_'3];I4VW@J0_.UVW[? M-[&.X40?(*H%E1?"SZ9.=8:65NG;<-U&]/NI"W%K7-1O->.V[TIW=U0X/?_4 M_I:V?_[:D/(@30]6.YS?[DN=MW, UU:TKVO)3BNG4T?%%:)1OMMOYW.V\YFL M*ELLIS)'\Q&3E]W.^A^O/5CZ MA&ODE06!IV_F>G)D"ZET<4U C_L]6@UKR>13^=Q\+>AE(O3EVY&9:>I^MO?5 M^+7C8)R[$[25Y5U0UJ4\(#K9;- -N0A?'H1@-B8:+W8_6^[GR\^/9W>Y -I" M?FO>U8@\NUHTXAC6-1-Y @7'3 B2B=68Z-'X-?TM>U9L_&[6LNM9C:?"]DXF M"LX&X9B#GZ'$=(A]'3@:SX7@S>PA>%<*P5O>0_"^7J@!R4Q#5 KWBG6 1ZNL MW8;GM#,#3H5)H.?S\]/R4?_,4T:\'?W^8M_G5//\>\'<&4TE2%4KQ$(0?#G^ MGCG^_OFNFB^\>5^I5ALWM;"">9^?MO@QE5K53QRFF= "Y?A^]W,&N1WUO[4; M/T[K;O=,WYG#R&MWTFVE.*YKG1 MD3G2'JW>QT*N^*IP ;)2)II>.*V,'MH?RP^]?2;:;F2BR4W"1;?/AD[.9XG' M1THJ*V?545=KWH[:F8Z?U:YRF5Y[0\ED&"X'?AT;YMF^E*:YZ[L6U^<16,U' M*\Q=>GTKO *\@.(",9%G9H>-60JHK\@UW*?ZM&MZKI_6^FJ[URG=K3;7FFUG_L,3UNNY];_Y?"J_IC:LE1!E@T^LRMMQQ*$% MA*+MY/[C#_?'S8^+E^RX+$C;S $@E(B9B[269"%8HN*NY0H]<:F>6\.:3I6S MSUVJ^?7PK"!WPLZ/ORCFAVRO-#IJ/]RW-I3V\^>@9DS=D[4(L70J4UIAHL>? MD0'\A'UZ+E-('2W0/WY-^;TSN 1EY 1LHG7T4_TX&AS_SI>V.1]'9?,)T#1> M=8+'B[*3/)BAN5QQGX&SM@UZ+A_)(T#&FMH=/P4@PZY=>=,S9SW)RY 9\=@O;0(%$=GNV MXQU@]SO1@L'J+M",28:]/;-52\36)6-F8!6L(L^,*N?24J,EO"1URX4;%_9- M"D.B2- UT(-/B0K*\T^#VF6][M0[O2"5"C\+6@=]=A['CR%Q6H^D\@'0&O1( MFB1F03EP@-< M>[K%TM/@Q'*BW DIP==YN7YC8U^E'G]&FW]]Y2O=.+W^5?F@T<"N'<95O=*6_04BY%%G+>S Z,-94_*H9CAZ&QL>$89BIV.T M028%:./* 'MW@1+^RO)$7T _/54-AQ),0Y5S:B,>.9-[YGNWH_N;XDFCKZJM MIK9[NFII4E=%N*)LJWFJ7A_UO[7?O#^MU!O*U\K934TYKU6:-XT:HD.]XNRW MG2$_TC--M51S.,*<,=.4^H,9 9-TF9;4T55LI$X]1,%Z[BEF:-@'!6#>$!B9 MIK-,=NR/)G<_)6KD]]WX./'"83-_Q-PPT>34D4B5XX\*G(I['+>M@$ ME36>-ASJYNSH0%!+Q39HO%&::3^@J#"QOR7.Q+ &OLX@?6!F*&.2J#@^ 50-_%Y#%U/ O#JI8&H+;3:D)SRP[ MQ9)IE6+G6'4Z$,>CF# M;;F!;D?9XW*Z6_=T]==.=5AD&L11+,;KQ>?FE?J[73LN]-Z\KUZ>G]>O26L@ MB,GJY<5U_>)#[:):?\U9]#M#/NND>PGVLHHG-9DX P&)8:=]2]R-BTBAWIFT M)8H!TJAM.P/;80UFT3ITN:ZF,G?.@6\ MKAD>I5CQ$15,G=?%L!;(1W$VV"B!H@7B4G^@!'QFQ9I#[,#[X!@>>I$_>4%'56"M?_P]6O'PR9SW%TADS6W?CWZ MD;77Z1:7K],MSUF3B5+=TL?'W^G+TK5[T5K;FJRN6CVT7JV_XM89.T,^YA1\\BT])IV@#?\U=518)X-T^9EWH:'?P\\Z_:$Y M !;)%;1BH* 5<^G;4?[ZEZ.>Z>W!<497EXP_%P,]+#B02X] M_])/$ E*V 'H60>@_VA@ZVAZKAGF(Q-;RMPH<]QU9)5V,N."Y!@!:8M(9:*Q8W6I1QRSR2 M@>_1Q8@B\Z"#-'/TC@E*'VVHWNG@CUQUC)D<"*%PWY.)OJH!K0!V.P% MOH2DD)(+GVNJ*I\Q%W^&ISS8OLE=F@\H"UNZ,*7( C)ON#1KUS<#^F2Z MDHFZ%=A]J?$_\Q<#-SP0*WEGI:/,V4YTF] _ZX"9B%(5Z)FP-S)CKC+;HM>N M5.?28=%;BK9=Z4X3)RX"T.WP?/?:1=.R6V?7-T?!^>84T"Q2(<'S;)$%")@6 M06:W8?$HL6R77-'(+F:WI--QB'#L$@0G_+4I(SM#/C,OJK9%>>(M$T3W%; MW<';1L=F;VQLD9L,M7O5]WHV \Q0@0%YY-::$+0GT=Z;;$>9S**K60E&00;4 M#CU"VL^/E_;W4_5K-_0(A4>"\Q_.LD-2%FA(.(.$%>3"1UF08#_9-'I'9GI( M^%1@"0?CLYR9!1:=T2SN+BVN4S,_Y[-?6]6J/FUQ%^?MBU&P\K4=9^^9Z>P] M$*LAHU>NP!AV%!ZU-F!0LE+]E@D*F@T*AT,N^KK/I?^I7E_13YI]WXS:V MBY'*\1VJS3GV=7HMNBM20I=0A:H8J;_LT(OC25] (9S=Z. B^:O;S8]:/\V; MG]7VW,M#,WC*O6%SF-FQ(DC\FD[LL^Y5(94M%U/I?%PEP]QKI>F8P$!:*+ S M1J)2.51 9?ODF^@G$A2'8(4#S=^(X M/)]SS$IZSTQ/>@:@_/A M1>ENQ7S^Y79+W.#\X70-:HD;#)=5?VSW5*O+DH$G;NJ$?X@MPHF/1Y@EJS/M MQG=@&!>Q\BB;Z64N:^5D6+./.U8]%ZIO34F:LYS!8(:P$I:-#G^>/<6BT3S' M2N2#SSL9RZS"5MWQ[&%<(6KTR+";'=@W@;^E'1JD,4OH,."AB:5\95Z$);"% MLWMLX95B"V?2>W#AU2)F[K@7!L,=F"_K:*2?4ZHYJ2%X7C$5F]*5E!-NVH2\ M;:HL3)$;/$A]G2LZR3V.&G RP64-9?[Z'B6AHR:L,J\]Q:7YN& ^"[6):<^J M#[=;I2MF#@6;92S4GE"BLF,55IS"^.S$O;?/4 ML,^-4'/VJ<05#<*(6 :]0X,)\ F["^'M+S/?%Q>\\69Y*5](%0IQW3UX-I!O M4C4DRPM'5%K,!7==XO+!&21Q'(8[J-A.1+C"!60576_1(0J:A=+&F 0?N6B:9%DS,'(E&R63(ALLQ2-,H%#FYHX M0KDY]MQER >#BDY;]KQ^_/'K\^GGHCYJ9.=ZYB2F.@[U' WO+4<)Q^\]^W)> MNLO<5]HG\QWL44J6MB E6A9V Q^X>AOYS@/(.E>WYC.=U9,5![*R-%F6'<,& MX_FB8(\3_B8UL@.OS+S8'?)%D!*%4C*QCTIN ?E/C$JFXW,CXD*2(B>"\^_1 MG5-X^#WXU/VH3LF)6#HF.8. M04D,_E4]JB0*L6V_1Z/G,AJ6$PT\N3IB29\ M4:LM][AC%HRK1C%V4=>?9[+*0.2,/).X0&3=4B[L^P 3)Q/U*[-B2HPX2>E+ MK/P"1J)$))8&I--K5F!XR'H2VTD*[+VTQ^_6D;=\G[T-G5;,@>9#&)0 'FW$>J>9^&D,OELZJ@P?:]% M-MFD.5M=\9*KC_*2W]P_M+K?A^:O1VTKEERF[F585B0;D(3"E.!,;M9&2)&9 M*+/J]6\>[?) RYWCT4?MUJE]\&KG&F_=4)7%P7&G6L/#\''M)5:[KEQ?[ M$HF-DQ^QD;J.BAGV]@"/KRAIQ@J ;#J35YA+$%12C&!A$C_V@U;>HF;)$^'P M%R(3[E"Y"=!K\/<3U6>2#@IZ$'T:BYS9I]%+ZP_B%"2Y>CB\5?*]JS@.:D%X MRXZ'$Q>O\J Z&G/!7W:XQG*O&B:ZET]MYP/2$06#Y**]W/]FV_Z9K^5#"41/ M\_5*+>,(6Q?E*] ,YJ9)3<^EG$RRB):.C*M>\)#NW,[N+IQ"P[SQ/CKF_&IBNX.83#P)-V Y=^0(L@(DHL*U>Z1Q0DA-7BW2TY3A?"_- Q MMBU614N%Z4-==5A];$MOVWV=1ZST1]UI&RQ,%>!D87$ZAE[Y4$9_8+N4(S#X0?HP70@[CZ[%A0M< 3-X> SJ@%VTMK1. 5;)V[:C M:X;W+LC$$NG\4OXRV5V])+M\[E]U:VG9Y<_U6%V+5W-Y M[\3;7O!"W4(C*TBH.^-:\%@R70/,<[R.%4L[04!B>X /\]%$^*N4=_H?)B^S;+6Q%3^KG KCT9WJ]TGI[G>ZDEMO(]>Q#IX1W\^84^)Y MOD9*")WF5V3D<>=BX*EYS3U'G\TQ5P&FG"F44L7,?&5AWRUV/:SOZ4P,H5?B M,B WT42V>COZ?O/UIWIR?W?ZH;@S238O'_Z*/S$4ON>!U J&'0UO>(TK/RW. M58B-GZ C:U7Z"O;^ETW+TO@HF&'!3]F^4AZAL8#]/:M/%?OW6L%CBSKO=FWFE MVW7T+B8"L;D8,$/#WK\+F.[6B0;7B4 M6T6V(==@I(DQAG)K-*4BD;'(=.F#/_C>_%RI2B50?"!%&BFEM'20973*6ZJ) MV2MOQJ>.6S75\!!=@3N7)<7KAW"66NS\J,IEW;F#W,K#&BLE>\M MMF6S7_H#9O L$;E$K.;-^P\L,7EV9#YF@#E2[62%[(=(=.L62S?]X-BN.YW/ M5"[R9[Y:^I*1 B%4.-SG95=$+''$%'CP'@\Z!D:&*!_*S"UK/'8R8B^%'[=G7\L=P9>87%&M-+]*:?WK&@K6=$J MTEE.;:>C&Y+NM-EDAO NKJ1^D5]%/DD?RSTMK?8X,'@EB;B:,S2QZV;U<_>J M\%#Z-$_T3BU[$;/S+N).)K"L1]^>N^=/8\=?K:\Y?>@-*[]+"[/C MESXF<[7ZES\FZ_CB$B;K?L++)C:]D%X\*9=XVLB8=SN*BK.IU),785PQ[N_: M='YTT[.=TZ,S\\ME<;;[F_<''G<[KB-YYF5_OY^<=8LG^B5]M-M\;(M1>#6/LU[K3S]YJWH\I?IB?];MJ^:MV48OQ1"KBQ@0#*]+("@Z= MDJ_/(KV2YZ6>$D2SYCN8"S"1!O?R*_?F?>[P: IN^HZ>\S@^ODI[6%KENDB$ M( Q7Y-RQA[!U5:LU?W[J98_#)@QA3D4P".M.\QKX=71=5L"A)])[LZ5,*EN> M7U[WO/3>M8?>MM>WMJ=F5ZC9)L/SJTX]3AAB5@A'M?TVZ%+!BSF,D"T"\YOI M;?CQVL9?U<(%6< T/;O^^*-FWOT\\XQ)UVG\,F^U=%AT4=9HK>92V>0W:=?&H6CNY$U8IUT[<:.>89TM M?1RF&6V9Z>;NR?'=Z;6AGE[US2>:NU/NV99;OJM;6S2(2Z_?(%XJ9>S9?"XP M=A#WL_8DM#6?! M_B^$EWR!W4.)R1.L+X%[R']'S.0+V_NA>R&:,N+^1SMRG@X?SZ[N/QM&,Q-( MPAO+"=Z(0(3,$UIKHWL5?3,GI%)L;TJ&!.]/6P'XA^O)@,OP]@&;CB+7MKN' M"DOQ9[LH[CO>:]QUR_EZMWOTYF3DQ0MW#V M53&3GZMX+3V')^",K*:/:K1VGIU@P'"[70:938U/@FK[+2+Z[49NHA M'6G-SL_N4>%\.%EJPQIA33NA"YR%([:NT]F?' M.\?01P4AP&."C\UD#6O8EMB;>5_66UJAT3OK9\QE,GNUFSAT?3&^[95DP+EIU5J'?<'F#R()E84 #'" 38<,\QVJ&F MB2?"5=XVFC?N.^HG-G[C,R\@'L8E=H@=2V^CU3P)9,WG07SP!F@ZW!2^WU=,V!7 MX7'6"P_;4*'['DAQ_=8O^)AH:A.E*DHG:Y'%.]5XAN7;OBOZ9>%EL_UNCP81 M7;#P)"UIH*58U^E'$K! [RSS7>J]6E4'!BP#VZ0&[[!V:CNG/M:^U'FG'C3+ MVZN[0B4C?U_Y56L?ES7)IN=L)+"8%FT?N]@49EGH+W#ZC[*I='IZ9S?II,(2 M4"MP9)MPOS1='*_W5S/V*RT>\%#7EQQGDX$A36\DCC)8_8Z6PN'WV MNYDHPN4Y*,)/_]#MJ/.U>=?^?71S9:ZW1>9+H@=/^,C4O?W^]^G14R4_&'JQ]K)S=G-0(@/JW4&\K7RME-3:DT@1D3'O%N]*>EWZ>O@_L/@(?2S3Y_F0L;#++S)5240%Z>&5'8 \O"K;8* -@UON.Z*GO$C M45B%M1O$,20%0R02AE-K@."D+'QM<.M?@7H<'^=I_M:\#\V3L[,O(09P.,C: MC-7%Y[#Z8 THE!1\SDJG&Q?HS?MB[G"J=3J_+.NOC4+DL;5CH.-OHUCC+W6Z M)QC>4W*Z9YV,:/[[9!OB9J>Z3[:;"Y\8]X8&YJES[? M*X$YF,6 Q/2D\YV>=LXZDWW6\A_F9TB3:B7\C3>,ESO<)#O40U1>9K MKM'W3X:EB\[.N)KB?1[C$UV=/_&X7CG]^YOJD'_IQ'#;INW"EDWQ#*(6WX9) MV_V#@QDOW8ZJWVV[8]U[GS+9G5GZ?UOO+VQ/3R8RF<.QR,)1-G\[.L]WNM\_ M]KM#^^C-^V^51J-R<1UZ:%H37IJ]G^UER/\&6Z:VVR#%/(JS1B)H#_R4*IB' M:&"9 P;(L+D;1L8 D"ZH#SCHH?(M^+2C*YQ C/+#QU1WVO>,R'CP+CJ=Z9VVZO84 M5_= EN#X2#.+N.GTY[ZM(5DD):C$0QHF2+AF+:@P2DC1O'L:G''M&X=M'W'T7%=XBF!1=*5MJFZ+IP) M>4G$X_+2\ T ;J=A&TUT"EKDZ:/44HX4!%3HNH<$AJ'H%$4KVSV4G&XR ;.7 MPM22*WU <6,*1[DZ[94Q\Y.NZ%+.8MTZAXI-*0\]H]U3#%=Q=/H();[J*OPN M0F4R02Y^:0-XF-4 Z6FH)KG[Z7&^G:Y\I%];C&QGR)]20H5G;**=5C0CI*=J MLT/6>!,N.YQQ7#H-U'8E>*EH/M;HX=.WWZV'PL#7PI1$_JYB1]#;9B6%+?C- M;":+WVQX#Y\_]@?90;D[YYNS(]MSOKHV-)0UD+6*+EOY5#%?3I4+<;[EF?4U MH:205C]2G(')'(PU2-/B@(BGC1]U- M>_7?/_H?RQ.Y_5/F-GE]TJN<&+M7SYY8K5T?I8N-_L_TT1(36_XRS)O:0OF6 M$=J?'9)YJ5GP>[ZF610/IW M3_*9\QL"#$UPUDD&L!(0D26F/CV+\XE3=[(/ZOGWWZ/20V;>U-?CI%I@\DM6 M,$1F6,YF"IELX7FUK5LV]>E9JZN?>FQ9[X)Z2+3"%YWY-G 1LKK!&$(KQPH: M/@O-@S[[V@R:]3GM@C,86(XU-.7=:5Z[")K7M'=N1^G>KT[QH?*Y46OMH-,N M&^^TN[%_CBH?KIO=+'9\/V[6OMS4+JZ5VM?:WGNW#>13;J4PD,E=PGPKH5.$ MW%2\Z@M8C,OX#RHXH//8;7(Q@8[;\3"Y'G.[8228Z MA@5#H LF\/%PQJ;>JX9)Z7!%-I1;]"=(#>:C,O^]^@M,(=,0W,I*Y?U\Z3B4 !D-\@B8&J,+PP M&(!2"GSZS?MSU5*9EBZ\8 J&,7W7144?)4W%4LVA:U TY#3@GU5@L(8GGFGH MKF]Z],AEX/T_',_9WN'-V7G5PG"3";!]:,=X5,<%8B8V'W8/XWH4>H)';=^1 MA&8[LNE.N.EAR(?5G8<5(EKT,*G\,"43;U%,XV>SZ7_.3_Z?VA_\4Z%_9OYY MAP$C3'TB-PQH%SVCVS/1'T5CN'!\>>0/I+I*OS,L9N1)TX-7==/5'PC/S>#* MR!=?=8"=FT,XL@/;\5+)! W90R4#M1C@KQ3L@JG^\BVV7@^&UZ.5H'0LHP\7 M3O4U;$BXC)[!"P71(35!5S(Q3A@]C=^4OK3 ^+BH ON,?4O\5MH(XA?TRQ[, M%G=)[,/$>4@F5L4-^-Z25QT_C1F3W-$6$RLR+ (_I*V 54@F3F%[X3 ??(:Y MF_![VA, M/658R00M71!

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�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end